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(57) ABSTRACT 
Non-naturally occurring amine dehydrogenases (AmDH) 
and methods of use thereof the produce chiral amines are 
disclosed. The AmDH are variants of amino acid dehydroge-
nases. AmDH based on phenylalanine, leucine, and valine 
scaffolds are provided. The AmDH typically have one, two, 
three, four, or more amino acid alterations relative to the 
scaffold. The alterations to the scaffold result in an enzyme 
that accepts the analogous ketone, such as methyl isobutyl 
ketone (MIBK), instead of the wild-type a-keto acid. Chi-
meric AmDH are also disclosed. The chimeras are fusion 
proteins that include a substrate binding domain from a first 
AmDH and a cofactor binding domain from a secondAmDH. 
In a preferred embodiment, one of the domains is from a 
PheDH-based AmDH and one of the domains is from a 
LeuDH-basedAmDH. 
12 Claims, 12 Drawing Sheets 
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ENGINEERED AMINE DEHYDROGENASES 
AND METHODS OF USE THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. Provisional Appli-
cation No. 61/647,098, filed May 15, 2012, U.S. Provisional 
Application No. 61/682,369 filed Aug. 13, 2012, and U.S. 
Provisional Application No. 61/808,251, filed Apr. 4, 2013, 
each of which are herein incorporated by reference in its 
entirety. 
REFERENCE TO THE SEQUENCE LISTING 
The Sequence Listing submitted May 15, 2013 as a text file 
named "GTRC_6062_ST25.txt," created on May 15, 2013 
and have a size of 85,074 bytes is hereby incorporated by 
reference. 
FIELD OF THE INVENTION 
The invention is generally related to compositions and 
methods of making chiral amines. 
BACKGROUND OF THE INVENTION 
Enzymes are unique in their ability to significantly enhance 
reaction rates under mild conditions with high levels of effi-
ciency and selectivity. After substrates have bound to an 
enzyme's active site, their half-life is usually only a fraction 
of a second (Wolfenden, et al., Accounts of Chemical 
Research, 34, (12): 938-945 (2001 )). Some enzymes perform 
catalysis so well they border on the physical limitations of 
efficiency with encountering substrate in solution, and have 
been known to achieve rate enhancements (kca!kuncat) in 
excess of 19 orders of magnitude. These outstanding 
examples of enzymatic catalysis establish their remarkable 
power, and demonstrate their potential use in chemical syn-
thesis. 
2 
natively, chirality can be achieved through the resolution of a 
racemic mixture, as seen in the kinetic resolution of alcohols 
and amines through the application of lipases or esterases 
(Heine, et al., Protein Engineering Design and Selection, 20, 
5 (3): 125-131 (2007); Reetz, et al., CHIMIA International 
Journal for Chemistry, 50, (12): 668-669 (1996); Schmidt, 
Chembiochem, 7, (5): 805-809 (2006)). The major disadvan-
tage of kinetic resolution is an unfavorable equilibrium con-
stant, usually near unity. The use of a second reaction is 
10 required to drive the reaction to completion. Lastly, the chiral 
centers can be synthesized directly using an asymmetric cata-
lyst or enzyme. If the desired selectivity is not achieved 
initially, multiple enrichments, such as crystallization, can be 
required to achieve an increased selectivity. In comparison to 
15 other catalysts, enzymes usually offer superior enantio- and 
regioselectivity, commonly reporting enantiomeric excesses 
"e.e.'s" of >99.9% (Bommarius, et al., Wiley-VCR Verlag 
GmbH & Co., (2004). High initial selectivity eliminates the 
need for enrichment, significantly reducing the cost of pro-
20 duction. 
One of the short comings of biocatalysis is the limited 
number of reactions which have identified enzymatic routes. 
In 2005, the American Chemical Society's (ACS) Green 
Chemistry Institute (GCI) and several leading global pharma-
25 ceutical companies created the ACS GCI Pharmaceutical 
Roundtable. The goals ofthis center encompassed innovation 
in the discovery, development, and production of pharmaceu-
ticals. Consequently, the Roundtable identified the most aspi-
rational reactions currently challenging the pharmaceutical 
30 industry (Constable, et al., Green Chemistry, 9, (5): 411-420 
(2007). The reductive amination of a prochiral ketone with 
free ammonia to produce chiral amines ranked second on this 
list, and had yet to be achieved. 
Therefore, it is an object of the invention to provide com-
35 positions and methods for reductive amination of a prochiral 
ketone to produce chiral amines. 
40 
It is another object to provide recombinant enzymes for the 
production of chiral compounds. 
SUMMARY OF THE INVENTION 
In addition to rate enhancement, many enzymes are selec-
tive in their catalysis and allow for the direct production of 
single enantiomers. Single enantiomers of target product 
molecules have a large importance in the pharmaceutical and 
agricultural industries. Therapeutic compounds often act as 45 
structurally optimized inhibitors of biological processes. 
Since the human body functions using chiral chemistry, these 
compounds almost always contain chiral centers. In 2006, 
80% of small-molecule drugs approved by FDA were chiral 
and 75% were single enantiomers (Thayer, Chemical and 50 
Engineering News, 85, (32): 11-19 (2007). USA Food and 
Drug Administration (FDA) regulations require proof that 
any non-therapeutic isomer comprising over 1 % of the total 
composition be non-teratogenic. Thus, a racemic drug would 
require separate toxicology studies of each enantiomer. Fur- 55 
ther, as the complexity of these compounds increases, mol-
ecules often require more than one chiral center (Pollard, et 
al., Trends in Biotechnology, 25, (2): 66-73 (2007)). It is 
common for pharmaceutical processes to require a minimum 
acceptable enantiomeric excess ( e.e.) of 98% to circumvent 60 
these difficulties. 
Recombinant amine dehydrogenases (AmDHs) and meth-
ods of use thereof are disclosed. The AmDHs are genetically 
engineered amino acid dehydrogenases. AmDHs based on 
phenylalanine, leucine, and valine scaffolds are provided. 
The AmDHs typically have one, two, three, four, or more 
amino acid alterations relative to the amino dehydrogenase 
scaffold. The alterations to the amino dehydrogenase scaffold 
produce an enzyme that accepts the analogous ketone, such as 
methyl isobutyl ketone (MIBK) instead of the wild-type 
a-keto acid. 
Chimeric AmDHs are also disclosed. The chimeras are 
fusion proteins that include a substrate binding domain from 
a first AmDH and a cofactor binding domain from a second 
AmDH. In a preferred embodiment, one of the domains is 
from an amine dehydrogenase based on a phenylalanine 
dehydrogenase scaffold (PheDH-AmDH) and one of the 
domains is from a occurring amine dehydrogenase based on a 
leucine dehydrogenase scaffold (LeuDH-AmDH). 
Methods of making chiral amines using the AmDHs are 
also disclosed. The methods typically including reacting a 
substrate with an effective amount the amine dehydrogenase 
in a reaction mixture including a cofactor such as NADH to 
produce a chiral amine. In some embodiments, the reaction 
Chiral intermediates are classically prepared by three dif-
ferent routes Carey, et al., Organic & Biomolecular Chemis-
try, 4, (12): 2337-2347 (2006)). One method is to simply 
attain them through a naturally occurring chiral synthon. This 
allows for an inexpensive and readily available source of 
natural products, but this pool of compounds is limited. Alter-
65 mixture includes glucose and glucose dehydrogenase (GDH) 
or formate and formate dehydrogenase (FDH) to recycle the 
cofactor. In some embodiments, the reaction mixture includes 
US 8,835,136 B2 
3 4 
K77S N276L with normalized ellipticity representing the 
percentage of folded protein (protein concentrations 100 µg 
mL-1 in 50 mM sodium phosphate buffer pH 8.0) (Fraction 
Fold Protein vs. Temperature [0 C.]). 
FIG. 16 is a scatter plot showing the semi-log plot of 
fraction of folded PheDH/AmDH as measured by circular 
dichroism spectroscopy of wild type PheDH and top PheDH-
AmDH variant, K77S N27 6L with normalized ellipticity rep-
resenting the percentage of folded protein (protein concen-
trations 100 µg mL-1 in 50 mM sodium phosphate buffer pH 
8.0) (Log(Normalized Ellipticity) vs. Temperature [0 C.]). 
an organic solvent such as acetone. The reaction can be car-
ried out by whole cell catalysis or in an enzyme membrane 
reactor. In some embodiments, the amine dehydrogenase is a 
LeuDH-based amine dehydrogenase or a chimera thereof and 
the substrate is selected from the group consisting of methyl 5 
benzyl amine (MBA), cyclohexylamine, cylcohexanone, 
ethyl pyruvate, methyl aceto acetate, ethyl-3-oxohexanoate, 
and acetophenone. In some embodiments, the amine dehy-
drogenase is a PheDH-based amine dehydrogenase or a chi-
mera thereof and the substrate is methylketone such as para- 10 
fluoro phenyl acetone (PFPA), phenoxy-2-propanone, 
2-hexanone, methyl isobutyl ketone and 3-methyl-2-bu- FIG. 17 is a scatter plot showing the Specific Activity 
(U/mg) vs. Temperature (° C.) of PheDH-AmDH K77S 
15 N276L double variant. 
tanone. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an asymmetric synthesis reaction scheme show-
ing an amine dehydrogenase paired with a glucose dehydro-
genase cofactor recycling system. 
FIGS. 2A-2B are schemes showing the enzymatic reac-
tions driven by wild type LeuDH (2A) and engineered 
LeuDH-AmDH (2B). 
FIG. 3 is a diagram showing a NAD+ auto-fluorescence 
assay used for screening libraries 2 through 5 for active 
LeuDH-AmDH mutants. 
FIG. 4 is a diagram showing a formazan-based assay used 
for screening libraries 6 and 7 for active PheDH-AmDH 
mutants. 
FIG. 18 is a 1H nuclear magnetic resonance spectrogram 
showing indicating the presence of chiral 1-( 4-fluorophenyl)-
propane-2-amine: "A" labels a sextuplet splitting representa-
tive of the proton at the chiral center, and "B" labels a pair of 
20 doublet-doublet splits from the C3 hydrogens reflecting the 
chiral center. 
25 
FIG. 19 is a reaction scheme the desired reductive amina-
tion activity of ValDH-AmDH converting 2-methyl-3-bu-
tanone to (R)-1,2-dimethylpropylamine. 
FIG. 20 is a best-fit curve showing the specific activity [U 
mg- 1] of PheDH-AmDH K77M/N27 6V in acetone as a func-
tion of substrate concentration (PFPA concentration. [ mM]. 
FIG. 5 is a diagram showing a 1,3-DMBA deamination 
assay used for screening libraries 8-11 for active LeuDH- 30 
AmDH mutants. 
FIG. 21 is a drawing showing the design and domain struc-
ture ofCl-AmDH. 
FIGS. 22A and 22B are scatter plots showing the results of 
a temperature (° C.)vs. specific activity (U/mg) ofCl-AmDH 
for acetophenone (22A) and pFPA (22B). FIG. 6 is scatter plot showing correlation ofLeuDH vari-
ants' OD600 absorbance to background absorbance of 340 
nm in the 1,3-DMBA deamination assay depicted in FIG. 4. 
FIG. 7 is a scatter plot showing an example ofa typical well 
plate analyzed using the high-throughput absorbance-based 
assay with readings at 340 nm and 600 nm (library 11, plate 
9). 
FIG. 8 is best fit curve showing non-linear Michaelis-
Menten fit of MIBK amination activity by LeuDH-AmDH 
quadruple variant K67S/El 13V/N261L/V290C. 
FIG. 9 is a scatter plot showing the conversion calibration 
curve ofMIBK to 1,3-DMBA by LeuDH-AmDH quadruple 
variant K67S/El 13V/N261L/V290C. 
FIG. 23 is a gas chromatogram for 2 positive examples of 
product formation (methlybenzylamine and p-fluorophenyl-
35 propylamine) after 24 hours of conversion. 
FIGS. 24A and 24B are gas chromatograms. FIG. 24A 
shows a chromatogram of adamantylethylamine product 
formed with Cl-AmDH overlaid over a chromatogram for a 
racemic standard of adamantylethylamine. FIG. 24B shows a 
40 chromatogram for methylbenzylamine product formed with 
Cl-AmDH overlaid over a chromatogram for a racemic stan-
dard ofmethylbenzylamine. 
DETAILED DESCRIPTION OF THE INVENTION 
FIG. 10 is chromatogram showing chiral gas chromatog- 45 
raphy (FID) separation of derivatized racemic 1,3-DMBA 
standard. 
I. Definitions 
FIG. 11 is a scatter plot showing circular dichroism wave-
length scans of wild type LeuDH to determine the maximum 
ellipticity of the protein (Ellipicity, 8 [mdeg cm2 ] vs. Wave-
length [nm]). 
FIG. 12 is a scatter plot showing the fraction of folded 
LeuDH/AmDH as measured by circular dichroism spectros-
copy of wild type LeuDH and top LeuDH-AmDH variants 
with normalized ellipticity, representing the percentage of 
folded protein (Fraction Fold Protein vs. Temperature [0 C.]). 
FIG. 13 are schemes showing the enzymatic reactions 
driven by wild type PheDH and engineered PheDH-AmDH 
(B). 
FIG. 14 is a diagram showing a forward screening assay 
applied to PheDH library 1 for reductive amination activity of 
para-fluoro phenyl acetone in 500 mM NH4Cl/NH40H 
buffer pH 9.6, 200 µMNADHbased upon340 nmand600nm 
absorbance changes over multiple time points. 
FIG. 15 is a scatter plot showing the fraction of folded 
PheDH/AmDH as measured by circular dichroism spectros-
copy of wild type PheDH and top PheDH-AmDH variant, 
As used herein, a "LeuDH-AmDH" is a non-naturally 
occurring amine dehydrogenase based on a leucine dehydro-
50 genase scaffold. 
As used herein, a "PheDH-AmDH" is a non-naturally 
occurring amine dehydrogenase based on a phenylalanine 
dehydrogenase scaffold. 
As used herein, a "ValDH-AmDH" is a non-naturally 
55 occurring amine dehydrogenase based on a valine dehydro-
genase scaffold. 
The term "polypeptides" includes proteins and fragments 
thereof. Polypeptides are disclosed herein as amino acid resi-
due sequences. Those sequences are written left to right in the 
60 direction from the amino to the carboxy terminus. In accor-
dance with standard nomenclature, amino acid residue 
sequences are denominated by either a three letter or a single 
letter code as indicated as follows: Alanine (Ala, A), Arginine 
(Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cys-
65 teine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), 
Glycine (Gly, G), Histidine (His, H), Isoleucine (Ile, I), Leu-
cine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Pheny-
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!alanine (Phe, F), Praline (Pro, P), Serine (Ser, S), Tbreonine 
(Tbr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine 
(Val, V). 
The term "polypeptides" includes proteins and fragments 
thereof. Polypeptides are disclosed herein as amino acid resi- 5 
due sequences. Those sequences are written left to right in the 
direction from the amino to the carboxy terminus. In accor-
dance with standard nomenclature, amino acid residue 
sequences are denominated by either a three letter or a single 
letter code as indicated as follows: Alanine (Ala, A), Arginine 10 
(Arg, R), Asparagine (Asn, N), Aspartic Acid (Asp, D), Cys-
teine (Cys, C), Glutamine (Gin, Q), Glutamic Acid (Glu, E), 
Glycine (Gly, G), Histidine (His, H), Isoleucine (Ile, I), Leu-
cine (Leu, L), Lysine (Lys, K), Methionine (Met, M), Pheny- 15 
!alanine (Phe, F), Praline (Pro, P), Serine (Ser, S), Tbreonine 
(Tbr, T), Tryptophan (Trp, W), Tyrosine (Tyr, Y), and Valine 
(Val, V). 
As used herein, a "variant" polypeptide contains at least 
one amino acid sequence alterations as compared to the 20 
amino acid sequence of the corresponding wild-type or ref-
erence polypeptide. An amino acid sequence alteration can 
be, for example, a substitution, a deletion, or an insertion of 
one or more amino acids, or combinations thereof. 
A substituted or inserted amino acid residue may or may 25 
not be one encoded by the genetic code. A variant of a 
polypeptide may be naturally occurring such as an allelic 
variant, or it may be a variant that is not known to occur 
naturally. 
Modifications and changes can be made in the structure of 30 
the polypeptides disclosed and still obtain a molecule desired 
characteristics (e.g., a conservative amino acid substitution). 
For example, certain amino acids can be substituted for other 
amino acids in a sequence without appreciable loss of activity. 
Because it is the interactive capacity and nature of a polypep- 35 
tide that defines that polypeptide's biological functional 
activity, certain amino acid sequence substitutions can be 
made in a polypeptide sequence and nevertheless obtain a 
polypeptide with like properties. 
In making such changes, the hydropathic index of amino 40 
acids can be considered. The importance of the hydropathic 
amino acid index in conferring interactive biologic function 
6 
Substitution of like amino acids can also be made on the 
basis of hydrophilicity, particularly, where the biological 
functional equivalent polypeptide or peptide thereby created 
is intended for use in immunological embodiments. The fol-
lowing hydrophilicity values have been assigned to amino 
acid residues: arginine ( +3.0); lysine ( +3.0); aspartate 
(+3.0±1); glutamate (+3.0±1); serine (+0.3); asparagine 
( +0.2); glutamine ( +0.2); glycine (O); pro line (-0.5±1 ); threo-
nine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); 
methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine 
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan 
(-3.4). It is understood that an amino acid can be substituted 
for another having a similar hydrophilicity value and still 
obtain a biologically equivalent, and in particular, an immu-
nologically equivalent polypeptide. In such changes, the sub-
stitution of amino acids whose hydrophilicity values are 
within ±2 is preferred, those within ±1 are particularly pre-
ferred, and those within ±0.5 are even more particularly pre-
ferred. 
As outlined above, amino acid substitutions are generally 
based on the relative similarity of the amino acid side-chain 
substituents, for example, their hydrophobicity, hydrophilic-
ity, charge, size, and the like. Exemplary substitutions that 
take various of the foregoing characteristics into consider-
ation are well known to those of skill in the art and include 
(original residue: exemplary substitution): (Ala: Gly, Ser), 
(Arg: Lys), (Asn: Gin, His), (Asp: Glu, Cys, Ser), (Gin: Asn), 
(Glu: Asp), (Gly: Ala), (His: Asn, Gin), (Ile: Leu, Val), (Leu: 
Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Tbr), (Tbr: Ser), 
(Tip: Tyr), (Tyr: Trp, Phe), and (Val: Ile, Leu). Embodiments 
of this disclosure thus contemplate functional or biological 
equivalents of a polypeptide as set forth above. In particular, 
embodiments of the polypeptides can include variants having 
about 50%, 60%, 70%, 80%, 90%, and 95% sequence identity 
to the polypeptide of interest. 
"Identity," as known in the art, is a relationship between 
two or more polypeptide sequences, as determined by com-
paring the sequences. In the art, "identity" also means the 
degree of sequence relatedness between polypeptide as deter-
mined by the match between strings of such sequences. 
"Identity" can also mean the degree of sequence relatedness 
of a polypeptide compared to the full-length of a reference 
polypeptide. "Identity" and "similarity" can be readily calcu-
lated by known methods, including, but not limited to, those 
on a polypeptide is generally understood in the art. It is known 
that certain amino acids can be substituted for other amino 
acids having a similar hydropathic index or score and still 
result in a polypeptide with similar biological activity. Each 
amino acid has been assigned a hydropathic index on the basis 
of its hydrophobicity and charge characteristics. Those indi-
ces are: isoleucine ( +4.5); valine ( +4.2); leucine ( +3.8); phe-
nylalanine ( +2.8); cysteine/cysteine ( +2.5); methionine 
(+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); 
serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); praline 
(-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); 
aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and argin-
ine (-4.5). 
45 described in (Computational Molecular Biology, Lesk, A. M., 
Ed., Oxford University Press, New York, 1988; Biocomput-
ing: Informatics and Genome Projects, Smith, D. W., Ed., 
Academic Press, New York, 1993; Computer Analysis of 
Sequence Data, Part I, Griffin, A. M, and Griffin, H. G., Eds., 
It is believed that the relative hydropathic character of the 
amino acid determines the secondary structure of the result-
ant polypeptide, which in tum defines the interaction of the 
polypeptide with other molecules, such as enzymes, sub-
strates, receptors, antibodies, antigens, and the like. It is 
known in the art that an amino acid can be substituted by 
another amino acid having a similar hydropathic index and 
still obtain a functionally equivalent polypeptide. In such 
changes, the substitution of amino acids whose hydropathic 
indices are within ±2 is preferred, those within ±1 are par-
ticularly preferred, and those within ±0.5 are even more par-
ticularly preferred. 
50 Humana Press, New Jersey, 1994; Sequence Analysis in 
Molecular Biology, von Heinje, G., Academic Press, 1987; 
and Sequence Analysis Primer, Gribskov, M. and Devereux, 
J., Eds., M Stockton Press, New York, 1991; and Carillo, H., 
55 
and Lipman, D., SIAM J Applied Math., 48: 1073 (1988). 
Preferred methods to determine identity are designed to 
give the largest match between the sequences tested. Methods 
to determine identity and similarity are codified in publicly 
available computer programs. The percent identity between 
two sequences can be determined by using analysis software 
60 (i.e., Sequence Analysis Software Package of the Genetics 
Computer Group, Madison Wis.) that incorporates the 
Needelman and Wunsch, (J. Mo!. Biol., 48: 443-453, 1970) 
algorithm (e.g., NBLAST, and XBLAST). The default 
parameters are used to determine the identity for the polypep-
65 tides of the present disclosure. 
By way of example, a polypeptide sequence may be iden-
tical to the reference sequence, that is be 100% identical, or it 
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may include up to a certain integer number of amino acid 
alterations as compared to the reference sequence such that 
the% identity is less than 100%. Such alterations are selected 
from: at least one amino acid deletion, substitution, including 
conservative and non-conservative substitution, or insertion, 
and wherein said alterations may occur at the amino- or 
carboxy-terminal positions of the reference polypeptide 
sequence or anywhere between those terminal positions, 
interspersed either individually among the amino acids in the 
reference sequence or in one or more contiguous groups 10 
within the reference sequence. The number of amino acid 
alterations for a given% identity is determined by multiply-
ing the total number of amino acids in the reference polypep-
tide by the numerical percent of the respective percent iden-
tity (divided by 100) and then subtracting that product from 15 
said total number of amino acids in the reference polypeptide. 
some chemoenzymatic routes, particularly with transami-
nases (Koszelewski, et al., Trends in Biotechnology, 28, (6): 
324-332 (201 O); Stewart, Current Opinion in Chemical Biol-
ogy, 5, (2): 120-129 (2001); Taylor, et al., Trends in Biotech-
nology, 16, (10): 412-418 (1998); Truppo, et al., Chem 
Comm, 2009: 2127-2129 (2009); Tu:!Vesson, et al., Biotech-
nology and Bioengineering, 108, (7): 1479-1493 (2011)), 
have shown promise in the dynamic kinetic resolution of 
racemic amines (Truppo, et al., Chem Comm, 2009: 2127-
2129 (2009); Koszelewski, Advanced Synthesis & Catalysis, 
350, (17): 2761-2766. (2008); Pellissier, 2011, Tetrahedron, 
67, (21): 3769-3802 (2011)) and the direct asymmetric syn-
thesis of amines with w-transaminases ( w-TA), as used in the 
synthesis of sitagliptin (Koszelewski, et al., Angewandte Che-
mie International Edition, 47, ( 48): 9337-9340 (2008); Shin., 
et al., Biotechnology and Bioengineering, 65, (2): 206-211 
As used herein, the term "purified" and like terms relate to 
the isolation of a molecule or compound in a form that is 
substantially free (at least 60% free, preferably 7 5% free, and 
most preferably 90% free) from other components normally 20 
associated with the molecule or compound in a native envi-
ronment. 
(1999); Truppo, et al., Organic Process Research & Devel-
opment, 14, (1): 234-237 (2009). This process eliminated the 
use and removal of a less-selective rhodium catalyst, yet 
requires the use of a sacrificial amine source. The undesired 
ketone by-product must also be removed to shift the reaction 
equilibrium beyond about 50% conversion. 
As used herein the term "isolated" is meant to describe a 
compound of interest (e.g., nucleic acids, polypeptides, etc.) 
that is in an environment different from that in which the 25 
Non-naturally occurring amine dehydrogenases (AmDHs) 
also referred to as recombinant AmDH, and methods of use 
thereof are disclosed. The AmDHs are variants of amino acid 
dehydrogenases, or chimeric fusion proteins thereof. Instead compound naturally occurs, e.g., separated from its natural 
milieu such as by concentrating a peptide to a concentration at 
which it is not found in nature. "Isolated" is meant to include 
compounds that are within samples that are substantially 
enriched for the compound of interest and/or in which the 
compound of interest is partially or substantially purified. 
Isolated nucleic acids or polypeptides are at least 60% free, 
preferably 75% free, and most preferably 90% free from other 
associated components. 
As used herein, the terms "engineered" and "recombinant" 
cells are intended to refer to a cell into which an exogenous 
DNA segment or gene, such as a cDNA or gene has been 
introduced. Therefore, engineered cells are distinguishable 
from naturally occurring cells which do not contain a recom-
binantly introduced exogenous DNA segment or gene. Engi-
neered cells are thus cells having a gene or genes introduced 
through the hand of man. 
As used herein, "chiral" refers to a molecule that has a 
non-superposable mirror image. The feature that is most often 
the cause of chirality in molecules is the presence of an 
asymmetric carbon atom. 
As used herein, "enantiomer" refers to one of two stereoi-
somers that are mirror images of each other that are non-
superposable (not identical). 
As used herein, "enantiomeric excess" or "e.e." refers to 
the absolute difference between the mole fraction of each 
enantiomer. 
II. Recombinant Amine Dehydrogenases 
Biocatalysts are increasingly prevalent in the large-scale 
synthesis of enantiomerically pure compounds (EPCs ), 
which are mainly used as active pharmaceutical ingredients 
(APis). Enantiomerically pure forms can lead to lower dos-
ages and improved efficacy. However, many sought-after 
reactions lack a suitable enzymatic production route. 
Although chiral amines can be produced both chemically 
and enzymatically, the large-scale production of chiral 
amines is still challenging and heavily reliant on traditional 
methods of chemical synthesis. Common methods include 
resolution though fractional crystallization and the hydroge-
nation of C=N bonds, particularly in enamines. Nonetheless, 
of the wild-type a-keto acid, the amine dehydrogenases 
accept the analogous ketone, methyl isobutyl ketone (MIBK), 
which corresponds to replacement of the carboxyl moiety 
30 with a methyl group (FIG. 2). The amino dehydrogenases can 
be used without a rhodium catalyst and do not require the 
removal of ketone by-product. When paired with a cofactor 
recycling system, such as glucose/glucose dehydrogenase 
(GDH) or formate/formate dehydrogenase (FDH), the 
35 recombinant amine dehydrogenases allow for the direct pro-
duction of chiral amines, with the consumption of only an 
inexpensive reducing agent, such as glucose or formate, and 
free ammonia (FIG. 1). 
As discussed in more detail below, the disclosed recombi-
40 nant amine dehydrogenases are based on an amino acid dehy-
drogenase scaffold. Therefore, the amine dehydrogenases are 
variants of the amino acid dehydrogenase scaffold. The vari-
ant typically has one or more alterations in amino acid 
sequence compared to the reference sequence. The amino 
45 acid alterations include, without limitation, insertions, sub-
stitutions, and deletions. 
An amine dehydrogenase can have any combination of 
amino acid substitutions, deletions or insertions. In one 
embodiment, the AmD H has an integer number of amino acid 
50 alterations such that its amino acid sequence shares at least 
60, 70, 80, 85, 90, 95, 97, 98, 99, or 99.5% identity with an 
amino acid sequence of a reference or scaffold sequence. 
Amino acid substitutions in anAmDH may be conservative 
or non-conservative substitutions. It is understood that sub-
55 stitutions at the recited amino acid positions can be made 
using any amino acid or amino acid analog. For example, the 
substitutions at the recited positions can be made with any of 
the naturally-occurring amino acids (e.g., alanine, aspartic 
acid, asparagine, arginine, cysteine, glycine, glutamic acid, 
60 glutamine, histidine, leucine, valine, isoleucine, lysine, 
methionine, praline, threonine, serine, phenylalanine, tryp-
tophan, or tyrosine). 
While the substitutions described herein are with respect 
specific amino acid dehydrogenase scaffolds, it is noted that 
65 one of ordinary skill in the art could readily make equivalent 
alterations in the corresponding polypeptides from other spe-
cies, for example by sequence alignment. 
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The disclosedAmDHs exhibit amine dehydrogenase activ-
ity, however, it will be appreciated that differentAmDHs will 
have different amine dehydrogenase activities, and poten-
tially different specificities and activity toward various sub-
strate ketones. Methods of determining amine dehydrogenase 5 
activity, and methods for screening for active AmDH in a 
AmDH library are discussed in more detail below. The 
AmDH can also be characterized by substrate specificity, 
enantioselectivity, rate of conversion, and theromstability. In 
some embodiments the AmDH has an enantioselectivity of 10 
50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or greater than 99% 
(enantiomeric excess). In some embodiments theAmDH has 
a conversion of substrate to product of 50, 60, 70, 80, 90, 95, 
97, 98, 99, or greater than 99%. In some embodiments, the 
AmDH can convert 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 15 
greater than 99% of substrate to product in 10 or fewer days, 
preferable 5 or fewer days, more preferably 3 or fewer days, 
most preferably 2 or fewer days. In preferred embodiment the 
AmDH has both an enantioselectivity (enantiomeric excess) 
and a conversion of 50, 60, 70, 80, 90, 95, 96, 97, 98, 99, or 20 
greater than 99% in 10 or fewer days, preferable 5 or fewer 
days, more preferably 3 or fewer days, most preferably 2 or 
fewer days. Thermostabiliy can be determined based on, for 
example, melting temperature, temperature verse activity 
profile, or a combination thereof. Preferably, the enzyme is 25 
both stable (i.e., folded) and active at temperatures of 10, 20, 
30, 40, 45, 50, 55, 60, 65, 70, 80, 85° C., or greater. 
Active fragments are of the AmDHs are also disclosed. 
Fragments of a full-length enzyme can retain functional activ-
ity of the enzyme. Functionally active fragments of the dis- 30 
closed AmDHs typically retain amine dehydrogenase activ-
ity. The fragment can be less the 50, 50, 60, 70, 80, 85, 90, 95, 
97, 98, 99, or99.5% ofthelengthofthefull-lengthAmDH, or 
10 
FGGGKAVIIGDPQKDKSPELFRAF 
VLY-
GQFVDSLGGRFYTGTDMGTNMEDFI-
HAMKETNCIVGVPEAYGGGGDSSIPTAMG 
GIKATNKMLFGKDDLG-
GVTYAIQGLGKVGYKVAEGLLEEGAHLFVTDINEQ 
TLEAIQEKAKTTSGSVTVVAS-
DEIYSQEADVFVPCAFGGVVNDETMKQFKVKAI 
AGSANNQLLTEDHGRHLADKGILYAP-
DYIVNSGGLIQVADELYEVNKERVLAKT KHIYDAI-
LEVYQQAELDQITTMEAANRMCEQR-
MAARGRRNSFFTSSVKPKWDIR N 
(SEQ ID NO: 1, PheDH from Bacillus badius). Therefore, a 
PheDH-AmDHcan bea variant of SEQ IDNO:l with one or 
more insertions, deletions, or substitutions relative to SEQ ID 
NO: 1, that has amine dehydrogenase activity. 
In some embodiments the PheDH-AmDH is a variant of a 
PheDH such as SEQ ID NO:l that contains a substitution of 
the lysine at position 77, substitution of the threonine at 
position 123, a substitution of the asparagine at position 276, 
or a combination thereof. In some embodiments, a recombi-
nant Phe-AmDH amine dehydrogenase includes and amino 
acid sequence having at least 75%, 80%, 85%, 90%, 95%, 
96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1, 
wherein the lysine at position 77 of SEQ ID NO: 1 is substi-
tuted with an alternative amino acid including, but not limited 
to, a methionine, a serine, or a tryptophan, and the asparagine 
at position 27 6 of SEQ ID NO: 1 is substituted with an alter-
native amino acid including but, not limited to, a valine, a 
leucine, or a glutamic acid. For example, the PheDH-AmDH 
can be a variant ofa PheDH, for example a variant of SEQ ID 
NO:l, that contains a K77M substitution, a K77S substitu-
tion, or a K77W substitution. The PheDH-AmDH can be a 
variant of a PheDH, for example a variant of SEQ ID NO: 1, 
that contains a N276V substitution, a N276L substitution, or its full-length reference or scaffold amino acid dehydroge-
nase. 35 a N276E substitution. 
Amino acid sequences for exemplary AmDH and domains 
and chimeras thereof are provided below. The exemplary 
sequences can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more 
additional amino acids on the N-terminus or C-terminus. For 
example, the amino acid sequences fortheAmDH, and N-ter- 40 
minal fragments and chimeras thereof are provided without 
an N-terminal methionine. Therefore, in some embodiments 
the disclosed amino acid sequences include an N-terminal 
methionine. The amino acid sequences can also include addi-
tional sequences to enhance expression or purification of 45 
expressed protein. For example, the amino acid sequences 
can optional include a leader sequence to enhance secretion, 
In one preferred embodiment, the PheDH-AmDH is vari-
ant of SEQ ID NO: 1 with a K77S substitution in combination 
with a N276L substitution (also referred to as a "K77S/ 
N276L" variant). 
Therefore, a K 77S/N27 6L AmD H can have the amino acid 
sequence SLVEKTSIIKDFTLFEKMSEHEQV-
VFCNDPATGLRAIIAIHDTTLGPALGGCRM QPYNS-
VEEALEDALRLSKGMTYSCAASDVD-
FGGGKAVIIGDPQKDKSPELFRAF 
GQFVDSLGGRFYTGTDMGTNMEDFI-
HAMKETNCIVGVPEAYGGGGDSSIPTAMG VLY-
GIKATNKMLFGKDDLG-
GVTYAIQGLGKVGYKVAEGLLEEGAHLFVTDINEQ 
TLEAIQEKAKTTSGSVTVVAS-
or a purification tag to facilitate purification. The additional 
sequences can be added to the N-terminal or C-terminal end 
of the amino acid sequences provided below. 
A. PheDH-AmDH 
50 DEIYSQEADVFVPCAFGGVVNDETMKQFKVKAI 
AGSANLQLLTEDHGRHLADKGILYAP-
In some embodiments, the AmDH is engineered using a 
phenylalanine dehydrogenase (PheDH) backbone or scaf-
fold, referred to as a PheDH-AmDH and F-AmDH. The 
PheDH-AmDH is typically a modified version of a reference 55 
PheDH and has amine dehydrogenase activity. A reference 
PheDH typically has phenylalanine dehydrogenase activity, 
but little or no amine dehydrogenase activity. The reference 
PheDH can be a naturally occurring, or non-naturally occur-
ring PheDH. In some embodiments, the phenylalanine dehy- 60 
drogenase activity of the PheDH-AmDH is reduced or absent 
compared to a reference PheDH. 
In some embodiments, the reference PheD H has the amino 
acid sequence: 
DYIVNSGGLIQVADELYEVNKERVLAKT KHIYDAI-
LEVYQQAELDQITTMEAANRMCEQR-
MAARGRRNSFFTSSVKPKWDIR N 
(SEQ ID N0:2), or a variant thereof with 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:2), a serine at position 77, a leucine at position 276, 
and amine dehydrogenase activity. 
In an alternative embodiment, the PheD H-AmD H is a vari-
ant of SEQ ID NO: 1 with a K77W substitution in combina-
tion with a N276E substitution (also referred to as a "K77W/ 
N276E" variant). Mutations relative to SEQ ID NO:l are 
shown in bold. 
Therefore, the K77W /N276E AmDH can have the amino 
SLVEKTSIIKDFTLFEKMSEHEQV- 65 acid sequence SLVEKTSIIKDFTLFEKMSEHEQV-
VFCNDPATGLRAIIAIHDTTLGPALGGCRM QPYNS- VFCNDPATGLRAIIAIHDTTLGPALGGCRM QPYNS-
VEEALEDALRLSKGMTYKCAASDVD- VEEALEDALRLSKGMTYWCAASDVD-
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FGGGKAVIIGDPQKDKSPELFRAF 
AMGVLY-
GQFVDSLGGRFYTGTDMGTNMEDFI-
HAMKETNCIVGVPEAYGGGGDSSIPT 
GIKATNKMLFGKDDLG-
GVTYAIQGLGKVGYKVAEGLLEEGAHLFVTDI 
NEQTLEAIQEKAKTTSGSVTVVAS-
DEIYSQEADVFVPCAFGGVVNDETMKQFKV KAIAG-
SANEQLLTEDHGRHLADKGILYAP-
DYIVNSGGLIQVADELYEVNKERVL 
AKTKHIYDAILEVYQQAELDQITT-
MEAANRMCEQRMAARGRRNSFFTSSVKPKW DIRN 
(SEQ ID N0:3), or a variant thereof with 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:3, a tryptophan at position 77, a glutamic acid at 
position 276, and amine dehydrogenase activity. Mutations 
relative to SEQ ID NO: 1 are shown in bold. 
12 
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
SLEGKVVAVQGVGNVAYHLCRHLHEE-
GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-
5 INDQTIPQLKAKVIAGSADNQLKEPR HGDMIHEM-
GIVYAPDYVINAGGVINVADELYGYNR-
ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR (SEQ ID N0:4, LeuDH from 
10 Bacillus stearothermophilus). Therefore, a LeuDH-AmDH 
can be a variant of SEQ ID N0:4 with one or more insertions, 
deletions, or substitutions relative to SEQ ID N0:4, that has 
amine dehydrogenase activity. 
In some embodiments the LeuDH-AmDH is a variant of a 
15 LeuDH such as SEQ ID N0:4 that contains a substitution of 
the lysine at position 67, substitution of the glutamic acid at 
position 113, a substitution of the asparagine at position 261, 
a substitution of the valine at position 290, or a combination 
thereof. For example, the LeuDH-AmDH can be a variant of 
Sekimoto et al., J. Biol. Chem., 36:27039-27045 (1993) 
reported that residues Lys79andAspl14 ofleucine dehydro-
genase from Bacillus stereothermophilus (SEQ ID N0:4) are 
needed for the enzyme's catalytic mechanism. These residues 
correspond to residues Lys89 and Asp124 of PheDH from 
Bacillus badius, therefore in some embodiments, the Lys89, 
the Asp 124, or a combination thereof are not mutated. 
Accordingly, in some embodiments, the PheDH-AmDH dis-
closed herein are variants of SEQ ID NO: 1, 2, or 3 that have 25 
a lysine at position 89, an aspartic acid at position 124, or a 
combination thereof. 
20 a LeuDH, for example a variant of SEQ ID N0:4, that con-
tains a K67M substitution or a K67S substitution. The 
LeuDH-AmDH can be a variant of a LeuDH, for example a 
variant of SEQ ID N0:4, that contains a E113V substitution. 
TheLeuDH-AmDH can be a variantofa LeuDH, for example 
a variant of SEQ ID N0:4), that contains a N261C substitu-
tion, a N261V substitution, or a N261L substitution. The 
LeuDH-AmDH can be a variant of a LeuDH, for example a 
variant of SEQ ID N0:4, that contains a V290C substitution. Phe-DH from Bacillus sphaericus, Rhodococcus sp. M4, 
and Sporosarcina ureae, are related by sequence identity and 
similarity to the Phe-DH Bacillus badius Bachelor (SEQ ID 
NO: 1 ), and have well characterized activities and substrate 
profiles present in literature (Brunhuber, et al., Biochemistry, 
39, (31): 9174-9187 (2000);Asano, et al.,Journal of Biologi-
cal Chemistry, 262, (21): 10346-54 (1987); Asano, et., al., 
European Journal of Biochemistry, 168, (1): 153-159 (1987); 
Cooper., et al., Analytical Biochemistry, 183, (2): 210-214 
(1989); Hummel, et al., Applied Microbiology and Biotech-
nology, 26, (5): 409-416 (1987); Seah., et al, FEES Letters, 
370, (12): 93-96 (1995). Therefore, in some embodiments, 
the scaffold of a PheDH-AmDH is the PheDH of Bacillus 
sphaericus, Rhodococcus sp. M4, or Sporosarcina ureae. 
Amino acid sequence for the PheDH of Bacillus sphaericus, 
Rhodococcus sp. M4, or Sporosarcina ureae are known in the 
art, the residues in the PheDH of Bacillus sphaericus, Rhodo-
coccus sp. M4, or Sporosarcina ureae corresponding to K77 
and N276 PheDH in Bacillus badius (SEQ ID NO:l), can be 
identified by sequence alignment and altered using the muta-
tional strategies disclosed herein, particularly those discussed 
above with respect to SEQ ID N0:2 and SEQ ID N0:3. 
B. LeuDH-AmDH 
In some embodiments, the AmDH is engineered from a 
leucine dehydrogenase (PheDH) scaffold, referred to as a 
LeuDH-AmDH and L-AmDH. The LeuDH-AmDH is typi-
cally a variant of a reference LeuDH and has amine dehydro-
genase activity. A reference LeuDH typically has leucine 
dehydrogenase activity, but little or no amine dehydrogenase 
activity. The reference LeuDH can be a naturally occurring, 
or non-naturally occurring LeuDH. In some embodiments, 
the phenylalanine dehydrogenase activity of the LeuDH-
AmDH is reduced or absent compared to a reference LeuDH. 
In some embodiments, the reference LeuDH has the amino 
acid sequence: 
ELFQYMEKYDYEQVLFCQDKESGLKAI-
IVIHDTTLGPALGGTRMWMYNSEEEAL 
LARGMTYKNAAAGLNLGGGKTVIIGD-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAEDVGTTVADMDIIYQETDYVT-
EDALR-
In some embodiments, the LeuDH-based amine dehydro-
30 genase includes an amino acid sequence having at least 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
identity to SEQ ID N0:4, wherein the lysine at position 67 of 
SEQ ID N0:4 is substituted with an alternative amino acid 
including, but not limited to, a methionine or a serine, and the 
35 glutamic acid at position 113 of SEQ ID N0:4 is substituted 
with an alternative amino acid, including, but not limited to a 
valine. In some embodiments, the LeuD H-based amine dehy-
drogenase the asparagine at position 261 of SEQ ID N0:4 is 
substituted with an alternative amino acid, including, but not 
40 limited to, a valine, a leucine, or a cysteine. In some embodi-
ments, the LeuDH-based amine dehydrogenase the valine at 
position 290 of SEQ ID N0:4 is substituted with an alterna-
tive amino acid including, but not limited to, a cysteine. 
In one preferred embodiment, the LeuD H-AmD H is a vari-
45 ant of SEQ ID N0:4 with a K67M substitution in combination 
with a El 13V substitution (also referred to as a "K67M/ 
El 13V" variant). 
Therefore, a K67M/E113V AmDH can have the amino 
acid sequence ELFQYMEKYDYEQVLFCQDKESGLKAI-
50 IVIHDTTLGPALGGTRMWMYNSEEEAL EDALR-
LARGMTYMNAAAGLNLGGGKTVIIGD-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAVDVGTTVADMDIIYQETDYVT-
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
55 SLEGKVVAVQGVGNVAYHLCRHLHEE-
GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-
INDQTIPQLKAKVIAGSADNQLKEPR HGDMIHEM-
GIVYAPDYVINAGGVINVADELYGYNR-
60 ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR (SEQ ID N0:5), or a variant 
thereof with 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 
99% sequence identity to SEQ ID N0:5, a methionine at 
65 position 67, a valine at position 113, and amine dehydroge-
nase activity. Mutations relative to SEQ ID N0:4 are shown in 
bold. 
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In some embodiments, the K67M/E113V AmDH also 
includes a substitution at position 261, position 290, or a 
combination thereof. 
For example, the variant can be a K67M/E113V/N261V 
AmDH with the amino acid sequence 
EDALR-
ELFQYMEKYDYEQVLFCQDKESGLKAI-
IVIHDTTLGPALGGTRMWMYNSEEEAL 
LARGMTYMNAAAGLNLGGGKTVIIGD-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAVDVGTTVADMDIIYQETDYVT-
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
SLEGKVVAVQGVGNVAYHLCRHLHEE-
GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-
14 
Alternatively, the variant can be a K67M/El 13V/N261C/ 
V290C AmDH with the amino acid sequence 
ELFQYMEKYDYEQVLFCQDKESGLKAI-
IVIHDTTLGPALGGTRMWMYNSEEEAL 
5 LARGMTYMNAAAGLNLGGGKTVIIGD-
EDALR-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAVDVGTTVADMDIIYQETDYVT-
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
SLEGKVVAVQGVGNVAYHLCRHLHEE-
lO GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-
INDQTIPQLKAKVIAGSADCQLKEPR HGDMIHEM-
INDQTIPQLKAKVIAGSADVQLKEPR HGDMIHEM- 15 
GIVYAPDYVINAGGCINVADELYGYNR-
ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR 
GIVYAPDYVINAGGVINVADELYGYNR-
ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR (SEQ ID N0:6), or a variant 
thereof with 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 20 
99% sequence identity to SEQ ID N0:6, a methionine at 
position 67, a valine at position 113, a valine at position 261 
and amine dehydrogenase activity. Mutations relative to SEQ 
(SEQ ID N0:9), or a variant thereof with 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:9, a methionine at position 67, a valine at position 113, 
a cysteine at position 261, and cysteine at position 290 and 
amine dehydrogenase activity. Mutations relative to SEQ ID 
N0:4 are shown in bold. 
ID N0:4 are shown in bold. 
Alternatively, the variant can be a K67M/E113V/N261C 
AmDH with the amino acid sequence 
EDALR-
ELFQYMEKYDYEQVLFCQDKESGLKAI-
IVIHDTTLGPALGGTRMWMYNSEEEAL 
LARGMTYMNAAAGLNLGGGKTVIIGD-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAVDVGTTVADMDIIYQETDYVT-
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
SLEGKVVAVQGVGNVAYHLCRHLHEE-
GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-
INDQTIPQLKAKVIAGSADCQLKEPR HGDMIHEM-
In some embodiments, the alteration at position 67 is sub-
25 stitution oflysine for serine. For example, a LeuDH-AmDH 
can be a be a LeuDH variant with K67S substitution such as 
in the K67S/E113V/N261L/V290C AmDH with the amino 
acid sequence 
ELFQYMEKYDYEQVLFCQDKESGLKAI-
EDALR-30 IVIHDTTLGPALGGTRMWMYNSEEEAL 
LARGSTYMNAAAGLNLGGGKTVIIGD-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAVDVGTTVADMDIIYQETDYVT-
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
35 SLEGKVVAVQGVGNVAYHLCRHLHEE-
GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-GIVYAPDYVINAGGVINVADELYGYNR-
ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR (SEQ ID N0:7), or a variant 40 
thereof with 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 
99% sequence identity to SEQ ID N0:7, a methionine at 
position 67, a valineatposition 113, a cysteine atposition261 
and amine dehydrogenase activity. Mutations relative to SEQ 
INDQTIPQLKAKVIAGSADLQLKEPR HGDMIHEM-
GIVYAPDYVINAGGCINVADELYGYNR-
ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR 
(SEQ ID NO:lO), or a variant thereof with 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:4 are shown in bold. 
The variant can beaK67M/El 13V/N261 V/V290CAmDH 
with the amino acid sequence 
EDALR-
ELFQYMEKYDYEQVLFCQDKESGLKAI-
IVIHDTTLGPALGGTRMWMYNSEEEAL 
LARGMTYMNAAAGLNLGGGKTVIIGD-
PRKDKNEAMFRAFGRFIQGLNGR 
YITAVDVGTTVADMDIIYQETDYVT-
GISPEFGSSGNPSPATAYGVYRGMKA AAKEAFGSD-
SLEGKVVAVQGVGNVAYHLCRHLHEE-
GAKLIVTDINKEAVARAVE 
EFGAKAVDPNDIYGVECDIFAPCALGGI-
INDQTIPQLKAKVIAGSADVQLKEPR HGDMIHEM-
GIVYAPDYVINAGGCINVADELYGYNR-
ERAMKKIEQIYDNIEKVFA 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR 
(SEQ ID N0:8), or a variant thereof with 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:8, a methionine at position 67, a valine at position 113, 
45 ID NO:lO, a serine at position 67, a valine at position 113, a 
leucine at position 261, a cysteine at position 290, and amine 
dehydrogenase activity. Mutations relative to SEQ ID N0:4 
are shown in bold. 
In some embodiments, the aspartic acid at position 260 of 
50 SEQ ID N0:4 is a substituted with an alternative amino acid, 
including, but not limited to, an leucine. Therefore, a LeuDH-
AmDH has an amino acid sequence of SEQ ID N0:4, 5, 6, 7, 
8, 9, or 10, or functional fragment or variant thereof, with the 
aspartic acid at position 260 is substituted with an alternative 
55 amino acid. In some embodiments, the alternative amino acid 
is a leucine. 
For example, in some embodiments, the C-terminal 227 
amino acids of SEQ ID N0:4, 5, 6, 7, 8, 9, or 10, or functional 
fragment or variant thereof, is substituted with 
60 GSSGNPSPATAYGVYRGMKAAAKEAFGS-
DSLEGKVVAVQGVGNVAYHLCRHLHE EGAKLIVT-
DINKEAVARAVEEFGAKAVDPNDIYGV-
ECDIFAPCALGGIINDQTI 
a valine at position 261, a cysteine at position 290 and amine 65 
dehydrogenase activity. Mutations relative to SEQ ID N0:4 
are shown in bold. 
PQLKAKVIAGSALNQLKEPRHGDMIHEM-
GIVYAPDYVINAGGCINVADELYGYN RERAMKKIE-
QIYDNIEKVFAIAKRDNIPTY-
VAADRMAEERIETMRKARSQFLQN GHHILSRRRAR 
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(SEQ ID NO: 17), which contains a D260L substitution rela-
tive to the corresponding 227 C-terminal amino acids of SEQ 
ID N0:4. The mutation relative to SEQ ID N0:4 are shown in 
bold. 
In some embodiments, the amino acid of the LeuDH- 5 
AmDH at position 260 is an asparagine. 
Sekimoto et al., J. Biol. Chem., 36:27039-27045 (1993) 
reported that residues Lys79andAspl14 ofleucine dehydro-
genase from Bacillus stereothermophilus (SEQ ID N0:4) are 
needed for the enzyme's catalytic mechanism. Therefore in 10 
some embodiments, the Lys79, theAspl 14, or a combination 
thereof are not mutated. Accordingly, in some embodiments, 
the LeuDH-AmDH disclosed herein are variants of SEQ ID 
N0:4, 5, 6, 7, 8, 9, or 10, have lysine at position 79, aspartic 15 
acid at position 114, or a combination thereof. 
C. Alternative Scaffolds 
16 
Accordingly, in some embodiments the scaffold is a 
GluDH, or more preferably a Va!DH scaffold. 
Three exemplary ValDH scaffolds are from the Streptomy-
ces genus ofActinobacteria: Streptomyces coelicolor (Navar-
rete, et al., Journal of General Microbiology, 136, (2): 273-
281 (1990); Tang, et al., Journal of Bacteriology, 175, (13): 
417 6-4185 (1993 ); Turnbull, et al., Journal of Biological 
Chemistry, 272, ( 40): 25105-25111 (1997)), Streptomyces 
fradiae (Nguyen, et al., Microbiology, 141, (5): 1139-1145 
(1995); Tang, et al.,Journal of Bacteriology, 176, (19): 6107-
6119 (1994); Vancura, et al., Journal of General Microbiol-
ogy, 134, (12): 3213-3219 (1998)), and Streptomyces cinna-
monensis (Turnbull, et al., Journal of Biological Chemistry, 
272, (40): 25105-25111 (1997); Leiser, et al., Gene, 177, 
(12): 217-222 (1996); Priestley, et al., The Biochemical Jour-
nal, 261, (3): 853-861 (1989)). A resulting Va!DH-based 
AmDH (ValDH-AmDH) would convert 2-methyl-3-bu-
tanone to chiral 1,2-dimethylpropylamine (FIG. 19). 
For example, the ValDH scaffold can have the amino acid 
Leucine dehydrogenase from Bacillus stearothermophilus 
(SEQ ID N0:4), the scaffold of the LeuDH-AmDH disclosed 
above, belongs to the Glu-Leu-Phe-Val dehydrogenase sub-
family (NCBI Accession number: cd05211) of proteins. 
Other members of this family of enzymes can be used as 
scaffolds for the variant amino acid dehydrogenases with 
amine dehydrogenase activity disclosed herein. 
20 sequence TEADNGVLHTLFHSDQGGHEQVVLCQ-
DRASGLKAVIAIHSTALGPALGGTRFYP YATEEEAV-
ADVLNLSRGMSYKNAMAGLDHGGGKAVI-
IGDPEQIKSEDLLLAFGR 
FVASLGGRYVTACDVGTYVADMDVVARE-
The enzymes of this family are closely related in structure 
and function. Each enzyme similarly catalyzes the reversible 
amination and deamination of their respective keto- and 
amino acids with free ammonia, and is facilitated by the 
hydride transfer of an NAD(P)H cofactor. These enzymes 
consist of two domains separated by a deep cleft. One domain 
25 CRWTTGRSPENGGAGDSSVLTAF GVFQGMRASAE-
HLWGDPSLRGRKVGVAGVGKVGHHLVE-
HLLEDGADVVITDVRE 
ESVNRSTHKHPSVTAVADTEALIRTEG-
LDIYAPCALGGALDDDSVPVLTAKVVC GAAN-
30 NQLAHPGVEKDLADRSILYAPDYVVNAG-
GVIQVADELRGFDFDRCKAKAS 
KIFDTTLAIFARAKEDGIPPAAAADRIAEQRMSDAR 
(SEQ ID NO: 11, Va!DH from Streptomyces cinnamonensis). 
is responsible for binding the substrate and contains residues 
involved in catalysis (Brunhuber, et. Al., Critical Reviews in 
Biochemistry and Molecular Biology, 29, (6): 415-467 
(1984); Kataoka, et al., Journal of Biochemistry, 116, (4): 
931-936 (1994)). The other domain is responsible for binding 35 
the cofactor containing a characteristic ~a~ structure, known 
as the Rossmann fold, and is highly conserved among these 
dehydrogenases (Liu, et al., Nat Struct Mal Biol, 4, (4): 317-
326 (1997). This conserved structure and functionality makes 
the Glu-Leu-Phe-Val dehydrogenase sub-family part of the 40 
larger domain superfamily NADB_Rossmann (Accession 
number: cl09931); identifiable through the NCBI's Con-
served Domain Database (Marchler-Bauer, et al., Nucleic 
Acids Research, 2010). 
The Examples below show that K67 substitution (i.e., 45 
K67M or K67S) and N261 substitution (i.e, N261V, N261C, 
or N261L) (LeuDH nomenclature and equivalent PheDH 
residues) are important for amination activity. The mutation 
of these residues is believed to be broadly applicable across 
the Glu-Leu-Phe-Val dehydrogenase sub-family of enzymes. 50 
The Glu-Leu-Phe-Val dehydrogenase sub-family (NCBI 
Accession number: cd05211) contains a large number of 
characterized proteins which are further divided into smaller 
sub-families. The B. stearothermophilus LeuDH, Rhodococ-
cus sp. M4 PheDH and B. badius PheDH all exist within this 55 
large sub-family, and are even further grouped in a smaller 
sub-family NAD_bind_Leu_Phe_ Val_DH (Accession num-
ber: cd01075). This smaller sub-family grouping is a result of 
their highly conserved binding motifs of the NADH cofactor. 
Glutamate dehydrogenases (GluDH) are not a part of this 60 
smaller family, but are grouped into two separate GluDH 
subfamilies (Accession number: cd01076 and cd05313) 
within the greater Glu-Leu-Phe-Val dehydrogenase sub-fam-
ily. Consequently, Va!DH exhibits a much higher sequence 
identity to PheD H and LeuD H (typically greater than 60% ), 65 
and GluDHs are more distant relatives (typically near 30% 
identity). 
A ValDH-AmDH can be a variant ofValDH from S. cin-
namonensis, having a substitution of the lysine at position 75, 
substitution of the asparagine at position 272, or a combina-
tion thereof. In some embodiments, a ValDH-based amine 
dehydrogenase includes an amino acid sequence having 7 5%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence 
identity to SEQ ID NO:l 1, wherein the lysine at position 75 
of SEQ ID NO: 11 is substituted with an alternative amino 
acid including, but not limited to, a methionine or a serine and 
the asparagine at position 272 of SEQ ID NO: 11 is substituted 
with an alternative amino acid including, but not limited to, a 
valine, a leucine, or a cysteine. In some embodiments, the 
variant has a K75S or a K75M substitution; a N272V, a 
N272C, or a N272L substitution; or a combination thereof. 
For example, the ValDH-AmDH is a K75S/N272L variant 
with the amino acid sequence 
TEADNGVLHTLFHSDQGGHEQVVLCQ-
DRASGLKAVIAIHSTALGPALGGTRFYP YATEEEAV-
ADVLNLSRGMSYSNAMAGLDHGGGKAVI-
IGDPEQIKSEDLLLAFGR 
FVASLGGRYVTACDVGTYVADMDVVARE-
CRWTTGRSPENGGAGDSSVLTAFGVF QGMRASAE-
HLWGDPSLRGRKVGVAGVGKVGHHLVE-
HLLEDGADVVITDVREESV 
NRSTHKHPSVTAVADTEALIRTEG-
LDIYAPCALGGALDDDSVPVLTAKVVCGAA 
NLQLAHPGVEKDLADRSILYAPDYV-
VNAGGVIQVADELRGFDFDRCKAKASKIF DTTLAI-
FARAKEDGIPPAAAADRIAEQRMSDAR 
(SEQ ID N0:12), or a variant thereof with 75%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:12, a serine at position 75, leucine atposition272, and 
amine dehydrogenase activity. Mutations relative to SEQ ID 
NO: 11 are shown in bold. 
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D. Chimeric Amine Dehydrogenases 
The AmDH can be a chimeric amine dehydrogenase that 
includes at least one domain derived from at least two differ-
ent amino acid dehydrogenase scaffolds. The AmDH dis-
closed herein can be characterized as having at least two 5 
functional domains, a substrate binding domain (i.e., a ketone 
binding domain) and a co-factor binding (i.e., NADH) 
domain. Therefore, in some embodiments, the chimeric 
AmDH is a fusion protein that includes a substrate binding 
domain from a first AmDH and a cofactor binding domain 10 
from a secondAmDH. 
Fusion proteins disclosed herein can have the formula I: 
N-R1-R2-R3---{: 
18 
wildtype amino acid dehydrogenase scaffold (for example, 
SEQ ID NO: 1 (PheDH), SEQ ID N0:4 (LeuDH), or SEQ ID 
NO:ll (Va!DH)). 
a. Exemplary PheDH-AmDH Domains 
The substrate binding domain of a PheDH-AmDH can be 
the N-terminal 149 amino acids of a PheDH-AmDH, or a 
functional fragment or variant thereof. Therefore, in some 
embodiments, the substrate binding domain of a PheDH-
AmDH includes the N-terminal 149 amino acids of SEQ ID 
N0:2 or SEQ ID N0:3, or is a functional fragment or variant 
thereof. 
For example, the substrate binding domain of a PheDH-
AmDH can be SLVEKTSIIKDFTLFEKMSEHEQV-
15 VFCNDPATGLRAIIAIHDTTLGPALGGCRM QPYNS-wherein "N" represents the N-terminus of the fusion protein, 
"C" represents the C-terminus of the fusion protein, "Ri'' is a 
substrate binding domain from a first AmDH, "R2 " is an 
optional peptide/polypeptide linker domain, and "R3 " is a 
co-factor binding domain from a second AmDH. Alterna-
tively, R3 can be the substrate binding domain from a first 20 
AmDH and R1 can be the co-factor binding domain from a 
secondAmDH. 
VEEALEDALRLSKGMTYSCAASDVDFGGGKAVIIGD 
PQKDKSPELFRAF GQFVDSLGGRFYTGTDMGT-
NMEDFIHAMKETNCIVGVPEAY 
(SEQ ID NO: 13 ), or a functional fragment or variant thereof. 
The co-factor binding domain of a PheDH-AmDH can be 
the C-terminal 230 amino acids of a PheDH-AmDH, or a 
functional fragment or variant thereof. Therefore, in some 
embodiments, the substrate binding domain of a PheDH-
AmDH includes the C-terminal 230 amino acids of SEQ ID 
In some embodiments, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 
more than 90% of the fusion protein is derived from the first 
AmDH and the remainder of the fusion protein is derived 
from the second AmDH alone, or in combination with an 
option linker, orother domain(s) such as a purification tag that 
are not derived from the first or second AmDH. In some 
embodiments, 10, 20, 30, 40, 50, 60, 70, 80, 90, or more than 
90% of the fusion protein is derived from the secondAmDH 
and the remainder of the fusion protein is derived from the 
first AmDH alone, or in combination with an optional linker, 
25 N0:2 or SEQ ID N0:3, or is a functional fragment or variant 
thereof. 
For example, the cofactor binding domain of a PheDH-
AmDH can be GGGGDSSIPTAMGVLYGIKATNKMLF-
GKDDLGGVTYAIQGLGKVGYKVAEGLLE EGAHL-
or other domain(s) such as a purification tag that are not 
derived from the first or secondAmDH. 
30 FVTDINEQTLEAIQEKAKTTSGSVTVVASDEIYSQEA 
DVFVPCAFGGVV NDETMKQFKVKAIAGSANLQLLT-
EDHGRHLADKGILYAPDYIVNSGGLIQVADE 
LYEVNKERVLAKTKHIYDAI-
In some embodiments between about 25% and 75%, 
between about 30% and 70%, or between about 40% and 60% 
35 LEVYQQAELDQITTMEAANRMCEQRMAARGRRNS 
FFTSSVKPKWDIRN 
of the fusion protein is derived from the first AmDH and the 
remainder of the fusion protein is derived from the second 
AmDH alone, or in combination with an option linker, or 
other domain(s) that are not derived from the first or second 40 
AmDH. In some embodiments between about 25% and 75%, 
between about 30% and 70%, or between about 40% and 60% 
of the fusion protein is derived from the second AmDH and 
the remainder of the fusion protein is derived from the first 
AmDH alone, or in combination with an option linker, or 45 
other domain(s) that are not derived from the first or second 
AmDH. 
(SEQ ID NO: 14 ), or a functional fragment or variant thereof. 
b. Exemplary LeuDH-AmDH Domains 
The substrate binding domain of a LeuDH-AmDH can be 
the N-terminal 139 amino acids of a LeuDH-AmDH, or a 
functional fragment or variant thereof. Therefore, in some 
embodiments, the substrate binding domain of a LeuDH-
AmDH includes the N-terminal 139 amino acids of SEQ ID 
N0:5, 6, 7, 8, 9, or 10, or is a functional fragment or variant 
thereof. 
For example, the substrate binding domain of a LeuDH-
AmDH can be ELFQYMEKYDYEQVLFCQDKESGLKAI-
IVIHDTTLGPALGGTRMWMYNSEEEAL EDALR-
LARGSTYMNAAAGLNLGGGKTVIIGDPRKDKNEAM 
50 FRAFGRFIQGLNGR YITAVDVGTTVADMDIIYQET-
In preferred embodiments, the first and secondAmDHs are 
selected from the PheDH-AmDH, LeuDH-AmDH, and 
ValDH-AmDH disclosed herein. For example, in some 
embodiments, the first AmDH is a PheDH-AmDH and the 
second AmDH is a LeuDH-AmDH or a ValDH-AmDH. In 
some embodiments, the firstAmDH is a LeuDH-AmDH and 
the secondAmDH is a PheDH-AmDH or a ValDH-AmDH. In 
some embodiments, the first AmDH is a ValDH-AmDH and 55 
the secondAmDH is a PheDH-AmDH or a LeuDH-AmDH. 
In some embodiments, the first and second AmDH are two 
different PheDH-AmDHs, two different LeuDH-AmDHs, or 
two differentValDH-AmDHs. 
Exemplary substrate binding domains and co-factor bind- 60 
ing domains for chimeric AmDH are provided below. The 
exemplary domains can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more 
additional amino acids on the N-terminus or C-terminus. For 
example, the co-factor or substrate binding domains can be 1, 
2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acids shorter, or longer 65 
than the exemplary domains provided below. The additional 
amino acids can be the corresponding amino acids from the 
DYVTGISPEF 
(SEQ ID NO: 15), or a functional fragment or variant thereof. 
The co-factor binding domain of a LeuDH-AmDH 
includes the C-terminal 227 amino acids ofa LeuD H-AmD H, 
or a functional fragment or variant thereof. Therefore, in 
some embodiments, the substrate binding domain of a 
LeuDH-AmDH includes the C-terminal 227 amino acids of 
SEQ ID N0:5, 6, 7, 8, 9, or 10, or is a functional fragment or 
variant thereof. 
For example, the cofactor binding domain of a LeuDH-
AmDH can be GSSGNPSPATAYGVYRGM-
KAAAKEAFGSDSLEGKVVAVQGVGN-
VAYHLCRHLHE 
EGAKLIVTDINKEAVARAVEEFGAKAVD-
PNDIYGVECDIFAPCALGGIINDQTI PQLKAKVIAG-
SADLQLKEPRHGDMIHEMGIVYAPDYVI-
NAGGCINVADELYGYN 
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RERAMKKIEQIYDNIEKVFAIAKRDNIP-
TYVAADRMAEERIETMRKARSQFLQN GHHILSR-
RRAR 
(SEQ ID NO: 16) or a functional fragment or variant thereof; 
20 
SLVEKTSIIKDFTLFEKMSEHEQV-
VFCNDPATGLRAIIAIHDTTLGPALGGCRM QPYNS-
or GSSGNPSPATAYGVYRGMKAAAKEAFGS- 5 
VEEALEDALRLSKGMTYSCAASDVD-
FGGGKAVIIGDPQKDKSPELFRAF 
GQFVDSLGGRFYTGTDMGTNMEDFI-
HAMKETNCIVGVPEAYGSSGNPSPATAYG 
KAAAKEAFGSDSLEGKVVAVQGVGN-
VAYHLCRHLHEEGAKLIVTDINKE 
VYRGM-DSLEGKVVAVQGVGNVAYHLCRHLHE EGAKLIVT-
DINKEAVARAVEEFGAKAVDPNDIYGV-
ECDIFAPCALGGIINDQTI 
PQLKAKVIAGSALNQLKEPRHGDMIHEM-
GIVYAPDYVINAGGCINVADELYGYN RERAMKKIE- 10 
QIYDNIEKVFAIAKRDNIPTY-
VAADRMAEERIETMRKARSQFLQN GHHILSRRRAR 
(SEQ ID NO: 17) or a functional fragment or variant thereof. 
Mutations relative to the corresponding 227 C-terminal 
amino acids in SEQ ID N0:4 are in bold. 
AVARAVEEFGAKAVDPNDIYGVECDI-
FAPCALGGIINDQTIPQLKAKVIAGSAD 
LQLKEPRHGDMIHEMGIVYAPDYVINAG-
GCINVADELYGYNRERAMKKIEQIYD 
IAKRDNIPTYVAADRMAEERIETMRKAR-
NIEKVFA-
15 SQFLQNGHHILSRRRAR (SEQ ID N0:21), or 
SLVEKTSIIKDFTLFEKMSEHEQV-
VFCNDPATGLRAIIAIHDTTLGPALGGCRM 
VEEALEDALRLSKGMTYSCAASDVD-
c. ExemplaryValDH-AmDH Domains 
In some embodiments, the substrate binding domain of a 
ValDH-AmDH includes the N-terminal 139 amino acids of a 
QPYNS-
LeuDH-AmDH, or is a functional fragment or variant thereof. FGGGKAVIIGDPQKDKSPELFRAF 
Therefore, in some embodiments, the substrate binding 20 GQFVDSLGGRFYTGTDMGTNMEDFI-
domain of a ValDH-AmDH includes the N-terminal 147 HAMKETNCIVGVPEAYGSSGNPSPATAYG VYRGM-
amino acids of SEQ ID NO: 12, or is a functional fragment or 
variant thereof. 
For example, the substrate binding domain of a ValDH-
AmDH can be amino acids 
TEADNGVLHTLFHSDQGGHEQVVLCQ-
DRASGLKAVIAIHSTALGPALGGTRFYP YATEEEAV-
ADVLNLSRGMSYSNAMAGLDHGGGKAVI-
IGDPEQIKSEDLLLAFGR 
FVASLGGRYVTACDVGTYVADMDVVARE-
CRWTTGRSPEN 
(SEQ ID NO: 18), or a functional fragment or variant thereof. 
The co-factor binding domain ofa ValDH-AmDH includes 
the C-terminal 210 amino acids of a ValDH-AmDH, or a 
functional fragment or variant thereof. Therefore, in some 
embodiments, the substrate binding domain of a ValDH-
AmDH includes the C-terminal 210 amino acids of SEQ ID 
NO: 12 or is a functional fragment or variant thereof. 
For example, the cofactor binding domain of a ValDH-
AmDH can be amino acids 
GGAGDSSVLTAFGVFQGMRASAEHL-
WGDPSLRGRKVGVAGVGKVGHHLVEHLLE DGADV-
VITDVREESVNRSTHKHPSVTAVADTEA-
LIRTEGLDIYAPCALGGALDD 
DSVPVLTAKVVCGAANLQLAHPGVEKD-
LADRSILYAPDYVVNAGGVIQVADELR GFDFDRCK-
AKASKIFDTTLAIFARAKEDGIP-
PAAAADRIAEQRMSDAR 
(SEQ ID NO: 19), or a functional fragment or variant thereof. 
d. Exemplary Chimeric AmDH 
An exemplary chimeric AmDH is a fusion protein includ-
ing a substrate binding domain from a PheDH-AmDH and a 
co-factor binding domain of a LeuDH-AmDH. The chimeric 
AmDH can have the amino acid sequence, SLVEKTSIIKD-
FTLFEKMSEHEQVVFCNDPATGLRAII-
AIHDTTLGPALGGCRM QPYNSVEEALEDALRLSKG-
MTYSCAASDVDFGGGKAVIIGDPQKDKSPELFRAF 
GQFVDSLGGRFYTGTDMGTNMEDFI-
HAMKETNCIVGVPEAYGSSGNPSPATAYG VYRGM-
KAAAKEAFGSDSLEGKVVAVQGVGN-
VAYHLCRHLHEEGAKLIVTDINKE 
AVARAVEEFGAKAVDPNDIYGVECDI-
FAPCALGGIINDQTIPQLKAKVIAGSAL 
KAAAKEAFGSDSLEGKVVAVQGVGN-
VAYHLCRHLHEEGAKLIVTDINKE 
AVARAVEEFGAKAVDPNDIYGVECDI-
25 FAPCALGGIINDQTIPQLKAKVIAGSAL 
LQLKEPRHGDMIHEMGIVYAPDYVINAG-
GCINVADELYGYNRERAMKKIEQIYD 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR 
30 (SEQ ID N0:22), 
NIEKVFA-
or a variant of SEQ ID N0:20, 21, or 22 with 7 5%, 80%, 85%, 
90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ 
ID N0:20, 21, or 22, and amine dehydrogenase activity. 
In some embodiments, the amino acid of the LeuDH-
35 AmDH at position 270 of SEQ ID N0:20, 21, 22, or a func-
tional fragment or variant thereof is an asparagine. 
A second exemplary chimeric AmDH is a fusion protein 
including a substrate binding domain from a PheDH-AmDH 
and a co-factor binding domain of a ValDH-AmDH. The 
40 chimeric can have the amino acid sequence, 
SLVEKTSIIKDFTLFEKMSEHEQV-
VFCNDPATGLRAIIAIHDTTLGPALGGCRM QPYNS-
VEEALEDALRLSKGMTYSCAASDVD-
FGGGKAVIIGDPQKDKSPELFRAF 
45 GQFVDSLGGRFYTGTDMGTNMEDFI-
HAMKETNCIVGVPEAYGGAGDSSVLTAFG VFQGM-
RASAEHLWGDPSLR-
GRKVGVAGVGKVGHHLVEHLLEDGADVVITDVREE 
SVNRSTHKHPSVTAVADTEALIRTEG-
AAN-50 LDIYAPCALGGALDDDSVPVLTAKVVCG 
LQLAHPGVEKDLADRSILYAPDYVVNAG-
GVIQVADELRGFDFDRCKAKASK 
IFDTTLAIFARAKEDGIPPAAAADRIAEQRMSDAR 
(SEQ ID N0:23), or 
55 MSLVEKTSIIKDFTLFEKMSEHEQV-
VFCNDPATGLRAIIAIHDTTLGPALGGCR MQPYNS-
VEEALEDALRLSKGMTYSCAASDVD-
FGGGKAVIIGDPQKDKSPELFRA 
FGQFVDSLGGRFYTGTDMGTNMEDFI-
60 HAMKETNCIVGVPEAYGGAGDSSVLTAF GVFQGM-
RASAEHLWGDPSLR-
GRKVGVAGVGKVGHHLVEHLLEDGADVVITDVRE 
ESVNRSTHKHPSVTAVADTEALIRTEG-
LDIYAPCALGGALDDDSVPVLTAKVVC GAAN-
NIEKVFA- 65 
NQLKEPRHGDMIHEMGIVYAPDYVINAG-
GCINVADELYGYNRERAMKKIEQIYD 
IAKRDNIPTYVAADRMAEERIETMRKAR-
SQFLQNGHHILSRRRAR (SEQ ID N0:20), or 
LQLAHPGVEKDLADRSILYAPDYVVNAG-
GVIQVADELRGFDFDRCKAKAS 
KIFDTTLAIFARAKEDGIPPAAAADRIAEQRMSDAR, 
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(SEQ ID N0:24), or a variant of SEQ ID N0:23 or 24 with 
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% 
sequence identity to SEQ ID N0:23 or 24, and amine dehy-
drogenase activity. 
Methods of using domain shuffling to create chimeric, 
enzymatic fusion proteins are known in the art and include 
those discussed in Kataoka, et al., J. Biochem., 116:931-936 
(1994), which is specifically incorporated by reference herein 
in its entirety. 
E. Additional Modifications 
1. Mutation Strategies 
In some embodiments, the disclosed PheDH-AmDH, 
LeuDH-AmDH, ValDH-AmDH, or fragments or chimeras 
thereof include one or more additional amino acid alterations 
relative to the reference scaffold sequence that improves the 
catalytic constant kcao lowers the KM value, increases amine 
dehydrogenase activity, increases substrate binding, 
increases stability, for example, theromstability, or combina-
tions thereof for the enzyme. 
22 
High thermostability and activity of the enzyme catalyst 
are advantageous for achieving a robust industrial enzyme 
process. Numerous enzymes have been evolved to improve 
thermostability and tolerance to normative process condi-
tions through a variety of strategies. These strategies include 
introduction of disulfide bonds (Mansfeld, et al., Journal of 
Biological Chemistry, 272, (17): 11152-11156 (1987)), 
improved core packing (Filikov, et. al., Protein Science, 11, 
(6): 1452-1461 (2002); Korkegian, et al., Science, 308, 
10 (5723): 857-860 (2005); Sheffler, et al., Protein Science, 18, 
(1): 229-239 (2009); Sheffler, et al.,Protein Science, 19, (10): 
1991-1995 (2010), increased rigidity (Reetz., et al., Chemical 
Communications, 46, (45): 8657-8658 (2010); Matthews, et 
15 al., Proceedings of the National Academy of Sciences, 84, (19): 6663-6667 (1987), and optimized surface charges 
(Strickler, et al., Biochemistry, 45, (9): 2761-2766 (2006); 
Wunderlich, et al., Journal of Molecular Biology, 347, (5): 
1063-1076 (2005)). 
The first-shell residues of the activeAmDHs, such as those 20 
identified in Table 1, are responsible for both direct interac-
tions with active-site residues and binding of the substrate. In 
some embodiments, these residues are altered to improve 
protein-substrate interacts and resulting in increased catalytic 
constant kcat and a lower KM value. 
Several online tools allow for the prediction of potential 
disulfide bond pairs, i.e. SS-BOND or GDAP (Hazes, et al., 
Protein Engineering, 2, (2): 119-125 (1988); O'Connor, et 
al., Nucleic Acids Research, 32, (Web Server Issue): W360-
W364 (2004)). An example analysis of the Rhodococcus sp. 
M4 PheDH using SS-BOND can be found in Table 2. 
TABLE 1 
Alignment of binding pocket residues for B. stearothermophilus 
LeuDH, Rhodococcus sp. M4 PheDH, B. badius PheDH, and S. cinnamonensis 
VlDH. 
LeuDH PheDH ValDH 
B. Rho do coccus Bacillus Strep. 
stearothermophilus M4 badius Cinnamonensis Rationale for mutation 
L39 A38 L49 L47 Residues interact with the para-
G40 G39 G50 G48 substituted region of the Phe substrate 
G41 G40 G51 G49 
M64 M63 M74 M72 Side chain interactions with 
neighboring Lysine 
K67 K66 K77 K75 Direct interaction with the carboxyl 
of the keto-acid substrate, along with 
Asn. 
A112 Gll6 G122 A120 Residues interact with the posterior 
E113 P117 T123 C121 portion of the substrate, opposite the 
D114 D118 D124 D122 reacting ketone/amine. 
V115 V119 M125 V123 
T133 F137 V143 T141 Residues interact with the para-
substituted region of the Phe substrate 
D260 N262 N275 N271 
Or 
N260 
N261 N263 N276 N272 Direct interaction with the carboxyl 
of the keto-acid substrate, along with 
Lys. 
V290 A292 L305 V301 Residues shape substrate binding 
V293 L295 V308 V304 pocket 
55 
TABLE2 For example, theresiduesA38 andF137 (Rh. sp. M4 PheDH) 
are of particular interest due to their interactions with the 
para-substituted region of the PheDH substrate. The para-
fluoro substitution of phenyl acetone creates not only a larger, 
but more polar moiety at this position. Substituting the A38 
with a more polar side chain, or decreasing the size of the 
F137 may lead to more favorable substrate binding. Accord-
ingly, in some embodiments, the amino acid residues of the 
AmDH corresponding toA38 of Rh. sp. M4 PheDH, F137 of 
Rh. sp. M4 PheDH, or a combination thereof are altered. In 
some embodiments, residues corresponding to A3 8 and F 13 8 
are substituted with a polar amino acid, for example, serine, 
threonine, asparagine, or glutamine. 
Example output of SS-BOND in Rhodococcus sp. M4. PDB: lClD 
NR RES1--RES2 NAME! NAME2 CB DIST CA DIST 
60 5--50 ALA ALA 4.454 5.915 
2 5--53 ALA LEU 3.961 6.224 
10--30 GLY ASP 4.314 4.301 
4 12--29 MET LEU 4.446 5.162 
14--27 VAL ILE 3.989 4.922 
16--25 ARG PHE 4.269 5.065 
65 7 22--84 GLY PRO 3.442 5.439 
24--82 HIS ALA 3.885 5.026 
US 8,835,136 B2 
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TABLE 2-continued 
Example output of SS-BOND inRhodococcus sp. M4, PDB: lClD 
NR RES1--RES2 NAME! NAME2 CB DIST CA DIST 
9 26--56 VAL ALA 4.493 7.057 
10 26--80 VAL VAL 4.384 5.083 
11 28--56 ARG ALA 4.139 5.979 
12 28--60 ARG ALA 4.155 6.223 
13 29--37 LEU ALA 4.275 6.067 
14 29--77 LEU GLY 4.431 4.211 
15 30--60 ASP ALA 3.856 5.409 
16 30--76 ASP GLY 4.479 5.522 
17 31--64 SER THR 4.408 6.310 
18 32--75 THR GLY 4.076 4.389 
19 35--74 GLY MET 4.301 4.082 
20 37--75 ALA GLY 4.030 3.908 
21 37--77 ALA GLY 3.193 4.927 
22 38--74 ALA MET 4.353 6.422 
23 38--114 ALA TRP 4.489 4.724 
24 39--63 GLY MET 4.107 6.319 
25 39--77 GLY GLY 4.310 4.861 
26 39--78 GLY LYS 3.870 4.516 
27 40--116 GLY GLY 4.294 4.118 
28 40--118 GLY ASP 3.178 5.051 
29 41--79 THR SER 4.151 4.515 
30 42--118 ARG ASP 4.153 4.880 
31 43--81 ALA ILE 4.143 4.587 
32 43--120 ALA ASN 3.860 5.390 
33 46--51 TYR ASP 4.315 6.247 
34 46--52 TYR ALA 4.364 6.125 
35 52--82 ALA ALA 4.161 6.391 
This algorithm approximates the location of ~-carbon 
atoms from the position of the backbone, and screens this set 
for suitable ~-carbon to ~-carbon distances and bond angles 
favorable for a disulfide bond. The final confirmations are 
energy minimized and reported in the output. Accordingly, in 
some embodiments, one or more of the residues in anAmDH 
corresponding to the residues in Table 2 are altered to improve 
protein stabilization. For example, in some embodiments, the 
paired residues are substituted with cysteines, selenocys-
teines, or a combination thereof to introduce a disulfide or 
diselenide bond into the enzyme. 
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sequence complexity to form a stable duplex on both sides of 
the deletion junction being traversed. Typically, a primer of 
about 17 to 25 nucleotides in length is preferred, with about 5 
to 10 residues on both sides of the junction of the sequence 
being altered. 
In general, the technique of site-specific mutagenesis is 
well known in the art. As will be appreciated, the technique 
typically employs a bacteriophage vector that exists in both a 
single stranded and double stranded form. Typical vectors 
10 useful in site-directed mutagenesis include vectors such as 
the M13 phage. These phage vectors are commercially avail-
able and their use is generally well known to those skilled in 
the art. Double stranded plasmids are also routinely employed 
in site directed mutagenesis, which eliminates the step of 
15 transferring the gene of interest from a phage to a plasmid. 
In general, site-directed mutagenesis is performed by first 
obtaining a single-stranded vector, or melting of two strands 
of a double stranded vector which includes within its 
sequence a DNA sequence encoding the desired protein. An 
20 oligonucleotide primer bearing the desired mutated sequence 
is synthetically prepared. This primer is then annealed with 
the single-stranded DNA preparation, and subjected to DNA 
polymerizing enzymes such as E. coli polymerase I Kienow 
fragment, in order to complete the synthesis of the mutation-
25 bearing strand. Thus, a heteroduplex is formed wherein one 
strand encodes the original non-mutated sequence and the 
second strand bears the desired mutation. This heteroduplex 
vector is then used to transform appropriate cells, such as E. 
coli cells, and clones are selected that include recombinant 
30 vectors bearing the mutated sequence arrangement. 
The preparation of sequence variants of the selected gene 
using site-directed mutagenesis is provided as a means of 
producing potentially useful species and is not meant to be 
limiting, as there are other ways in which sequence variants of 
35 genes may be obtained. For example, recombinant vectors 
encoding the desired gene may be treated with mutagenic 
agents, such as hydroxylamine, to obtain sequence variants. 
40 
Methods of creating libraries of mutants for screening are 
known in the art, and described in the Examples below. 
F. Nucleic Acid Molecules and Vectors 
The tight packing of the protein's core can be important for 
stability, and the elimination of voids in the protein structure 
results in a decreased free energy. Software such as Rosetta-
Holes2 and RosettavIP can be used for quantitative and visual 
assessment of the packing in the protein core. These flaws in 45 
core packing can then be improved by altering the amino acid 
sequence oftheAmDH to create more energetically-favored 
folded protein states. Therefore, in some embodiments, 
amino acid sequence alterations are introduced into the amine 
dehydrogenase to increase packing, eliminate voids, improve 50 
stability, decrease free energy, or a combination thereof. 
1. Isolated Nucleic Acids 
Isolated nucleic acid sequences encoding AmDH are dis-
closed herein. As used herein, "isolated nucleic acid" refers to 
a nucleic acid that is separated from other nucleic acid mol-
ecules that are present in a mammalian genome. The term 
"isolated" as used herein with respect to nucleic acids also 
includes any non-naturally-occurring nucleic acid sequence, 
since such non-naturally-occurring sequences are not found 
in nature and do not have immediately contiguous sequences 
in a naturally-occurring genome. 
An isolated nucleic acid can be, for example, a DNA mol-
ecule, provided one of the nucleic acid sequences normally 
found immediately flanking that DNA molecule in a natu-
rally-occurring genome is removed or absent. Thus, an iso-
In one embodiment, AmDH can be modified to increase its 
stability in organic solvents by making conservative substa-
tions with amino acids having non-polar side chains. 
2. Methods of Making Mutations 
Site-specific mutagenesis is a technique useful in the 
preparation of individual peptides, or biologically functional 
equivalent proteins or peptides, through specific mutagenesis 
55 lated nucleic acid includes, without limitation, a DNA mol-
ecule that exists as a separate molecule independent of other 
sequences (e.g., a chemically synthesized nucleic acid, or a 
cDNA or genomic DNA fragment produced by PCR or 
of the underlying DNA. The technique further provides a 
ready ability to prepare and test sequence variants, incorpo- 60 
rating one or more of the foregoing considerations, by intro-
ducing one or more nucleotide sequence changes into the 
DNA. Site-specific mutagenesis allows the production of 
mutants through the use of specific oligonucleotide 
sequences which encode the DNA sequence of the desired 65 
mutation, as well as a sufficient number of adjacent nucle-
otides, to provide a primer sequence of sufficient size and 
restriction endonuclease treatment), as well as recombinant 
DNA that is incorporated into a vector, an autonomously 
replicating plasmid, a virus (e.g., a retrovirus, lentivirus, 
adenovirus, or herpes virus), or into the genomic DNA of a 
prokaryote or eukaryote. In addition, an isolated nucleic acid 
can include an engineered nucleic acid such as a recombinant 
DNA molecule that is part of a hybrid or fusion nucleic acid. 
A nucleic acid existing among hundreds to millions of other 
nucleic acids within, for example, a cDNA library or a 
US 8,835,136 B2 
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genomic library, or a gel slice containing a genomic DNA 
restriction digest, is not to be considered an isolated nucleic 
acid. 
Nucleic acids can be in sense or antisense orientation, or 
can be complementary to a reference sequence encoding an 
AmDH polypeptide. 
Nucleic acids can be DNA, RNA, or nucleic acid analogs. 
Nucleic acid analogs can be modified at the base moiety, 
sugar moiety, or phosphate backbone. Such modification can 
improve, for example, stability, hybridization, or solubility of 
the nucleic acid. Modifications at the base moiety can include 
deoxyuridine for deoxythymidine, and 5-methyl-2'-deoxycy-
tidine or 5-bromo-2'-deoxycytidine for deoxycytidine. Modi-
fications of the sugar moiety can include modification of the 
2' hydroxyl of the ribose sugar to form 2'-0-methyl or 2'-0-
allyl sugars. The deoxyribose phosphate backbone can be 
modified to produce morpholino nucleic acids, in which each 
base moiety is linked to a six membered, morpholino ring, or 
peptide nucleic acids, in which the deoxyphosphate backbone 
26 
viruses, cytomegalo virus, retroviruses, vaccmrn viruses, 
adenoviruses, and adeno-associated viruses. Numerous vec-
tors and expression systems are commercially available from 
such corporations as Novagen (Madison, Wis.), Clontech 
(Palo Alto, Calif.), Stratagene (La Jolla, Calif.), and Invitro-
gen Life Technologies (Carlsbad, Calif.). 
An expression vector can include a tag sequence. Tag 
sequences, are typically expressed as a fusion with the 
encoded polypeptide. Such tags can be inserted anywhere 
10 within the polypeptide including at either the carboxyl or 
amino terminus. Examples of useful tags include, but are not 
limited to, green fluorescent protein (GFP), glutathione 
S-transferase (GST), polyhistidine, c-myc, hemagglutinin, 
Flag™ tag (Kodak, New Haven, Conn.), maltose E binding 
15 protein and protein A. 
II. Methods of Making Recombinant Amine 
Dehydrogenases 
is replaced by a pseudopeptide backbone and the four bases 20 
are retained. See, for example, Summerton and Weller (1997) 
Antisense Nucleic Acid Drug Dev. 7:187-195; and Hyrup et 
A. Expression of Encoded Proteins 
The cDNA species encoding the disclosed AmDH can be 
expressed as encoded peptides or proteins. The engineering 
of DNA segment(s) for expression in a prokaryotic or eukary-
otic system may be performed by techniques generally known 
al. (1996) Bioorgan. Med. Chem. 4:5-23. In addition, the 
deoxyphosphate backbone can be replaced with, for example, 
a phosphorothioate or phosphorodithioate backbone, a phos- 25 
phoroamidite, or an alkyl phosphotriester backbone. 
to those of skill in recombinant expression. It is believed that 
virtually any expression system may be employed in the 
The coding sequence can be genetically engineered by 
altering the coding sequence for optimal expression in the 
host of interest. 
2. Vectors 
Nucleic acids, such as those described above, can be 
inserted into vectors for expression in cells. As used herein, a 
"vector" is a replicon, such as a plasmid, phage, or cosmid, 
into which another DNA segment may be inserted so as to 
bring about the replication of the inserted segment. Vectors 
can be expression vectors. An "expression vector" is a vector 
that includes one or more expression control sequences, and 
an "expression control sequence" is a DNA sequence that 
controls and regulates the transcription and/or translation of 
another DNA sequence. 
expression of the disclosed enzymes. 
Both cDNA and genomic sequences are suitable for 
enkaryotic expression, as the host cell will generally process 
30 the genomic transcripts to yield functional mRNA for trans-
lation into protein. Generally speaking, it may be more con-
venient to employ as the recombinant gene a cDNA version of 
the gene. It is believed that the use of a cDNA version will 
provide advantages in that the size of the gene will generally 
35 be much smaller and more readily employed to transfect the 
targeted cell than will a genomic gene, which will typically be 
up to an order of magnitude larger than the cDNA gene. 
Recombinant cells include those having an introduced 
cDNA or genomic DNA, and also include genes positioned 
40 adjacent to a promoter not naturally associated with the par-
ticular introduced gene. Nucleic acids in vectors can be operably linked to one or 
more expression control sequences. As used herein, "oper-
ably linked" means incorporated into a genetic construct so 
that expression control sequences effectively control expres-
sion of a coding sequence of interest. Examples of expression 
control sequences include promoters, enhancers, and tran-
scription terminating regions. A promoter is an expression 
control sequence composed of a region of a DNA molecule, 
typically within 100 nucleotides upstream of the point at 
which transcription starts (generally near the initiation site for 
RNA polymerase II). To bring a coding sequence under the 
control of a promoter, it is necessary to position the transla-
tion initiation site of the translational reading frame of the 
polypeptide between one and about fifty nucleotides down-
stream of the promoter. Enhancers provide expression speci- 55 
ficity in terms of time, location, and level. Unlike promoters, 
enhancers can function when located at various distances 
from the transcription site. An enhancer also can be located 
downstream from the transcription initiation site. A coding 
sequence is "operably linked" and "under the control" of 60 
expression control sequences in a cell when RNA polymerase 
To express a recombinant encoded protein or peptide, 
whether mutant or wild-type, one would prepare an expres-
sion vector that comprises one of the claimed isolated nucleic 
45 acids under the control of one or more promoters. To bring a 
coding sequence "under the control of' a promoter, one posi-
tions the 5' end of the translational initiation site of the reading 
frame generally between about 1 and 50 nucleotides "down-
stream" of (i.e., 3' of) the chosen promoter. The "upstream" 
50 promoter stimulates transcription of the inserted DNA and 
promotes expression of the encoded recombinant protein. 
This is the meaning of"recombinant expression" in the con-
text used here. 
Many standard techniques are available to construct 
expression vectors containing the appropriate nucleic acids 
and transcriptional/translational control sequences in order to 
achieve protein or peptide expression in a variety of host-
expression systems. Cell types available for expression 
include, but are not limited to, bacteria, such as E. coli and B. 
subtilis transformed with recombinant phage DNA, plasmid 
DNA or cosmid DNA expression vectors. 
is able to transcribe the coding sequence into mRNA, which 
then can be translated into the protein encoded by the coding 
sequence. 
Suitable expression vectors include, without limitation, 
plasmids and viral vectors derived from, for example, bacte-
riophage, baculoviruses, tobacco mosaic virus, herpes 
Certain examples of prokaryotic hosts are E. coli strain 
RR!, E. coli LE392, E. coli B, E. coli 1776 (ATCC No. 
31537) as well as E.coli W3110 (F-, lambda-, prototrophic, 
65 ATCC No. 273325); bacilli such as Bacillus subtilis; and 
other enterobacteriaceae such as Salmonella typhimurium, 
Serratia marcescens, and various Pseudomonas species. 
US 8,835,136 B2 
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In general, plasmid vectors containing replicon and control 
sequences that are derived from species compatible with the 
host cell are used in connection with these hosts. The vector 
ordinarily carries a replication site, as well as marking 
sequences that are capable of providing phenotypic selection 
in transformed cells. For example, E.coli is often transformed 
using pBR322, a plasmid derived from an E. coli species. 
Plasmid pBR322 contains genes for ampicillin and tetracy-
cline resistance and thus provides easy means for identifying 
transformed cells. The pBR322 plasmid, or other microbial 
plasmid or phage must also contain, or be modified to contain, 
promoters that can be used by the microbial organism for 
expression of its own proteins. 
In addition, phage vectors containing replicon and control 
sequences that are compatible with the host microorganism 
can be used as transforming vectors in connection with these 
hosts. For example, the phage lambda GEMTM-11 may be 
utilized in making a recombinant phage vector that can be 
used to transform host cells, such as E. coli LE392. 
Further useful vectors include pIN vectors and pGEX vec-
tors, for use in generating glutathione S-transferase (GST) 
soluble fusion proteins for later purification and separation or 
cleavage. Other suitable fusion proteins are those with ~-ga­
lactosidase, ubiquitin, or the like. 
Promoters that are most commonly used in recombinant 
DNA construction include the ~-lactamase (penicillinase), 
lactose and tryptophan (trp) promoter systems. While these 
are the most commonly used, other microbial promoters have 
been discovered and utilized, and details concerning their 
nucleotide sequences have been published, enabling those of 
skill in the art to ligate them functionally with plasmid vec-
tors. 
For expression in Saccharomyces, the plasmid YRp7, for 
example, is commonly used. This plasmid contains the trpl 
gene, which provides a selection marker for a mutant strain of 
yeast lacking the ability to grow in tryptophan, for example 
ATCC No. 44076 or PEP4-1. The presence of the trpl lesion 
as a characteristic of the yeast host cell genome then provides 
an effective environment for detecting transformation by 
growth in the absence oftryptophan. 
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virus, TMV) or transformed with recombinant plasmid 
expression vectors (e.g., Ti plasmid) containing one or more 
coding sequences. 
In a useful insect system, Autograph californica nuclear 
polyhidrosis virus (AcNPV) is used as a vector to express 
foreign genes. The virus grows in Spodoptera frugiperda 
cells. The isolated nucleic acid coding sequences are cloned 
into non-essential regions (for example the polyhedron gene) 
of the virus and placed under control of an AcNPV promoter 
10 (for example, the polyhedron promoter). Successful insertion 
of the coding sequences results in the inactivation of the 
polyhedron gene and production of non-occluded recombi-
nant virus (i.e., virus lacking the proteinaceous coat coded for 
15 by the polyhedron gene). These recombinant viruses are then 
used to infect Spodoptera frugiperda cells in which the 
inserted gene is expressed. 
Examples of useful manmialian host cell lines are VERO 
and HeLa cells, Chinese hamster ovary (CHO) cell lines, 
20 W138, BHK, COS-7, 293, HepG2, NIH3T3, RIN andMDCK 
cell lines. In addition, a host cell may be chosen that modu-
lates the expression of the inserted sequences, or modifies and 
processes the gene product in the specific fashion desired. 
Such modifications (e.g., glycosylation) and processing (e.g., 
25 cleavage) of protein products may be important for the func-
tion of the encoded protein. 
Different host cells have characteristic and specific mecha-
nisms for the post-translational processing and modification 
of proteins. Appropriate cell lines or host systems can be 
30 
chosen to ensure the correct modification and processing of 
the foreign protein expressed. Expression vectors for use in 
mammalian cells ordinarily include an origin of replication 
(as necessary), a promoter located in front of the gene to be 
35 expressed, along with any necessary ribosome binding sites, 
RNA splice sites, polyadenylation site, and transcriptional 
terminator sequences. The origin of replication may be pro-
vided either by construction of the vector to include an exog-
enous origin, such as may be derived from SV 40 or other viral 
40 (e.g., Polyoma, Adena, VSV, BPV) source, or may be pro-
vided by the host cell chromosomal replication mechanism. If 
the vector is integrated into the host cell chromosome, the 
latter is often sufficient. 
Suitable promoting sequences in yeast vectors include the 
promoters for 3-phosphoglycerate kinase or other glycolytic 
enzymes, such as enolase, glyceraldehyde-3-phosphate 
dehydrogenase, hexokinase, pyruvate decarboxylase, phos- 45 
phofructokinase, glucose-6-phosphate isomerase, 3-phos-
phoglycerate mutase, pyruvate kinase, triosephosphate 
isomerase, phosphoglucose isomerase, and glucokinase. In 
constructing suitable expression plasmids, the termination 
sequences associated with these genes are also ligated into the 50 
expression vector3' of the sequence desired to be expressed to 
provide polyadenylation of the mRNA and termination. 
The promoters may be derived from the genome of mam-
malian cells (e.g., metallothionein promoter) or from mam-
malian viruses (e.g., the adenovirus late promoter; the vac-
cinia virus 7.5K promoter). Further, it is also possible, and 
may be desirable, to utilize promoter or control sequences 
normally associated with the desired gene sequence, provided 
such control sequences are compatible with the host cell 
systems. 
A number of viral based expression systems may be uti-
Other suitable promoters, which have the additional advan-
tage of transcription controlled by growth conditions, include 
the promoter region for alcohol dehydrogenase 2, isocyto- 55 
chrome C, acid phosphatase, degradative enzymes associated 
with nitrogen metabolism, and the aforementioned glyceral-
dehyde-3-phosphate dehydrogenase, and enzymes respon-
sible for maltose and galactose utilization. 
lized, for example, commonly used promoters are derived 
from polyoma, Adenovirus 2, cytomegalovirus and Simian 
Virus 40 (SV 40). The early and late promoters of SV 40 virus 
are useful because both are obtained easily from the virus as 
a fragment which also contains the SV 40 viral origin of 
replication. Smaller or larger SV 40 fragments may also be 
used, provided there is included the approximately 250 bp 
sequence extending from the HinDIII site toward the Bg!I site 
located in the viral origin of replication. 
In addition to micro-organisms, cultures of cells derived 60 
from multicellular organisms may also be used as hosts. In 
principle, any such cell culture is workable, whether from 
vertebrate or invertebrate culture. In addition to mammalian 
cells, these include insect cell systems infected with recom-
binant virus expression vectors (e.g., baculovirus); and plant 
cell systems infected with recombinant virus expression vec-
tors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic 
In cases where an adenovirus is used as an expression 
vector, the coding sequences may be ligated to an adenovirus 
transcription/translation control complex, e.g., the late pro-
65 mater and tripartite leader sequence. This chimeric gene may 
then be inserted in the adenovirus genome by in vitro or in 
vivo recombination. Insertion in a non-essential region of the 
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viral genome (e.g., region El or E3) will result in a recombi-
nant virus that is viable and capable of expressing proteins in 
infected hosts. 
Specific initiation signals may also be required for efficient 
translation of the claimed isolated nucleic acid coding 
sequences. These signals include the ATG initiation codon 
and adjacent sequences. Exogenous translational control sig-
nals, including the ATG initiation codon, may additionally 
need to be provided. One of ordinary skill in the art would 
readily be capable of determining this need and providing the 
necessary signals. It is well known that the initiation codon 
must be in-frame (or in-phase) with the reading frame of the 
desired coding sequence to ensure translation of the entire 
insert. These exogenous translational control signals and ini-
tiation codons can be of a variety of origins, both natural and 
synthetic. The efficiency of expression may be enhanced by 
the inclusion of appropriate transcription enhancer elements 
or transcription terminators. 
In eukaryotic expression, one will also typically desire to 
incorporate into the transcriptional unit an appropriate poly-
adenylation site (e.g., 5'-AATAAA-3') if one was not con-
tained within the original cloned segment. Typically, the poly 
A addition site is placed about 30 to 2000 nucleotides down-
stream of the termination site of the protein at a position prior 
to transcription termination. 
For long-term, high-yield production ofrecombinant pro-
teins, stable expression is preferred. For example, cell lines 
that stably express constructs encoding proteins may be engi-
neered. Rather than using expression vectors that contain 
viral origins of replication, host cells can be transformed with 
vectors controlled by appropriate expression control ele-
ments (e.g., promoter, enhancer, sequences, transcription ter-
minators, polyadenylation sites, etc.), and a selectable 
marker. Following the introduction of foreign DNA, engi-
neered cells may be allowed to grow for 1-2 days in an 
enriched medium, and then are switched to a selective 
medium. The selectable marker in the recombinant plasmid 
confers resistance to the selection and allows cells to stably 
integrate the plasmid into their chromosomes and grow to 
form foci, which in turn can be cloned and expanded into cell 
lines. 
A number of selection systems may be used, including, but 
not limited, to the herpes simplex virus thymidine kinase, 
hypoxanthine-guanine phosphoribosyltransferase and 
adenine phosphoribosyltransferase genes, in tk-, hgprt- or 
aprt- cells, respectively. Also, antimetabolite resistance can 
be used as the basis of selection for dhfr, which confers 
resistance to methotrexate; gpt, which confers resistance to 
mycophenolic acid; neo, which confers resistance to the ami-
noglycoside G-418; and hygro, which confers resistance to 
hygromycin. 
The AmD H can optionally include additional sequences or 
moieties, including, but not limited to linkers and purification 
tags. 
In a preferred embodiment the purification tag is a 
polypeptide. Polypeptide purification tags are known in the 
art and include, but are not limited to His tags which typically 
include six or more, typically consecutive, histidine residues; 
FLAG tags, which typically include the sequence DYKD-
DDDK (SEQ ID N0:25); haemagglutinin (HA) for example, 
YPYDVP (SEQ ID N0:26); MYC tag for example 
ILKKATAYIL (SEQ ID N0:27) or EQKLISEEDL (SEQ ID 
N0:28). Methods of using purification tags to facilitate pro-
tein purification are known in the art and include, for 
example, a chromatography step wherein the tag reversibly 
binds to a chromatography resin. 
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Purifications tags can be N-terminal or C-terminal to the 
fusion protein. The purification tags N-terminal to the fusion 
protein are typically separated from the polypeptide of inter-
est at the time of the cleavage in vivo. Therefore, purification 
tags N-terminal to the fusion protein can be used to remove 
the fusion protein from a cellular lysate following expression 
and extraction of the expression or solubility enhancing 
amino acid sequence, but cannot be used to remove the 
polypeptide of interest. Purification tags C-terminal to the 
10 fusion protein can be used to remove the polypeptide of 
interest from a cellular lysate following expression of the 
fusion protein, but cannot be used to remove the expression or 
solubility enhancing amino acid sequence. Purification tags 
that are C-terminal to the expression or solubility enhancing 
15 amino acid sequence can be N-terminal to, C-terminal to, or 
incorporated within the sequence of the polypeptide of inter-
est. 
In some embodiments, to fusion protein includes one or 
more linkers or spacers. In some embodiments linker or 
20 spacer is one or more polypeptides. In some embodiments, 
the linker includes a glycine-glutamic acid di-amino acid 
sequence. The linkers can be used to link or connect two 
domains, regions, or sequences of the fusion protein. 
It is contemplated that the isolated nucleic acids of the 
25 invention may be "overexpressed", i.e., expressed in 
increased levels relative to its natural expression in human 
cells, or even relative to the expression of other proteins in the 
recombinant host cell. Such overexpression may be assessed 
by a variety of methods, including radio-labeling and/or pro-
30 tein purification. However, simple and direct methods are 
preferred, for example, those involving SDS/PAGE and pro-
tein staining or western blotting, followed by quantitative 
analyses, such as densitometric scanning of the resultant gel 
or blot. A specific increase in the level of the recombinant 
35 protein or peptide in comparison to the level in natural human 
cells is indicative of overexpression, as is a relative abundance 
of the specific protein in relation to the other proteins pro-
duced by the host cell and, e.g., visible on a gel. 
Although many proteins with therapeutic or commercial 
40 uses can be produced by recombinant organisms, the yield 
and quality of the expressed protein are variable due to many 
factors. For example, heterologous protein expression by 
genetically engineered organisms can be affected by the size 
and source of the protein to be expressed, the presence of an 
45 affinity tag linked to the protein to be expressed, codon bias-
ing, the strain of the microorganism, the culture conditions of 
microorganism, and the in vivo degradation of the expressed 
protein. Some of these problems can be mitigated by fusing 
the protein ofinterest to an expression or solubility enhancing 
50 amino acid sequence. Exemplary expression or solubility 
enhancing amino acid sequences include maltose-binding 
protein (MBP), glutathione S-transferase (GST), thioredoxin 
(TRX), NUS A, ubiquitin (Ub ), and a small ubiquitin-related 
modifier (SUMO). 
55 In some embodiments, the compositions disclosed herein 
include expression or solubility enhancing amino acid 
sequence. In some embodiments, the expression or solubility 
enhancing amino acid sequence is cleaved prior administra-
tion of the composition to a subject in need thereof. The 
60 expression or solubility enhancing amino acid sequence can 
be cleaved in the recombinant expression system, or after the 
expressed protein in purified. In some embodiments, the 
expression or solubility enhancing is a ULPl or SUMO 
sequence. Recombinant protein expression systems that 
65 incorporate the SUMO protein ("SUMO fusion systems") 
have been shown to increase efficiency and reduce defective 
expression of recombinant proteins in E. coli., see for 
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example Malakhov, et al., J. Struct. Funct. Genomics, 5: 
75-86 (2004), U.S. Pat. No. 7,060,461, and U.S. Pat. No. 
6,872,551. SUMO fusion systems enhance expression and 
solubility of certain proteins, including severe acute respira-
tory syndrome coronavirus (SARS-CoV) 3CL protease, 
nucleocapsid, and membrane proteins (Zuo et al., J. Struct. 
Funct. Genomics, 6:103-111 (2005)). 
B. Purification of Expressed Proteins 
Composition and methods for purification, or the substan-
tial purification, of an encoded protein or peptide are also 10 
disclosed. The term "purified protein or peptide" as used 
herein, is intended to refer to a composition, isolatable from 
other components, wherein the protein or peptide is purified 
to any degree relative to its naturally-obtainable state, i.e., in 
this case, relative to its purity within a hepatocyte or p-cell 15 
extract. A purified protein or peptide therefore also refers to a 
protein or peptide, free from the environment in which it may 
naturally occur. 
Generally, "purified" will refer to a protein or peptide com-
position that has been subjected to fractionation to remove 20 
various other components, and which composition substan-
tially retains its expressed biological activity. Where the term 
"substantially purified" is used, this designation will refer to 
a composition in which the protein or peptide forms the major 
component of the composition, such as constituting about 25 
50% or more of the proteins in the composition. 
Various methods for quantifying the degree of purification 
of the protein or peptide will be known to those of skill in the 
art in light of the present disclosure. These include, for 
example, determining the specific activity of an active frac- 30 
ti on, or assessing the number of polypeptides within a frac-
tion by SDS/PAGE analysis. A preferred method for assess-
ing the purity of a fraction is to calculate the specific activity 
of the fraction, to compare it to the specific activity of the 
initial extract, and to thus calculate the degree of purity, 35 
herein assessed by a "-fold purification number". The actual 
units used to represent the amount of activity will, of course, 
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It is known that the migration of a polypeptide can vary, 
sometimes significantly, with different conditions of SDS/ 
PAGE. It will therefore be appreciated that under differing 
electrophoresis conditions, the apparent molecular weights of 
purified or partially purified expression products may vary. 
III. Methods of Identifying and Testing Activity of 
Amine Dehydrogenases 
Compositions and methods of screening a library of amino 
acid dehydrogenase variants for amine dehydrogenase activ-
ity and characterizing the amine dehydrogenase activity of an 
AmDH are disclosed. 
A. Methods of Screening for Amine DehydrogenaseActiv-
ity 
Methods of screening for amino acid dehydrogenase vari-
ants with amine dehydrogenase activity are known in the art 
and describe in the Examples below. For example, in some 
embodiments, AmDHs are identified as having amine dehy-
drogenase activity using a NAD+ auto-fluorescence assay, a 
formazan-based assay, a deamination of 1,3 DMBA assay, or 
a combination thereof. 
1. NAD+Auto-fluorescence Assay 
NAD+ auto-fluorescence assay are known in the art, see, 
for example, (Kaplan, et al., Journal of Biological Chemistry, 
191, (2): 461-472 (1951); Lowry, et al., J. Biol. Chem., 224: 
1047-1064 (1957); Tsotsou, et al., Biosensors and Bioelec-
tronics, 17, (12): 119-131 (2002)). In an optimal system, 
sensitivities as low as 0.01 µM NAD(P)+ fluorophore were 
observed (Seidemann, New York, N.Y. Academic Press 
(1973)). Generally, expression plates containing cell culture 
pellets are resuspended in Cell Lysing agent. The resulting 
cell lysate divided into two separate plates, one reaction plate 
and one background plate. For the background plate, reaction 
buffer only is added. No substrate is added to the background 
plate. A buffer can be, for example, 1.1 mM NADH in 500 
mM NH4 Cl/NH4 0H buffer pH 9.6 which will only result in 
background conversion rates. Reaction buffer containing a 
ketone substrate, such as MIBK, is added reaction plates. The 
be dependent upon the particular assay technique chosen to 
follow the purification and whether or not the expressed pro-
tein or peptide exhibits a detectable activity. 40 plates are incubated for period of time to allow for conversion. 
Various techniques suitable for use in protein purification 
will be well known to those of skill in the art. These include, 
for example, precipitation with anm10nium sulphate, polyeth-
ylene glycol, antibodies and the like or by heat denaturation, 
followed by centrifugation; chromatography steps such as ion 45 
exchange, gel filtration, reverse phase, hydroxylapatite and 
affinity chromatography; isoelectric focusing; gel electro-
phoresis; and combinations of such and other techniques. As 
is generally known in the art, it is believed that the order of 
conducting the various purification steps may be changed, or 50 
that certain steps may be omitted, and still result in a suitable 
method for the preparation of a substantially purified protein 
or peptide. 
There is no general requirement that the protein or peptide 
always be provided in their most purified state. Indeed, it is 55 
contemplated that less substantially purified products will 
have utility in certain embodiments. Partial purification may 
be accomplished by using fewer purification steps in combi-
nation, or by utilizing different forms of the same general 
purification scheme. For example, it is appreciated that a 60 
cation-exchange colunm chromatography performed utiliz-
ing an HPLC apparatus will generally result in a greater-fold 
purification than the same technique utilizing a low pressure 
chromatography system. Methods exhibiting a lower degree 
of relative purification may have advantages in total recovery 65 
of protein product, or in maintaining the activity of an 
expressed protein. 
After reaction, the fluorophore is generated through a pH 
shift. First the residual NADH is removed by adjusting the pH 
to 1.0 through the addition of an acid, such as 6N HCI, and 
incubated for a suitable period of time, for example about 30 
minutes. At this pH value, the NADH will rapidly degrade 
while leaving the stable NAD+. To create the NAD+ fluores-
cence, the pH value was re-adjust to> 13.0 by adding a base, 
for example, 10 N NaOH and incubated in the dark for a 
suitable period of time, for example about 2.5 hours. Fluo-
rescence can be measured using a spectrofluorometer at an 
excitation wavelength of360 nm and emission wavelength of 
455 nm. 
Wells containing lysates from different AmDH can be 
ranked based upon the differential increase in fluorescence 
over the background plate. NAD+ concentrations can be dis-
tinguished as low as 1-2 µmo! to above 100 µmo!. This allows 
for the identification of very slight improvements in AmDH 
activity. 
2. Formazan-BasedAssay 
Formazan-based assays are known in the art, see, for 
example, (Chen, et al., Journal of Biotechnology, 142, (2): 
127-134 (2009)). This assay takes advantage of the elevated 
activity in the deamination direction, giving the assay a good 
signal-to-noise ratio. The reaction scheme is represented in 
FIG. 4. The enzymatic deamination activity is related to con-
version of NAD+ cofactor to produce NADH, which is re-
oxidized back to NAD+ by phenazine ethosulfate. The result-
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ing reduced PES subsequently reduces 2-(4-iodophenyl)-3-
( 4-nitrophenyl)-5-phenyltetrazolium chloride hydrate (INT, 
Sigma Aldrich) to create formazan. Formazan creates a deep 
red color which can be characterized by absorbance at 495 
nm. Cell lysate are prepared as discussed above for the NAD+ 
auto-fluorescence assay. Deamination buffer, for example, 1 
mM NAD+, a catalytic amount of PES, and 0.1 M glycine 
buffer at pH 10.0 is added to the background plate. The 
reaction plate buffer also contains a substrate, for example, 80 
mM 1,3-DMBA. Plates are allowed to incubate for a suitable 10 
period, for example, 30 min at room temperature, and absor-
bance readings are taken. 
3. Assay Measuring the Deamination of 1,3-DMBA 
A third assay involves measuring the absorbencies at two 15 
wavelengths, 340 nm and 600 nm. The increased absorbance 
at 340 nm corresponds to the production of NADH in the 
deamination of 1,3-DMBA, while the 600 nm reading 
roughly estimates the biomass present in the well. The absor-
bance at 600 nm correlates strongly the background absor- 20 
bance at 340 nm (see, for example, FIG. 6). 
The absorbance at 340 nm is normalized by the 600 nm 
absorbance reading for both the reaction and background 
plates. Variants are scored by their proportional increase over 
the background observed in each well (Equation 1, below). 25 
This method reduces background noise of the assay by 
accounting for differences in expression levels, resulting in 
more accurate determination of enzymatic activity and 
decreasing false positives. The resulting quantity roughly 
estimates the specific activity of the overexpressed mutant 30 
protein. 
Equation 1 
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14, 15, 16, 17, 18, 24, 36, 48 or more hours. In some embodi-
ments, the reaction is treated with addition AmDH and 
allowed to react for an additional 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 
12, 13, 14, 15, 16, 17, 18, 24, 36, 48 or more hours. The 
replicates can then be compared against a calibration curve 
derived by the same procedure with simulated levels of con-
version to determine the rate of conversion. 
The product amine can also be identified through 1 H NMR. 
3. Enantioselectivity 
The enantioselectivity can be estimated for the disclosed 
AmDH. For example, enantioselectivity can be estimated by 
measuring the deamination activity toward individual enan-
tiomers ofmethylbenzylamine (MBA). 
Derivatization with trifluoroacetic anhydride (TFAA) and 
chiral gas chromatography can also be used to separate and 
quantify individual enantiomers (Supelco, Sigma-Aldrich: 
Bellefonte, Pa., ( 1997)). 
Enantiomers can also be identified by optical rotation. 
4. Thermostability 
The thermostability of AmDH can be compared to the 
scaffold amino acid dehydrogenase, for example, by circular 
dichroism. Each protein can be analyzed over a range of 
temperatures, for example from 25° C. to 95° C., to determine 
melting temperature and characterize stability. In some 
embodiments, the AmDH is analyzed using a temperature 
verse activity assay such as those described in the Examples 
below. 
IV. Methods ofUsing Recombinant Amine 
Dehydrogenases 
Compositions including AmDHs and methods of use 
thereof are also disclosed. Asymmetric synthesis by amine 
dehydrogenases (AmDHs) is a preferred method of making 
340 nmR/B 
600 nmR/B 
Reaction 
Ratio of activity ----
Background 
Reaction 
Ratio of biomass Background 
B. Methods of Characterizing Amine Dehydrogenase 
Activity 
35 chiral amines. Chiral amines have found widespread applica-
tion in asymmetric synthesis serving, for instance, as chiral 
bases in enantioselective deprotonation reactions or being 
valuable substances for resolving racemic mixtures of acids. 
Additionally, chiral amines are prevalent, important parts of 
40 many drugs and drug candidates. For example, chiral amines 
are utilized when designing alkaloids, and are preferred for 
drug development because they hold greater diversification 
potential verses secondary or tertiary chiral amine building 
blocks. 
The activity of the AmDH can be characterized using 
assays that measure, for example, deamination, amination, 
substrate selectivity, conversion of the substrate to product, 
enantioselectivity, thermostability, or combinations thereof. 
Methods for determining such characteristics are known in 45 
the art, and exemplary methods are provided in the Examples 
below. 
1. Amination and Deamination 
Generally, methods of making chiral amines include react-
ing or contacting a suitable substrate with an effective amount 
of AmDH or a fragment thereof in combination with a co-
factor such as NADH to produce a chiral amine. The reaction 
is typically carried out in a reaction mixture, which typically Amination and deamination activity and substrate speci-
ficity can be tested over a range of concentrations for different 
ketones and amines. For example, MIBK and 1,3-D MBA can 
be used to determine kcat and KM of the amination and deami-
nation reactions, respectively. 
50 includes a suitable buffer. 
2. Conversion 
In some embodiments, the buffer contains NH4 COO (am-
monium formate) in a range from about 200 mM to about 5 M. 
The buffer can have a pH range from between about 9.5 and 
about 10.0. For example the pH can be 9.6. Suitable salts 
55 include, but are not limited to, NaCl, NH4 Cl, (NH4)2S04, 
and NH4CH3COO. 
Initial rate kinetic measurements are used primarily in the 
determination of kinetic parameters to avoid second-order 
effects and product inhibition. The enzyme's ability to reach 
complete substrate conversion cannot be determined from 
these initial rate experiments, but can instead be evaluated by 
chiral GC of conversion with a GDH recycle system. The 60 
GDH regenerates the expensive NADH by redox reaction of 
NAD+ and inexpensive glucose (FIG. 1). For example, in 1.5 
mL reactions, replicates containing substrate (for example, 
10 mM MIBK or 20 mM PFPA) can be mixed with an excess 
of glucose (i.e., 12 mM), GDH (i.e., 10 U), and a catalytic 65 
amount ofNADH (200 µM); mixed withAmDH and allowed 
to react, for example, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 
An exemplary buffer is a NH4 Cl/NH40H buffer, for 
example, 225 mM NH4 Cl/NH4 0H buffer at pH 9.6. 
The aqueous phase containing the enzyme and cofactor can 
contact an organic phase of a solvent or solvent mixture with 
limited miscibility with water, which contains part of the 
ketone substrate. Examples of suitable organic solvents can 
contain hydrocarbons, such as heptane, hexane, or octane, 
ethers, such as methyl-tert.-butyl ether (MTBE), diisopropy-
lether (DIPE), di-n-butylether, esters, such as ethyl acetate, 
butyl acetate, isoamyl acetate, or isopropyl acetate, and (het-
ero )aromatics, such as toluene. 
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Once the compound having a chiral amine is produced, it 
can be isolated, concentrated, or reacted with at least a second 
reagent to produce a desired enantiomeric product. 
Compositions and methods for attaching an AmDH on a 
solid support through adsorption, electrostatic interactions, 
covalent bonding, or entrapment are also disclosed. Such a 
solid support can be employed as a single bead or in a packed-
bed reactor. 
36 
gram of soluble protein allowing for successful catalysis. A 
two plasmid system is preferred for AmD H with high specific 
activity. 
This approach was applied to the whole-cell asymmetric 
reductive amination of a-keto acids which represents a useful 
methodology for the synthesis of a-amino acid L-leucine 
(Bommarius, Wiley-VCR. p. 1047-1063 (2002)). LeuDH 
from B. cereus was chosen for the reductive amination and 
FDH from C. boidinii for the cofactor regeneration. The main In some embodiments, the AmDH in a gel, such as those 
created with aqueous buffer, hydrocarbon, and surfactant 
molecules, such as alkyl-ethoxyalcohols of structure (Cn 
H2n+l)m(EO)P--OH, where m, n, and peach are greater than 
or equal to 2. Such gels are useful for preserving activity and 
stability, allowing use in liquid media, and in uses requiring 
applications of the enzyme-gel system in a layer, such as in 
coating or personal care applications. 
10 challenge for successful co-expression of this system was the 
large discrepancy of specific activity between the two 
enzymes; -400 U/mg for LeuDH and only 6 U/mg for FDH. 
This obstacle was overcome by creating a co-expression sys-
tem based on the same inducible promoter, but locating the 
15 genes on two E. coli plasmids with different copy numbers. 
Another embodiment provides a method for using AmDH 
To compensate for its low activity, FDH was expressed in 
plasmid pAM3-25 which has a higher copy number. Con-
versely, LeuDH was expressed in plasmid pAMl0-1, a 
medium copy number plasmid (Menzel, et al., Eng. Life Sci., as a biosensor for NADH-specific events in unknown probes, 
such as aqueous solutions, tissues, or fermentation samples. 
A. Cofactor Recycling 
20 4:573-576 (2004)). The two plasmids were transformed into 
BW3110, an E.coli strain suitable for high-density fermen-
tation (Wilms, et al., Biotechnology and Bioengineering, 73, 
(2): 95-103 (2001)). The resulting combination gave similar 
specific activities per gram of soluble protein and in specific 
When paired with a cofactor recycling system, such as 
glucose/glucose dehydrogenase (GDH) or formate/formate 
dehydrogenase (FDH), amine dehydrogenases, such as those 
disclosed herein, allow for the direct production of chiral 
amines, with the consumption of only an inexpensive reduc-
ing agent, such as glucose or formate, and free ammonia 
(FIG. 1) (Vaquez-Figueroa, Chembiochem, 8, (18): 2295-
2301 (2007); Ma, et al., Green Chemistry, 12, (1): 81-86 
(2010); Popov, et al., The Biochemical Journal, 301 (Pt 3): 30 
625-643 (1994); Van Der Dank, et al., Current Opinion in 
Biotechnology, 14, (4): 421-426 (2003)). The regeneration of 
the cofactor significantly reduces the substrate cost by requir-
ing only catalytic amounts of the expensive cofactor, instead 
oflarge stoichiometric quantities. The Examples below illus- 35 
tratethat glucose dehydrogenase (GDH) can be used to regen-
erate NADH. Accordingly, in some embodiments, theAmDH 
are used in combination with a glucose dehydrogenase for 
synthesizing chiral amines. 
25 cases achieved nearly 100% conversion to L-leucine. Similar 
strategies can be applied can be used in a co-expression 
system utilizing the disclosedAmDH and a cofactor such as 
GDHorFDH. 
2. Enzyme Membrane Reactor 
An alternative option to whole-cell catalysis is an enzyme 
membrane reactor (EMR); which have been successful in the 
industrial application of enzymatic processes. In these sys-
tems, enzymes do not require simultaneous expression and 
instead can be combined at the appropriate ratio within the 
reactor. EMR reactors do however require purification of the 
desired enzymes, which can be achieved through various 
purification techniques known in the art (Bommarius, et al., 
Wiley-VCR Verlag GmbH & Co., (2004)). This system 
would utilize the same AmDH and FDH enzymes as the 
whole-cell system discussed above. Each enzyme is indepen-
dently expressed and loaded to the reactor to yield similar 
specific activities per gram of protein. Reaction conditions 
such as flow rate, temperature, substrate concentration, and 
enzyme loading are optimized to increase conversion. 
Enzymes can easily be contained within the reactor by restric-
tion of the membrane pore size. To keep the cofactor from 
penetrating the membrane, it may be enlarged with polyeth-
ylene glycol (PEG) (Wolfgang, et al., Biotechnology and 
Bioengineering, 32, (2): 130-139 (1988)). Otherwise, it can 
A second cofactor recycle system is formate dehydroge- 40 
nase (FDH). FDH allows for the same regeneration of cofac-
tor, and simultaneously allow for improved atom economy 
relative to GDH. Instead of supplying the additional glucose 
substrate for the GDH system, the formate dehydrogenase 
could rely on formate present in an ammonium formate buffer 45 
system. Formate dehydrogenases offer the additional advan-
tage of having specific activities more closely to that of the 
AmDHs, approximately 10 U mg- 1 simplifying the use of 
co-expression (Slusarczyk, et al., European Journal of Bio-
chemistry, 267, (5): 1280-1289 (2000)). 50 simply be recharged along with substrate. Lastly, this final-
ized reaction process would be used to isolate the reaction 
product (-10 g) for analysis of chemical and enantiomeric 
purity. 
B. Methods of Making Chiral Amines 
The AmDH disclosed herein can be used in enzymatic 
reactions, including industrial scale enzymatic reactions, to 
produce chiral amines. Methods of using enzymes, such as 
AmDH, to produce chiral amines are known in the art. Two 55 
exemplary enzymatic schemes include i) whole-cell catalysis 
containing a suitable co-expression system capable of cofac-
tor recycle, and ii) an enzyme membrane reactor capable of 
continuous production of chiral amine and co-factor recycle. 
1. Whole Cell Catalysis 
With nearly equivalent specific activities, theAmDH (1-10 
U mg- 1 ) and formate dehydrogenase (FDH), such as formate 
dehydrogenase from Candida boidinii (6 U mg- 1), can be 
expressed on separate plasmids, or a dual gene plasmid, such 
3. Organic Co-Solvent Systems 
Enzymatic synthesis in non-aqueous media is a suitable 
alternative to traditional chemical synthesis. Many target 
active pharmaceutical intermediates, such as tetralones or 
diketones (i.e., l-phenyl-1,2-propanedione, alpha-tetralone, 
beta-tetralone, etc.), have limited solubility in aqueous 
60 media. An organic cosolvent can be used increase the solu-
bility of these substrates. Solvent selection is important and 
can greatly impact the hazard, environmental-friendliness, 
and cost of synthesis. Preferably, the organic solvent would 
as pETduet-1 (Merck Millipore, Billerica, Mass.) in expres- 65 
sion competent cells such as E.coli BL21 (DE3). The result-
ing co-expression should give similar specific activities per 
comply with ACS GCI Pharmaceutical Roundtable Solvent 
Selection Guide to maintain the green benefits of an enzy-
matic reaction. Amino acid dehydrogenases have been stud-
ied in organic solvents (Cainelli, et al., Organic & Biomo-
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lecular Chemistry, 3, (24): 4316-4320 (2005)). It is believed 
that strategies developed for co-solvent system utilizing 
amino acid dehydrogenases can also be utilized with the 
AmDH disclosed herein (see Example 5 below). 
Therefore, in some embodiments, the AmDH is stable in a 5 
solution including an organic solvent. Stable refers to retain-
ing amine dehydrogenase activity in the presence of organic 
solvents. Representative organic solvents include, but are not 
limited to acetone, acetonitrile, HEPES, triethanolamine, 
dioxane, and tetrahydrofuran. In certain embodiments, the 10 
AmDH is stable in from about 1.0% to about 60% organic 
solvent or more than 10%, 20%, 30%, 40% or 50% organic 
solvent. 
In some embodiments, an AmD H that retains amine dehy-
drogenase activity in solutions including about 60% organic 15 
solvent compared to the AmDH in the absence of organic 
solvents. In certain embodiments, the AmDH retains at least 
30% amine dehydrogenase activity in the presence of about 
15% organic solvent, or at least 15% activity in about 30% 
organic solvent, or at least about 5% activity in 40% organic 20 
solvent. 
38 
limited to, codeine (3-methylmorphine), ZOLOFT® (sertra-
line), PRANDIN® (repaglinide), methadone, FLOMAX® 
(tamsulosin), JANlNIA® (sitagliptin), TAMIFLU® (oselta-
mivir phosphate), sibutramine, cinacalcet, EXELON® (ri-
vastigmine ), lariam, ethambutol, and lopinavir. 
EXAMPLES 
Example 1 
Preparation of Leucine dehydrogenase Variants with 
Amine Dehydrogenase Activity 
Materials and Methods 
gDNA Preparation, Gene Isolation and Overexpression 
Leucine dehydrogenase (E.C. 1.4.1.9) from Bacillus 
stearothermophilus was donated by Assistant Professor Bert 
C. Lampson from East Tennessee State University, followed 
by isolation of the genomic DNA through application of 
method B described by Mehling et al. (Mehling, et al., FEMS 
Microbiology Letters, 128, (2): 119-125 (1995)). The isolated 
gene (1104 bp) was inserted into pETl 7b vector (Life Tech-
nologies-Invitrogen, Grand Island, N.Y., USA) at the restric-
tion sites NdeI and HindIII (New England Biolabs) using T4 
Still another embodiment provides a vector comprising a 
nucleic acid of encoding an AmDH operably linked to a 
promoter. The vector expresses the encoded polypeptide in a 
form that retains amine dehydrogenase activity in the pres-
ence of about 1 % to about 60% organic solvent. 
C. Substrates and Products 
a. Substrates 
25 DNA Ligase (Roche, South San Francisco, Calif., USA) at 
16° C., 8 hours. This allowed for overexpression upon trans-
formation into E. coli BL21 DE3 competent cells (Life Tech-
nologies). Cultures were expressed at 37° C. in LB media for 
24 hours. Cultures were induced with IPTG at and OD600 The AmDHs disclosed herein can be used in combination 
with a variety of substrates to produce chiral amines. Sub-
strates can be selected by one of skill in the art based on the 
specificity and activity oftheAmDH. Instead of the wild-type 
alpha-keto acid, the amine dehydrogenases disclosed herein 
accept the analogous ketone, methyl isobutyl ketone (MIBK), 
corresponding to removal of the carboxyl moiety in a reduc- 35 
tive amination reaction (FIG. 1). 
30 between 0.4 and 0.6 absorbance. Overexpression was evident 
by SDS-PAGE identifying a high protein concentration at 
40.5 kDa. 
The Examples below illustrate the LeuDH-AmDH dis-
closed herein have activity toward a number of different sub-
strates including, MBA, cyclohexylamine, cylcohexanone, 
ethyl pyruvate, methyl aceto acetate, ethyl-3-oxohexanoate, 40 
and acetophenone. 
Protein Purification 
For purification, proteins were expressed in pET28a vector 
(Life Technologies) in BL21 (DE3) with an N-terminal 
Histag. The gene was inserted in the vector at restriction sites 
NdeI and HindIII. His-tagged proteins were expressed in a 
similar manor as (Section 3.2.1) at 37° C. for 24 hours. 
His-tagged proteins were subsequently purified using immo-
bilized metal ion affinity chromatography (IMAC) with a 
Ni-NTA resin (Thermo Scientific, Rockford, Ill., USA). Cell 
culture pellets were made by centrifugation ( 4000 rpm, 30 
min, 4° C.) in 50 mL aliquots. Cell pellets were resuspended 
in 50 mM phosphate buffer (6 mL) at pH 8.0 containing 20 
mM imidazole and 300 mM NaCl. This was followed by 
sonication and centrifugation to remove cell debris. The clari-
fied cell lysate was bound to the Ni-NTA resin by shaking on 
ice for 1 hour, and subsequently purified by colunm affinity 
chromatography. Protein-bound resin and clarified cell 
The Examples below also illustrate that the PheDH-
AmDH disclosed herein typically have increased specific 
activity and broader substrate scope than the LeuDH-AmDH 
counterparts. The substrate scope of Phe-DH-AmDH include 45 
amination of diverse ketones, including aromatic ketones. 
The ranges of ketone substrates varies in structure from small 
aliphatic ketones such as 3-methyl-2-butanone, to larger aro-
matic ketones with additional functionality, such as phenoxy-
2-propanone. 
The Examples below illustrate that a preferred PheDH-
AmDH, K77S/N276L, exhibits elevated activity toward 
methylketones versus ethylketones or cyclic ketones. The top 
five most active ketones; PFPA, phenoxy-2-propanone, 
2-hexanone, methyl isobutyl ketone and 3-methyl-2-bu- 55 
tanone are all methyl-ketones. This specificity is also 
observed in the large differences in activity toward 2-hex-
anone (155.7 mU/mg) versus 3-hexanone (1.6 mU/mg): 
despite their structural similarities, the methylketone 2-hex-
anone exhibited approximately 100-fold higher activity. 1,3 60 
Phenylbutanedione exhibits an activity level of30 mU/mg. 
50 extract was poured over a colunm, and washed twice with 50 
mm phosphate buffer (5 mL) at pH 8.0 containing 50 mM 
imidazole and 300 mM NaCl. Purified protein was eluted 
with the same buffer solution containing 250 mM imidazole 
b. Products 
AmDH can be used in the synthesis of a number of com-
pounds. In preferred embodiments, the AmDH is used to 
prepare amine-based compounds, such as amine-based phar-
maceutical drugs. Exemplary pharmaceutical drugs have 
chiral amine moieties. Exemplary drugs include, but are not 
(2 mL). An SDS-PAGE gel of a representative purification 
can be seen below. The leucine dehydrogenase protein can be 
seen at 42.5 kDa with his-tag attached. 
Spectrophotometric Assay 
Activity of purified proteins was measured using a spec-
trophotometric assay at 340 nm, corresponding to the cofac-
tor nicotinamide adenine dinucleotide (NADH, E 340=6220 
M- 1 cm- 1 ) (Dawson, et al., Clarendon Press, (1989). For 
reductive amination, reactions took place in 500 mM NH4Cl/ 
NH4 0H at pH 9.6, with 200 µM NADH and 20 mM of the 
ketone substrate, unless otherwise specified. For oxidative 
65 deamination, reactions took place in 0.1 MNaHC03 /Na2 C03 
buffer at pH 10.0, with 1 mMNAD+with lOmMoftheamine 
substrate of interest. All reactions were performed at 25° C. 
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unless otherwise specified. Enzyme was added in 10 µL ali-
quots in dilute concentrations. Enzyme concentrations varied 
upon activity levels with the substrate present, but were dilute 
enough to ensure linear conversion kinetics over the analyti-
cal time period (10 min to 30 min). Specific activities were 
then calculated from the stoichiometric conversion of cofac-
tor as determine by the change in absorbance at 340 nm over 
time. 
the primers used in amplification of each library is provided in 
Table 3. 
The randomized libraries were plated on Genetix 1O"xl0" 
in. agar plates (Molecular Devices, Sunnyvale, Calif., USA) 
containing 200 mL of LB-agar with 50 µg/mL ampicillin, and 
allow to grow for 18-24 hours at 37° C. The resulting colonies 
were autonomously picked using a Genetix QPix2 Colony 
Picker (Molecular Devices), and inoculated in 96-well micro-
titer plates containing 200 µL of LB media with 50 µg/mL 
Mutagenesis and Library Generation 
Mutant libraries were generated using overlap extension 
PCR. After identification of mutational sites, primers were 
designed according to the guidelines of the 
QUIKCHANGE® Site Directed Mutagenesis Protocol (Agi-
lent Technologies, Santa Clara, Calif., USA). These primers 
were then used in the overlap extension protocol described in 
Molecular Cloning: A Laboratory Manual. The overlap 
extension method has several advantages. It requires the suc-
cessive amplification of DNA segments, making it easier to 
troubleshoot than the blind success or failure of the 
QUIKCHANGE® protocol. Additionally, the overlap exten-
10 
ampicillin (LB-AMP). The plates were covered in Parafilm M 
(Bremis, Neenah, Wis., USA) to prevent cross contamination 
between wells, and incubated at 37° C., 200 rpmfor 24 hours. 
The plates were then replicated into expression plates con-
taining 250 µL of auto-inducing MAGICMEDIA™ (Life 
Technologies) containing 50 µg/mL ampicillin. Glycerol 
15 (100 µL) was added to the LB-AMP 'master' plate, and stored 
at -80° C. for later sequence resurrection and identification. 
The expression plates were covered with Parafilm M and 
incubated at 37° C. for 24 hours, resulting in the overexpres-
sion of protein variants (FIG. 3 .5). The expression plates were 
20 centrifuged (1,000 rpm, 30 min, 4° C.), decanted, and stored 
at -80° C. until screened. 
TABLE 3 
Table of forward (Fwd) and reverse (Rev) primers used in the 
generation of LeuDH mutant libraries. 
Library Primer 
3 Fwd 5'AGGGCTGAACGGCCGCTACATTACGGBGNNTRABRTKGGCACGACCGTTGCCGATATGGA 3' (SEQ 
Rev 5'ATCCATATCGGCAACGGTCGTGCCMAYVTYANNCVCCGTAATGTAGCGGCCGTTCAGCCCT 3' (SEQ 
4 Fwd 5'ATTCATGACACGACGCTCGGCCCGGCGDBWGBCDBWACGCGCATGTGGATGTACAATTC 3' (SEQ 
Rev 5'GAATTGTACATCCACATGCGCGTWVHGVCWVHCGCCGGGCCGAGCGTCGTGTCATGAAT 3' (SEQ 
5 Fwd 5'GATTATGTGATCAACNNKGGCGGCGTCATCAACG 3' (SEQ 
Rev 5'CGTTGATGACGCCGCCMNNGTTGATCACATAATC 3' (SEQ 
6 Fwd 5'CAACGCCGGCGGCDBSATCAACDBSGCCGATGAGCTGTACGGC 3' (SEQ 
Rev 5'GCCGTACAGCTCATCGGCSVHGTTGATSVHGCCGCCGGCGTTG 3' (SEQ 
7 Fwd 5'CTGAACGGCCGCTACATTACGNNKGTTGACGTTGGCACGACCG 3' (SEQ 
Rev 5'CGGTCGTGCCAACGTCAACMNNCGTAATGTAGCGGCCGTTCAG 3' (SEQ 
8 Fwd 5'CGCCGGCGGCGTCNNKAACGTCGCCGATGAGCTGTA 3' (SEQ 
Rev 5'TACAGCTCATCGGCGACGTTMNNGACGCCGCCGGCG 3' (SEQ 
9 Fwd 5'CGTCATCAACGTCGCCGATNNKCTGTACGGCTACAACCGTGAACG 3' (SEQ 
Rev 5'CGTTCACGGTTGTAGCCGTACAGMNNATCGGCGACGTTGATGACG 3' (SEQ 
10 Fwd 5'CGCCGGCTCGGCGNNKAATCAGCTGAAAGAGCCGCG 3' (SEQ 
Rev 5'CGCGGCTCTTTCAGCTGATTMNNCGCCGAGCCGGCG 3' (SEQ 
11 Fwd 5'CCCGCGGCATGACGTACDDKAACGCGGCCGCCG 3' (SEQ 
Rev 5'CGGCGGCCGCGTTMHHGTACGTCATGCCGCGGG 3' (SEQ 
Fwd 5'CGCCGGCTCGGCGDDKAATCAGCTGAAAGAGCCGCG 3' (SEQ 
Rev 5'CGCGGCTCTTTCAGCTGATTMHHCGCCGAGCCGGCG 3' (SEQ 
Results 
ID NO, 29) 
ID NO, 30) 
ID NO, 31) 
ID NO, 32) 
ID NO, 33) 
ID NO, 34) 
ID NO, 35) 
ID NO, 36) 
ID NO, 37) 
ID NO, 38) 
ID NO, 39) 
ID NO, 40) 
ID NO, 41) 
ID NO, 42) 
ID NO, 43) 
ID NO, 44) 
ID NO, 45) 
ID NO, 46) 
ID NO, 47) 
ID NO, 48) 
sion method does not potentially carry over whole plasmid 
from the parent DNA into the final transformation. This sig-
nificantly decreases the amount of non-mutated colonies 
present in the screened library. After mutation, the resulting 65 
mutated gene was digested using Ndel and HindIII, ligated 
into pETl 7b, and expressed as described below. A listing of 
Previously characterized amine dehydrogenases were 
incapable of effecting the reductive amination ofketones and 
lacked stereoselectivity (Itoh, et al., Journal of Molecular 
Catalysis B: Enzymatic, 10, (13): 281-290 (2000)). There-
fore, as discussed in more detail below, beginning with an 
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existing amino acid dehydrogenase scaffold, the substrate 
specificity of the enzyme was altered through several rounds 
of protein engineering to create an amine dehydrogenase. 
Instead of the wild-type a-keto acid, the amine dehydroge-
nase now accepts the analogous ketone, methyl isobutyl 
ketone (MIBK), which corresponds to replacement of the 
carboxyl moiety with a methyl group (FIG. 2). 
Leucine dehydrogenase from Bacillus stereothermophilus 
served as the initial protein scaffold. The wild-type leucine 
dehydrogenase exhibited no measurable activity toward the 10 
reductive amination of MIBK. 
42 
chance of altering the substrate specificity. The number of 
colonies required to achieve 95% statistical coverage was 
calculated using Equation 2. 
ln(l-P) 
N=---· 1n(1-~)' 
N = number of colonies required in screening, 
P = statistical percent of coverage of library, 
1 
- = proportion of the least represented codon 
n 
Equation 2 
An example set of the degenerate codons applied in library 
3 demonstrates the breadth of mutation over the four residues; 
Alal 12, Glu113, Asp114, and Vall 15 (Table 5). These four 
residues create a loop region along the binding pocket. The 
side chains ofresidues 113 and 115 face toward the binding 
pocket, while 112 and 114 are directed outward. Residues 113 
and 115 are believed to have strong interactions in stabilizing 
the imine intermediate, and for this reason will be widely 
mutated excluding only mutations which create unfavorable 
Residue Lys67 ofLeuDH directly interacts with the carbo-
nyl moiety of the amino acid substrate through favorable 
charge interactions, and was chosen as the initial point of 15 
mutation (Brunhuber, et al., Biochemistry, 39, (31 ): 917 4-
9187 (2000); Sekimoto, et al., Journal of Biological Chemis-
try, 268, (36): 27039-27045 (1993)). Library 1 included 
mutation to each of the remaining 19 amino acids. The result-
ing variants were cloned into pET28a vector and BL21 (DE3) 20 
competent cells for subsequent expression and His-tag puri-
fication. Each purified variant was analyzed spectrophoto-
metrically at 340 nm to correlate the NADH/NAD+ cofactor 
conversion with the amination and deamination activity (93 ). 
25 charge interactions or drastic steric hindrance. Conversely, 
residues 113 and 115 are likely to have less interaction. These 
residues' mutations will be restricted to amino acids similar 
to the wild type residues, limiting mutational breadth to 
greatly reduce the required screening effort. 
TABLE4 
Grouping of active-site residues in B. stearothermophilus LeuDH. 
Library PheDH LeuDH with degenerate codons Library screening size[a] 
2 
4 
7 
9 
10 
11 
K66 
M63 
K66 
Gll6 
P117 
D118 
V119 
A38 
G39 
G40 
S189 
A292 
L295 
Gll6 
1293 
E299 
N263 
K66 
N263 
K67[bJ 20 
M64NNK 3066 
K67NNK 
A112 GBC 3450 
E113 NNT 
D114 RAB 
V115 RTK 
L39DBW 2910 
G40 GBC 
G41 DBW 
H187 NNK 94 
V290 DBS 969 
V293 DBS 
A112NNK 94 
1291 NNK 94 
E296NNK 94 
N261 NNK 94 
K67 DDK 969 
N261 DDK 
[a]Required screening for 95% statistical coverage of library sequence space. 
[b]Analyzed as individual mutants using purified protein 
30 
35 
40 
45 
The remaining binding pocket residues were broken into 
groups on the basis of CASTing principles to create libraries 50 
2, 3, 4, and 6 (Table 4) (Reetz, et al., Angewandte Chemie-
International Edition, 44, (27): 4192-4196 (2005)). Regions 
of the binding pocket were grouped based upon their primary 
structure. The breadth of mutation at each position was then 55 
narrowed by their interactions based upon secondary struc-
ture. For example, every other amino acid side chain interacts 
with one another in a ~-sheet, while only every fourth amino 
acid of an a-helix does the same. Interacting residues within 
each group were mutated simultaneously to capture any syn- 60 
ergistic effects with neighboring residues. The mutational 
breadth at each position was constrained through degenerate 
codons to avoid amino acid substitutions which were likely 
detrimental to substrate binding (such as clear steric hin-
drance or unfavorable charge interactions). Removing a sub- 65 
set of detrimental amino acids limits the library size, so as to 
improve screening efficiency, while maintaining an increased 
Residue 
Codon 
Ala[AJ 
Arg [RJ 
Asn [NJ 
Asp [DJ 
Cys [CJ 
Gln[QJ 
Glu [EJ 
Gly[GJ 
His [HJ 
Ile [IJ 
Leu [LJ 
Lys [KJ 
Met[MJ 
Phe [FJ 
Pro [PJ 
Ser [SJ 
Thr [TJ 
Trp [WJ 
Tyr[YJ 
Val[VJ 
Stop 
Codons 
AA 
TABLES 
LeuDH library 3 distribution of degenerate codon 
amino acids at positions 113 through 116 
A112 
GBG 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
E113 
NNT 
0 
0 
0 
0 
2 
0 
0 
16 
15 
Single residue libraries (5, 7, 8, and 9) were broadly 
mutated to all 20 amino acids (codon: NNK), because of their 
small size and the insignificant decrease in the required 
screening effort by applying a more restrictive degenerate 
codon. 
Library 10 included mutation of binding pocket residue 
N261. This position was not initially considered for mutation, 
despite its interaction with the carboxy moiety of the wild-
type ligand, because of its involvement in binding the cofac-
tor. However, as only the backbone amino group of the resi-
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due interacts with the cofactor, an exception was made for 
mutation at this position. The desired protein interactions 
with the cofactor will be mostly preserved after substitution 
of the side chain due to the universal peptide backbone struc-
ture. Being a single residue library, N261 was broadly 
mutated to all 20 amino acids (codon: NNK) 
44 
Lastly, residues K67 and N261 were mutated simulta-
neously to create library 11. These residues have a synergistic 
effect with respect to binding the wild-type substrate's car-
boxyl moiety, and interact directly with one another. 
Example 2 
phenazine ethosulfate (PES, Sigma Aldrich). The resulting 
reduced PES subsequently reduces 2-( 4-iodophenyl)-3-( 4-
nitrophenyl)-5-phenyltetrazolium chloride hydrate (INT, 
Sigma Aldrich) to create formazan. Formazan creates a deep 
red color which can be characterized by absorbance at 495 
nm. Cell lysate was split in the same way as the previous 
assay. Deamination buffer(180 µL) containing 1 mMNAD+, 
a catalytic amount of PES, and 0.1 M glycine buffer at pH 
10.0 was added to the background plate. The reaction plate 
10 buffer also contained 80 mM 1,3-DMBA substrate. Plates 
were allowed to incubate for 30 min at room temperature 
before absorbance readings. 
Variant K67S/El 13V/N261LN290C is an Amine 
Dehydrogenase 
Production ofNADH in the Deamination of 1,3-DMBA 
15 Assay 
Materials and Methods 
Three different assays were used over the course of evalu-
ating the mutant libraries. Each subsequent assay method 
improved the quality of screening over previous methods. 
NAD+ Auto-Fluorescence Assay 
Libraries 2-5 were screened using an NAD+ auto-fluores-
cence assay (84-86). In an optimal system, sensitivities as low 
The final assay (FIG. 5) was used in the analysis oflibraries 
8 through 11. The assay involved reading the wells' absor-
bences at two wavelengths, 340 nm and 600 nm. The 
increased absorbance at 340 nm corresponds to the produc-
20 tion ofNADH in the deamination of 1,3-DMBA, while the 
600 nm reading roughly estimates the biomass present in the 
well. The absorbance at 600 nm correlates strongly the back-
ground absorbance at 340 nm (FIG. 6) as 0.01 µM NAD(P)+ fluorophore were observed (Seide-
mann, New York, N.Y. Academic Press (1973)). Expression 25 
plates containing cell culture pellets were resuspended in 50 
µL of B-Per Cell Lysing agent (Thermo Scientific). The 
resulting cell lysate was split into 20 µL aliquots in two 
separate plates, one reaction plate and one background plate. 
For the background plate, 180 µL of 1.1 mM NADH in 500 30 
mM NH4 Cl/NH40H buffer pH 9.6 was added to each well. 
This plate lacks the ketone substrate and will only result in 
background conversion rates. Similarly, 180 µL of the same 
buffer was added to the reaction plates, containing an addi-
tional 80 mM MIBK substrate. The plates were incubated at 35 
room temperature for 2 hours to allow for conversion. 
After reaction, the fluorophore was generated through a pH 
shift. First the residual NADH was removed by adjusting the 
pH to 1.0 through the addition of 30 µL, of 6N HCI and 
incubated for 25 minutes. At this pH value, the NADH will 40 
rapidly degrade while leaving the stable NAD+. To create the 
NAD+ fluorescence, the pH value was re-adjust to > 13 .0 by 
adding 80 µL, ofl 0 N N aO H and incubated in the dark for 2 .5 
hours. Fluorescence was measured using a Gemini Spectra-
max Microplate Spectrofluorometer (Molecular Devices, 45 
Downingtown, Pa., USA) at an excitation wavelength of360 
nm and emission wavelength of 455 nm (FIG. 3) (Tsotsou, et 
al., Biosensors andBioelectronics, 17, (12): 119-131 (2002)). 
Wells were ranked based upon the differential increase in 
fluorescence over the background plate. NAD+ concentra- 50 
tions can be distinguished as low as 1-2 µmo! to above 100 
mmol. This allows for the identification of very slight 
improvements in AmDH activity. The control experiment 
however, did not account for variations in expression levels 
between wells. This variation significantly reduced the sen- 55 
sitivity of the assay, and increased the identification of false 
positives. While the assay did yield successful mutants, its 
long reaction time and low signal to noise ratio were not ideal. 
F ormazan-Based Assay 
Libraries 6 and 7 were analyzed using a formazan-based 60 
assay developed by Chen et. al. (Chen, et al., Journal of 
Biotechnology, 142, (2): 127-134 (2009)). This assay takes 
advantage of the elevated activity in the deamination direc-
tion, giving the assay a better signal-to-noise ratio. The reac-
tion scheme is represented in FIG. 4. The enzymatic deami- 65 
nation activity is related to conversion of NAD+ cofactor to 
produce NADH, which is re-oxidized back to NAD+ by 
The absorbance at 340 nm was normalized by the 600 nm 
absorbance reading for both the reaction and background 
plates. Variants were then scored by their proportional 
increase over the background observed in each well (Equa-
tion 1, below). This method significantly reduces the back-
ground noise of the assay by accounting for differences in 
expression levels, causing more accurate determination of 
enzymatic activity and decreasing false positives. The result-
ing quantity roughly estimates the specific activity of the 
overexpressed mutant protein. 
340 nmR/B 
600 nmR/B 
Results 
Reaction 
Ratio of activity -B-ac_k_gr_o_un_d 
Reaction 
Ratio of biomass ~--­
Background 
Equation 1 
Library Diversity Verification and Assay Characterization 
Prior to screening, each library was checked for diversity at 
the target residues by sequencing randomly selected colonies 
(10-20 colonies), and comparing their distribution to the 
applied degenerate codon. Table 6 gives an example of 20 
randomly selected wells from library. The diversity at posi-
tions 39-41 indicates successful application of the mutagen-
esis protocol. Similar diversity was observed for all libraries. 
The NAD+ auto-fluorescence assay (libraries 2-5) typi-
cally indicated a net negative value for non-beneficial muta-
tions; the net relative fluorescence units (RFU) ranged from 0 
to -500. Beneficial mutations gave net positive RFU, and 
were easily identifiable over background. 
FIG. 7 contains an example of a typical well plate analyzed 
using the absorbance-based assay with readings at 340 nm 
and 600 nm. Normalized absorbance values were calculated 
using Equation 2. Unsuccessful mutants show a normalized 
absorbance of approximately unity indicating no enhance-
ment over background, while the successful mutants indi-
cated the desired catalytic activity with normalized absor-
bance beyond 1.5. 
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TABLE6 
Sequencing results of random LeuDH library 4 colonies to confirm 
diversity after the application of degenerate codons 
Residue 39 40 41 
WT Leu Gly Gly 
Ala Val Ala 
2 STP Val Ser 
Phe Ala Ile 
4 Ala Val Ala 
Val Gly Thr 
Ala Val Ser 
7 Arg Ala Ser 
Val Gly Thr 
9 Cys Gly Thr 
10 Arg Val Ser 
11 Thr Gly Ile 
12 Thr Val Val 
13 Cys Val Ile 
14 Val Gly Ser 
15 Ala Arg Thr 
16 Thr Leu Ser 
17 Ile Gly STP 
18 Gly Gly Phe 
19 Val Ala Val 
20 Ala Gly Ser 
Identification of Active Mutants 
The individual analysis of library variants yielded a 
single beneficial mutation, Lys67Met that exhibited low, yet 
unprecedented activity for reductive amination (0.2 mU 
mg- 1).Ahigher activity of3.4 mU mg- 1 was observed in the 
oxidative deamination ofracemic 1,3-dimethyl butyl amine 
(1,3-DMBA). This mutation was carried over into the subse-
quent libraries. 
The top performers of each high-throughput library (librar-
ies 2-11) were sent for sequencing. The resulting sequences 
resulted in either the identification of beneficial mutations, or 
a large presence of parental variants. When beneficial muta-
10 
15 
20 
25 
30 
35 
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of activity, each hit was further evaluated as purified protein. 
The hits were expressed and purified as described in the 
materials and methods. The purified protein's activity was 
measured over a range of MIBK and 1,3-D MBA concentra-
tions to determine kcat and KM of the amination and deami-
nationreactions, respectively. An example of these results can 
be seen in Table 7 for the analysis of library 11. 
TABLES 
LeuDH library 3 hit sequencing. These sequences represent the top 10 
performing colonies as indicated by the high-throughput assay. Repeat 
identifications of beneficial mutations are grouped at the top of the table. The 
top variants also returned the wild type sequence (italics). 
Residue 
A112 E113 D114 V115 
Ala Val Asp Val 
Ala Val Asp Val 
Ala Val Asp Val 
Ala Leu Asp Val 
Ala Leu Asp Val 
Val Ala Asp Met 
Gly Phe Asn Ile 
Ala Phe Asn Val 
Ala Glu Asp Val 
Ala Cys Asp Val 
TABLES 
Characterization ofLeuDH library 11 hits and comparison to previous 
best preforming variants from library 10 (n.m. ~not measurable (<0.1 mU mg- 1). 
Residue Amination ofMIBK Deamination of 1 3-DMBA 
Well K67 
LiblO Met 
B2 
LiblO Met 
H3 
2Bl Ser 
1C9 Ser 
1H4 Val 
2Bll Gly 
1G2 Leu 
1A2 Leu 
2E12 Gly 
2G8 Gly 
tions were identified, they often appeared multiple times in 60 
the sequenced hits. (Table 7) The assay accurately and repeat-
edly identified beneficial mutations. When all or mostly 
parental variants were identified as the best performing 
mutants, these libraries failed to identify further mutations. 
The enrichment of parental variants from a random library 65 
further supports the accuracy and robustness of the successful 
high-throughput screen. To get a more detailed determination 
N261 vmax KM vmax KM 
Previous Top Variants 
Cys 0.236 ± 0.04 21.6 ± 11.5 1.76 ±0.20 14.8 ± 6.1 
Val 0.084 ± 0.01 21.01 ± 8.5 2.894 ± 0.44 33.1±13.0 
Library 11 Hits 
Leu 0.331 ± 0.07 18.7 ± 11.7 2.350 ± 0.26 41.9 ± 9.7 
Met 0.326 ± 0.02 61.1 ± 6.2 1.381±0.17 28.3 ± 8.3 
Met 0.240 ± 0.04 37.6 ± 14.4 4.841±3.44 251.7 ± 224 
Leu 0.211±0.07 37.7 ± 27.2 1.710±0.17 111.4±17.7 
Leu 0.159 ± 0.04 27.2 ± 19.0 6.688 ± 18 498.0 ± 1551 
Val 0.022 ± 0.00 16.7±8.0 0.976 33.8 
Gly 2.4E+09 3.8E+13 n.m. n.m. 
Cys 7.2E+15 8.2E+18 5.lE+ll 7.0E+13 
After the screening of 11 libraries, four beneficial muta-
tions were identified. Early rounds of mutation (libraries 1-9) 
identified either the wild-type sequence or single variants 
which improved the activity simultaneously in both the ami-
nation and deamination directions, thus allowing for the 
straightforward selection of the top variant. Library 10 iden-
tified distinct mutations for the most-active amination and 
deamination variants (Table 9). The most active amination 
US 8,835,136 B2 
47 
and deamination mutations were with pos1t10n Asn261 
exchanged by Cys and Val, respectively. Library 11 further 
improved the amination activity by identifying synergistic 
mutations at positions 67 and 261, with these positions 
mutated from those identified in libraries 1 and 10. Libraries 
2, 4, 5, and 7-9 were unsuccessful in identifying beneficial 
mutations, returning the parental sequence as hits. The final 
amine dehydrogenase contained four mutations, which are 
surmnarized in Table 9. 
TABLE9 
Accumulated mutations and resulting improvements to the specific 
activity and KM of LeuDH. Error values represent 95% 
confidence intervals of nonlinear fit parameters. 
Reductive Oxidative 
arnination dearnination 
Li- Muta- specific specific 
brary tions activity[a] KM[b] activity[ a] KM[b] 
WT n.m.[cl n.m. n.m. n.m. 
K67M 0.0002 n.m. 0.0034 n.m. 
K67M, O.G15 n.m. 0.65 48 
E113V 
K67M, 0.016 ±0.004 70.2 ±35 1.02 ±0.41 77.1 ±66 
E113V, 
V290C 
lO[dJ K67M, 0.089 ±0.007 10.3 ±3.6 2.81 ±0.44 30.9 ±13 
E113V, 
N261V, 
V290C 
K67M, 0.236 ±0.04 21.6 ±12 1.76 ±0.20 14.8 ±6.0 
E113V, 
N261C, 
V290C 
Substrate[ a] 
(R)-MBA 
(S)-MBA 
10 
15 
20 
25 
30 
48 
The resulting quadruple variant (K67S/El 13V/N261L/ 
V290C) gave the highest amination activity of 0.69 U mg- 1 
with a corresponding kcat value of 0.46 s- 1 , as determined by 
a non-linear fit (FIG. 8) of the Michaelis-Menten equation 
(Equation 3) using MATLAB. 
d[P] VmaxlS] 
v=--=---· 
dt KM+ [SJ' 
v=reaction rate, 
[P]=product concentration, 
[S]=substrate concentration, 
Equation 3 
v max =maximum rate under saturated conditions 
Characterization ofVariant K67S/El 13V/N261L/V290C 
The most-active variants showed amination and deamina-
tion activity toward a number ofketones and amines, respec-
tively (Table 10). Since MIBK most closely mimics the wild-
type keto-acid, 3-oxo-2-pentanoate, it was not surprisingly 
the most activity of the ketones tested. The detailed measure-
ments of the final variant (K67S/E113V/N261L/V290C) 
kinetics showed enhanced amination activity over the previ-
ous library 10 mutant toward all the ketones investigated, 
except methyl acetoacetate. 
TABLE 10 
Substrate profile of top arnination and dearnination variants. 
K67M/El 13V/N261 V/N290C[bJ K67S/El 13V/N261LN290C[bJ 
476.5 ±1.4 586.3 ±4.1 
5.0 ±0.0 1.6 ±0.0 
(R/S)-MBA[cJ 484.0 ±3.5 784.6 ±13.4 
cyclohexylamine 56.0 ±0.0 
cyclohexanone 18.8 ±0.0 123.4 ±3.5 
ethyl pyruvate 19.8 ±7.0 13.2 ±5.8 
methyl acetoacetate 4.5 ±0.7 4.5 ±0.6 
ethyl-3-oxohexanoate 6.4 ±4.9 14.0 ±1.2 
acetophenone 3.5 ±0.7 58.8 ±1.7 
[a]Activity measured with 20 mM substrate. 
[blspecific activity in mU mg-1 protein, with the error representing one standard deviation. 
[cl Activity measured with 40 mM racemic methyl benzyl amine (MBA), 20 mM of each enantiomer. 
50 
TABLE 9-continued Conversion and GDH Cofactor Recycle System 
Accumulated mutations and resulting improvements to the specific 
activity and KM ofLeuDH. Error values represent 95% 
confidence intervals of nonlinear fit parameters. 
Initial rate kinetic measurements are used primarily in the 
determination of kinetic parameters to avoid second-order 
55 effects and product inhibition. The enzyme's ability to reach 
complete substrate conversion camiot be determined from 
these initial rate experiments, and was instead evaluated by 
chiral GC of overnight conversion with a GDH recycle sys-
tem. The GDH regenerates the expensive NADH by redox 
Li-
brary 
11 
Muta-
tions 
K67S, 
E113V, 
N261L, 
V290C 
Reductive 
amination 
specific 
activity[a] 
0.690 ±0.07 15.1 
[alMaximum specific activity (U mg-1 protein). 
[b]MIBK or l,3-DMBA substrate (mM). 
[cln.m. =not measurable (<0.1 mU mg-1). 
±5.1 
Oxidative 
deamination 
specific 
activity[ a] 
2.64 ±0.28 57. 5 ±12.5 60 
reaction ofNAD+ and inexpensive glucose (FIG. 1). In 1.5 
mL reactions, replicates containing 10 mM MIBK substrate 
was mixed with an excess ofl 2 mM glucose, 10 U GDH, and 
a catalytic amount ofNADH (200 µM). Histag purified K67S/ 
El 13V/N261L/V290C LeuDH-AmDH (0.13 mg) was added 
[dlseparate variants gave maximum amination and deamination activity. 
65 to each reaction and allowed to convert for 18 hours. An 
additional 0.13 mg of enzyme was then added and allowed to 
react for 10 hours to achieve the maximum conversion. One 
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mL aliquots of the final reaction media were adjusted to 
pH>13 by the addition of 100 µL of 10 N NaOH and deriva-
tized in toluene according to the TFAA protocol. The repli-
cates were then compared against a calibration curve derived 
by the same procedure with simulated levels of conversion 5 
(FIG. 9), and an average substrate conversion of 92.5%±2.6 
was achieved. 
3.4.3 1H NMR Product Confirmation 
The product amine was additionally confirmed through 1 H 10 
NMR. A 175 mL-scale amination reaction with GDH cofac-
50 
TABLE 11 
Optical rotations of 1,3-DMBA enantiomers. neat, at 589 nm. 
Enantiomer of 1,3-
DMBA 
(R)-enantiomer 
(S)-enantiomer 
Thermo stability 
Optical rotation @ 
589 nm (neat) 
-11.2° 
+11.2° 
The thermostability of the top LeuD H-AmD H variants was 
compared to the wild type LeuDH by circular dichroism. 
Each protein was histag purified and dialyzed in 50 mM 
sodium phosphate buffer pH 8.0, 300 mM NaCl, removing 
tor recycle was performed similar to previous conversion 
experiments. The reaction media was a 500 mM NH4 Cl/ 
NH4 0H buffer at pH 9.6 containing; 10 mM MIBK, 12 mM 
glucose, 1 mM NADH, 2 mg GDH (85 U/mg). The histag 
purified quadruple variant (K67S/El 13V/N261LN290C @ 
1314 µg/mL) was added in two 10 mL aliquots, initially and 
after 24 hrs. After 48 hours, the pH was increased(> 12) with 
15 the imidazole from the purification procedure. Each protein 
was diluted to 50 µg mL- 1 in a 0.1 cm quartz cuvette for 
analysis. Ellipticity was measured at 222 nm, corresponding 
to the maximum ellipticity of the protein as indicated by the 
the addition 25 mL 10 N NaOH. The deprotonated amine 20 
product was then extracted with 40 mL methyl tert-butyl 
wavelength scan (FIG. 11). Each protein was analyzed from 
25° C. to 95° C. with a ramp rate of 1 ° C. min- 1 . All three 
proteins exhibited nearly identical unfolding with melting 
temperatures (TM) between 65° C. and 68° C., making any 
differences in stability difficult to characterize (FIG. 12). The 
four mutations within the LeuDH binding pocket did not 
ether. Following separation, the solvent was removed through 
rotovap distillation, and the purified product was analyzed by 
1H NMR. The reaction showed 84.7% conversion, yielding 
29.5 mg (R)-1,3-DMBA (>99.3% e.e.) with spectra matching 
the standard. [1H NMR (400 MHz, CDC13 ) ll 2.94 (sex, lH, 
1=6.4 Hz), 1.65 (sep, lH, 6.8 Hz), 1.24-1.02 (m, 2H), 1.04 ( d, 
3H, 6.4 Hz), 0.89 (d, 6H, 6.8 Hz)]. 
25 destabilize the protein scaffold compared to the wild type. 
Summary 
An amine dehydrogenase was successfully developed 
from an existing amino acid dehydrogenase template by 
active-site targeted protein engineering. Eleven rounds of 
Enantioselectivity 
The enantioselectivity was initially estimated by measur-
ing the deamination activity toward individual enantiomers of 
methylbenzylamine (MBA). MBA was used in place of 1,3-
DMBA for selectivity experiments since it had a reasonable 
level of activity and individual enantiomers of MBA were 
commercially available (Sigma Aldrich). A preference 
towards (R)-MBA over the corresponding (S)-enantiomer 
was evident in the discrepancies between the deamination 
activities of 0.586 U mg- 1 and 0.002 U mg-1, respectively. 
These preliminary results were corroborated through direct 
measurement of the enantioselectivity of the MIBK amina-
tion in producing chiral 1,3-DMBA. 
30 directed evolution have completely altered the enzyme's 
specificity and created amination activity. Each round of 
mutagenesis focused on a region of the binding pocket, 
including simultaneous mutation of neighboring residues to 
capture synergistic effects. These variants were screened by 
35 various high-throughput assays identifying minute increases 
in amination activity, and successful mutations were carried 
into future rounds ofmutagenesis. 
The largest improvements in activity were achieved by the 
cooperative mutation ofresidues K67 and N261. Their simul-
40 taneous mutation ultimately identified the most active qua-
druple mutant, K67S/El 13V/N261LN290C with novel 
reductive amination activity of 0.69 U mg- 1 with a corre-
sponding kcat value of 0.46 s- 1 . Within the first round of 
Derivatization with trifluoroacetic anhydride (TFAA) and 45 
chiral gas chromatography allowed for the separation and 
quantification ofindividual enantiomers. The derivatized 1,3-
D MBA enantiomers gave adequate baseline separation of the 
peaks, with elution times of 47.5 and48.9 minforthe (S)- and 50 
mutation, the native activity toward 1-Leu of 112 U mg- 1 was 
greatly decreased to less than 2 mU mg- 1 ; completely invert-
ing the enzyme's specificity. The enantioselectivity of the 
wild-type enzyme was maintained despite the drastic changes 
to the binding pocket and yielded (R)-1,3-DMBA with an e.e. 
value of99.8% at 92.5% conversion. This amine dehydroge-
nase exhibited activity toward a number of different sub-
strates. The enzyme has also maintained its wild type stability 
making it an attractive catalyst in the synthesis of chiral 
amines. This is an example of a cofactor-dependent amine 
dehydrogenase capable of selectively synthesizing chiral 
55 amines from a prochiral ketone and free ammonia. 
(R)-enantiomers, respectively. (FIG. 10) Overnight reactions 
were pH adjusted to 13 with 10 N NaOH and extracted from 
the aqueous phase into benzene. The amine was derivatized 
and concentrated through evaporation of benzene. The prod-
uct was composed of the single (R)-enantiomer of DMBA. 
The product amine was injected in increasing concentrations 
until the (S)-enantiomer could be observed. The quadruple 
variant exhibited an e.e. of 99.8%. Pure enantiomers of 1,3-
DMBA are not available commerically. Therefore, the prod- 60 
uct enantiomer was identified by optical rotation. Optical 
rotations of each enantiomer are represented in Table 11. The 
extracted product amine in methanol gave an optical rotation 
of -0.0039°, indicating the production of the (R)-enantiomer. 65 
This level of enantioselectivity was maintained even beyond 
90% substrate conversion. 
Example 3 
Preparation of Phenylalanine Dehydrogenase 
Variants with Amine Dehydrogenase Activity 
Materials and Methods 
gDNA Preparation, Gene Isolation and Overexpression 
Genomic DNA from Bacillus badius Bachelor 
(ATCC#l4574) was purchased from the American Type Cul-
ture Collection (ATCC, Manassas, Va.). The PheDH gene 
could not be successfully amplified out of the fully intact 
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genome. The genome had to instead be digested prior to 
amplification using restriction sites; BamHI, Bg!II, EcoRI, 
and Ndel. These restriction sites are known not to cut within 
the PheDH gene, but would cut at several instances within the 
organism's genomic DNA. This allowed for a more manage-
able DNA template to amplify the PheDH gene. The gene was 
amplified using a standard PCR protocol with the forward 
primer, 5'-GGAATTCCATATGAGCTTAGTA-
GAAAAAACATCCATCA-3' (SEQ ID N0:49) and reverse 
primer, 5'-CCGCTCGAGTATTAGTTGCGAATATC- 10 
CCATTTTG-3' (SEQ ID N0:50). These primers simulta-
neously inserted the restriction sites Ndel and Xhol prior to 
and following the gene, respectively. The locations of the 
restriction sites are indicated by bold font with each primer. 
This made for simple digestion and ligation into either 15 
pETl 7b or pET28a plasmids. 
Protein Purification 
PheDH from Bacillus badius was expressed and purified in 
a manner analogous to that described in Example 1, above. 
52 
Mutants and libraries were generated using an analogous 
protocol to that described in Example 1, above, with the only 
difference that the restriction site Xhol was used in place of 
HindIII Single and multiple variants containing mutations 
analogous to those found in 'LeuDH-AmDH library lO'were 
created using combinations of the primers in Table 12. 
LeuDH-AmDH library 11 had not yet been screened at the 
time of this experiment. The final variants were amplified 
from the respective mutational portions to yield the complete 
gene as described in the overlap extension protocol, and 
ligated into pET28a for subsequent expression and purifica-
tion as detailed in Example 1, above. 
The first library of PheDH-AmDH variants contained 
mutations at both positions K77 and N276. The directly sub-
stituted mutations from LeuDH-AmDH did not necessarily 
identify the optimal combination of mutations at these posi-
tions. 
TABLE 12 
Mutational primers applied to B. badius PheDH to create 
mutations analogous to those observed in LeuDH-AmDH 
LeuDH PheDH 
Mutant Mutant Primer 
K67M K77M Fwd5' GCCTTTCCAAAGGAATGACTTACATGTGCGCGGCG 3' 
TCCG (SEQ ID NO, 51) 
Rev5' CGGACGCCGCGCACATGTAAGTCATTCCTTTGGAA 3' 
AGGC (SEQ ID NO, 52) 
E13V T123V Fwd5' GGCGGCCGTTTCTATACAGGTGTGGATATGGGAAC 3' 
GAATATGGAAGATTTC (SEQ ID NO, 53) 
Rev5' GAAATCTTCCATATTCGTTCCCATATCCACACCTGT 3' 
ATAGAAACGGCCGCC (SEQ ID NO, 54) 
N261V N276V Fwd5' GCAATCGCCGGTTCAGCCGTGAATCAGCTGCTTAC 3' 
GGAGGATCAC (SEQ ID NO, 55) 
Successful IMAC purification with the histag was confirmed 
through SDS-PAGE of the purification fractions. Overexpres-
45 
sion of the enzyme is indicated by a heavy band at 44 kDa in 
the clarified cell lysate and protein fractions. The removal of 
cellular proteins can be seen in the wash fractions. Faint bands 
of these proteins are observable in the purified fraction only 
after overloading. Under normal loading conditions, only the 50 
purified PheDH band is visible. 
Spectrophotometric Assay 
The activity of the purified protein was evaluated using a 
spectrophotometric assay at 340 nm as described in Section 
3.2.3 at 25° C. in various concentrations ofNH4 Cl/NH40H 55 
buffer pH 9.6. 
Mutagenesis and Library Generation 
After eleven rounds of mutagenesis, three mutations were 
previously identified to be most influential in creating reduc-
tive amination activity in a LeuDH-based scaffold; 60 
Lys67Met, Glu113Val, and Asn261Val (Examples 1-2, 
above). Analogous mutations to these were identified through 
sequence alignment and applied to a similar amino acid dehy-
drogenase scaffold, phenylalanine dehydrogenase (PheDH) 
from Bacillus badius ( 48% identity, 66% similarity). Each of 
the point mutations, as well as combinations of these muta-
tions, was evaluated for amination activity. 
65 
Rev5' GTGATCCTCCGTAAGCAGCTGATTCACGGCTGAAC 3' 
CGGCGATTGC (SEQ ID NO, 56) 
Simultaneous mutation of these residues can be used to iden-
tify any synergistic effects between their side chains. Since 
previous libraries had identified LeuDH K67M as a beneficial 
mutation, it was essential that the degenerate codon at that 
position contain methionine to ensure the identification of the 
best variant. The efficient NDT codon was excluded for this 
reason. With a two site library, codon selection must also be 
efficient to reduce the screening effort. A two site NNK 
library would require the screening of3066 colonies, which is 
near the maximum screening capacity of the high throughput 
assay. The DDK codon greatly reduced the screening require-
ment to 969 colonies, while still including methionine and 
maintaining a broad range of mutation (Table 13). 
TABLE 13 
Comparison of degenerate codon distributions of PheDH library 1. 
Amino Codon Codon Codon 
Acid DDK NDT NNK 
Ala[AJ 2 
Arg [RJ 
Asn [NJ 
Asp [DJ 
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TABLE 13-continued 
Comparison of degenerate codon distributions of PheDH library 1. 
Amino 
Acid 
Codon 
DDK 
2 
2 
Codon 
NDT 
Codon 
NNK 
2 
2 
2 
2 
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be observed over multiple time points, and gave low absor-
bance in the initial time point. These variants were included 
for further characterization. The successful variants were 
sequenced (MWG Operon), and each unique sequence was 
5 expressed in pET28a/BL21 for histag purification and deter-
mination ofkcat and KM values with PFPA. 
10 
Results 
Rhodococcus Sp. M4 Phenylalanine Dehydrogenase 
K66M Mutants were Difficult to Express 
The wild-type gene sequence of phenylalanine dehydroge-
nase from Rhodococcus sp. M 4 was attained from Brunhuber 
et al. (Brunhuber, et. Al., Critical Reviews in Biochemistry 
and Molecular Biology, 29, (6): 415-467 (1984)). The nucleic 
acid sequence was synthesized by an external vendor (MWG 
15 Operon) and provided in a pUC57 vector. The gene was 
amplified out of the host plasmid, along with the simulta-
neous insertion of restriction sites NdeI and HindIII (bold) 
using the primers; N-terminal 5'-GGGAATTCCATATGAG-
TATCGACAGCGCACTGAAC-3' (SEQ ID N0:57), and 
Cys [CJ 
Gln[QJ 
Glu [EJ 
Gly[GJ 
His [HJ 
Ile [IJ 
Leu [LJ 
Lys [KJ 
Met[MJ 
Phe [FJ 
Pro [PJ 
Ser [SJ 
Thr [TJ 
Trp [WJ 
Tyr[YJ 
Val[VJ 
Stop 
-------------- 20 C-terminal 5'-CCATGATTACGCCAAGCTTGC-3' (SEQ ID 
Codons 
AA 
18 
15 
12 
12 
Screening ofLeuDH Mutants and Libraries 
32 
20 
N0:58). A second amplification was performed to insert a 
STOP codon at the C-terminus of the protein sequence and 
allow for proper translation and expression. The forward and 
Each of the single mutants and combinations of these 25 
mutations were individually expressed and purified. Each 
variant was evaluated for activity toward 20 mM 1,3-DMBA 
using the 340 nm spectrophotometric assay. The best combi-
nation of mutations was determined by the specific activity. 30 
reverse primers, 5'-CGACAACGACAGCGACTGC-
CTAGGGCCCGTCGACTGCAG-3' (SEQ ID N0:59) and 
5'-CTGCAGTCGACGGGCCCTAG-
GCAGTCGCTGTCGTTGTCG-3' (SEQ ID N0:60) respec-
tively, were used in this amplification. The final insert was 
then digested and ligated into pET28a for overexpression and 
histag purification as described in Example 1, above. The 
wild-type protein was successfully purified and activity con-The best variant was further characterized for activity 
toward para-fluoro phenyl acetone (PFPA). PheDH's wild 
type keto-acid substrate is phenylpyruvate, and the equivalent 
AmDH ketone substrate would be phenylacetone (FIG. 13). 
Phenylacetone is not commercially available, because it is 35 
regulated as a Schedule 2 narcotic. This was overcome by the 
use of a fluorinated derivative, para-fluoro phenyl acetone 
(SigmaAldrich) which is commercially available and unregu-
lated. 
firmed (39.5 kDa, 46 U mg- 1). 
The wild-type gene was then mutated with the analogous 
mutations beneficial to creating AmDH in the LeuDH scaf-
fold (Example 2, above). These residues were identified 
through sequence alignment. 
The K66M mutation was created by applying the primers, 
5'-GGGGGCGATGACGTTGATGATGGCAGT-
GAGCAACCTTCC-3' (SEQ ID N0:61) and 5'-GGAAGGT-
TGCTCACTGCCATCATCAACGTCATCGCCCCC-3' 
(SEQ ID N0:62), in the overlap extension protocol described 
The evaluation of the LeuDH-AmDH mutations on the 40 
PheDH scaffold identified the double variant K77M N276V 
as the most active, with a kcat value of0.128 s- 1 anda reason-
able KM value of 4.61 mM. Future variants with activity 
below this level were no longer considered significance. This 
elevated activity allowed for the application of a stringent 
screening assay (FIG. 15) in screening the K77DDK 
N276DDK library. Screening in the deamination direction to 
exploit the higher activity was no longer necessary. Instead, 
the amination activity was directly evaluated using a similar 
absorbance-based assay. 
After mutagenesis, colonies were picked and expressed as 
described in Section 3.2.4. As the expression plates thawed, 
the cell pellets were gently vortexed with 30 µL ofB-PER to 
uniformly resuspend and lyse the cells. The crude cell lysate 
was split in 10 µL aliquots into two plates; a reaction and 
background plate. A reaction mixture (200 µL) containing 10 
mM PFPA and 200 µM NADH in 500 mM NH4 Cl/NH40H 
buffer was added to each well. The same mixture lacking 
PFPA was added to the background plate. Absorbance mea-
surements at 340 nm and 600 nm began immediately unlike 
the previous end-point assays, and continued periodically 
over the course of 1.5 hours. 
Active variants were identified by the rate of change in 
absorbance at 340 nm, corresponding to the fastest activity. 
The wells exhibiting the fastest rate change over that of the 
background plate were selected for further characterization. 
Some variants consumed the cofactor too quickly ( <5 min) to 
in Sambrook et al. After sequence confirmation, overexpres-
sion of the K66M single mutant was attempted in pET28a 
vector and BL21 competent cells. This overexpression was 
45 unsuccessful, and the protein was not expressed. The K66M 
mutant DNA was then used as a template for mutation back to 
the parental sequence, K66. Upon mutation back to the paren-
tal sequence, successful overexpression of the protein was 
restored. This indicated that the Rhodococcus sp. M4 PheDH 
50 was not tolerant to mutation at this position without introduc-
ing difficulties in expression. An alternative PheDH gene 
from Bacillus badius was used in future experiments to cir-
cumvent these complex problems with overexpression. 
Evolution of Phenylalanine Dehydrogenase from Bacillus 
55 badius Bachelor 
Phenylalanine dehydrogenase from Bacillus badius Bach-
elor was chosen as an alternative scaffold to the Rhodococcus 
sp. M4 gene. The B. badius gene has been shown to be 
reasonably active with a kcat value of 39 s- 1 and has been 
60 characterized in literature (Asano, et., al., European Journal 
of Biochemistry, 168, (1): 153-159 (1987); Villalonga, et al., 
Sensors and Actuators B: Chemical, 129, (1): 195-199 
(2008); Villalonga, et al., Enzyme and Microbial Technology, 
40, (3): 471-475 (2007); Villalonga, et al., Biotechnology 
65 Letters, 27, (17): 1311-1317 (2005)). Another advantage of 
the B. badius PheDH is its increased similarity to the LeuDH 
scaffold (66% similarity) compared to the Rhodococcus sp. 
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M4 (54% similarity). This increased the chances of success-
ful translation of AmDH mutations from the previous scaf-
fold. 
The Rhodococcus sp. M4 and B. badius PheDHs are very 
different from each other on a sequence level, sharing only 
32% identity and 50% similarity. Coming from the same 
structural sub-family, they share a much stronger correlation 
in their folding motifs. Since there currently is no crystal 
structure available fortheB. badius PheDH, the sequence was 
folded over the 1BW9 crystal structure and superimposed 
over the original scaffold using SuperPose. The resulting B. 
badius structure is nearly identical to the 1BW9 crystal struc-
ture with a backbone RMSD of only 1.69 A, with the major 
deviation occurring at a loop region evident in the primary 
sequence. This tertiary structure similarity attests to the use of 
the 1BW9 crystal structure as a model of protein-substrate 
interactions. 
Wild-Type PheDHActivity 
The wild-type PheDH fromB. badius was characterized to 
ensure proper expression and folding prior to mutation. The 
purified PheDH exhibited activity levels greater than 257 U 
mg- 1 in the amination of phenylpyruvate (500 mM NH4 Cl/ 
NH4 0H buffer pH 9.6, 200 µM NADH, 5 mM phenylpyru-
vate at 25° C.), and 39.5 U mg- 1 in the deamination ofL-Phe 
(0.1 M Glycine buffer pH 10.0, 1 mM NAD+, 20 mM L-Phe 
at 25° C.). KM values were determinedforthe substrates when 
possible, and corresponded well to those values found in 
literature (110). Additionally, the Kl value of ammonia was 
56 
Screening of Library and Hits Characterization 
Prior to the screening of the PheDH K77DDK N276DDK 
library, the diversity of the mutations were checked. Twenty 
colonies were sequenced to ensure the desired breadth of 
mutation was achieved at each position, and a large percent-
age of parental variants were not present. 
A total of 36 wells were labeled as highly active by the 
assay for subsequent characterization. Sequencing of these 
hits yielded 21 unique pairs of mutations, each of which were 
10 transformed into a pET28a plasmid for subsequent expres-
sion and his-tag purification. These purified proteins were 
individually characterized for activity toward the amination 
of PFPA to more accurately determine which combination of 
mutations performed best (Table 16). All 21 pairs of muta-
15 tions were active amine dehydrogenases, eight of which pro-
vided kcat values greater than 1 s- 1 in the amination of PFPA. 
The top variant 1H4 contained the mutations K77S N276L 
with an apparent kcat value of 2.8 s- 1 and KM. PFPA value of 
4.37 mM in 500 mM NH4Cl/NH4 0H buffer pH 9.6 with 200 20 µM NADH. The K77W N276E variant also exhibited excep-
tionally high levels of activity with an apparent kcat value of 
2.63 s- 1 and a KM PFPA value of5.32 mM. The K77S N276L 
variant was selected as the top candidate for further charac-
terization, since it had the highest apparent kcat value and a 
25 lower KM than the K77W N276E variant. 
TABLE 15 
determined to be 5 .0 M. The KM of phenylpyruvate could not Randomly selected colonies orPheDH library 1 confirming 
be determined due to its high absorbance at the analytical 30 diversity at positions K77 and N276 by successful 
· d b application of overlap extension mutagenesis wavelength. The wild-type enzyme was determme to e --------'~"""'"""'""'-"-'-'"""''""""""'"""'"""===-----
properly folded and active. 
Comparison of Beneficial Mutations Identified in LeuDH-
AmDH 
To directly and easily create a basis of PheDH-AmDH 35 
activity, each of the mutations identified in LeuDH-AmDH 
were tested individually and in combination on the PheDH 
scaffold for the identification of residues which were influ-
ential in creatingAmDH activity. The specific activities of the 
variants with 1,3-DMBA can be seen in Table 12 40 
The PheDH double variant, K77M/N276V was the best 
combination of the LeuDH mutations. Both of these residues 
are known to interact with the wild-type substrate at the 
carboxyl moiety, and their synergistic effects are reflected in 
the large increase inAmDH activity when compared to their 45 
individual substitutions. 
TABLE 14 
Colony 
2 
4 
7 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
K77 N276 
Leu Trp 
Asn Phe 
Val Phe 
Val Asp 
Arg Gly 
Arg Asp 
Asn Lys 
Gly Ile 
Tyr Cys 
Ser Leu 
Gly Gly 
Trp Ile 
Glu Arg 
Asp Lys 
Trp Met 
Glu Lys 
Glu Glu 
Cys Cys 
Gly Leu 
Lys Trp 
AmDH activity on 1,3-DMBA and MIBK by PheDH 50 ------------------------
variants derived from analogous LeuDH-ArnDH mutations. 
Dearnination Activity Amination Activity TABLE 16 LeuDH PheDH 40 mM 1,3-DMBA, 40mMMIBK, 
Variant Variant kca' (s-1) kca' (s-1) Characterization ofhistag purified PheDH library 1 hits. Kinetic 
Wild Type Wild Type -No Activity- 55 parameters kcat and KM determined by non-linear fit for the arnination 
Lys67Met Lys77Met 0.0033 ± 0.000 0.0009 ± 0.000 orPFPA in 500 mM NH,Cl/NH,OH pH 9.6. 200 µM NADH 
Glu113Val Thr123Val 0.0013 ± 0.000 n.m. 
Asn261Val Asn276Val 0.0016 ± 0.000 n.m. K77 N276 Non-Linear Michaelis Menten 
Lys 67Met Lys77Met 0.0010 ± 0.000 n.m. 
Hit Residue Residue kca' (s-1) KM(mM) Glu113Val Thr123Val 
Lys67Met Lys77Met 0.0722 ± 0.004 0.0037 ± 0.000 60 1H4 Ser Leu 2.802 ± 0.536 4.4 ± 1.6 Asn261Val Asn276Val 7F10 Trp Glu 2.631 ± 0.159 5.3 ± 0.6 Lys67Met Lys77Met 4H6 Met Met 1.818 ± 0.190 7.9 ± 1.3 Glu113Val Thr123Val 0.0011 ± 0.000 n.m. 7A3 Ser Met 1.513 ± 1.900 42.4 ± 50.0 Asn261Val Asn276Val 4D2 Ser Ser 1.307 ± 0.364 14.5 ± 5.2 
10F12 Cys Leu 1.285 ± 0.246 3.5 ± 1.4 Amination: 500 mM NR,Cl/N1LiOH buffer pH 9 .6, 200 µM NADH, 40 mM MIBK at 25° 65 2F4 Met Leu 1.283 ± 0.100 4.2 ± 0.6 g~amination: O.lM Glycine buffer pH 10.0, 1 mMNAD+, 20 mM 1,3-DMBA at 25° C. 3G7 Ser Val 1.055 ± 0.185 4.4 ± 1.5 
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TABLE 16-continued 
Characterization ofhistag purified PheDH library 1 hits. Kinetic 
parameters kcat and KM determined by non-linear fit for the arnination 
orPFPA in 500 mM NH,Cl/NH,OH pH 9.6, 200 µM NADH 
K77 N276 Non-Linear Michaelis Menten 
Hit Residue Residue kca' (s-1) KM(mM) 
5A3 Met Cys 0.896 ± 0.080 1.5 ± 0.4 
8D10 Met Leu 0.858±0.175 4.6 ± 1.8 
6D12 Ser Phe 0.792 ± 0.180 22.2 ± 0.4 
9G3 Met Ser 0.661 ± 0.074 4.9 ± 1.0 
10G6 Val Leu 0.558 ± 0.064 3.3 ± 0.8 
!Ell Cys Ile 0.549 ± 0.062 7.7 ± 1.4 
4A9 Gly Ile 0.339 ± 0.065 5.9 ± 2.0 
llEl Ser Gly 0.275 ± 0.066 6.8 ± 2.7 
9All Gly Cys 0.029 ± 0.000 
10A6 Ser Glu 0.024 ± 0.013 9.0 ± 7.6 
10H2 Trp Ile 0.019 ± 0.010 
12D6 Trp Gly 0.017 ± 0.023 
4C8 Gly Val 0.017 ± 0.008 
Example 4 
Variant K77S/N276L is an Amine Dehydrogenase 
The K77S N276L variant was characterized in detail for a 
number of properties including; pertinent kinetic parameters, 
the breadth of substrate specificity, thermo-stability, overall 
conversion, and enantioselectivity. 
AmDH Activity and Substrate Specificity 
10 
15 
58 
TABLE 17 
Substrate specificity of top variant, K77S N276L PheDH. Amination 
in 500 mM NH4 Cl/NH4 0H, pH 9.6, 200 µM NADH, 20 mM 
substrate at 25° C. 
Activity Activity 
Substrate (mU/mg) Substrate (mU/mg) 
R-MBAt 1.9 ± 1.8 cyclopentanone 0.9 ± 0.5 
S-MBAt <1.0 cyclohexanone 27.5 ± 1.4 
R/S-MBA*·t 0.5 ± 0.2 ethylpyruvate 18.4 ± 5.9 
MIBK 77.0 ± 1.3 benzaldehyde 31.4 ± 8.7 
1,3-DMBAt 166.3 ± 0.0 2-methylcyclohexanone 19.3 ± 1.1 
acetophenone <1.0 3-methylcyclohexanone 41.1±2.1 
phenoxy-2-propanone 540.8 ± 6.9 3-methyl-2-butanone 72.7 ± 1.4 
2-hexanone 155.7 ± 1.4 1-Boc-piperidone 7.8 ± 1.1 
3-hexanone 1.6 ± 0.5 Benzyloxyacetic acid 22.6 ± 0.7 
3-pentanone 1.3 ± 0.0 
*40 mM, 20 mM of each enantiomer. 
tDeamination in O.lM glycine buffer, pH 10.0, 1mMNAD+,20 mM substrate at 25° C. 
20 
The enzyme shows increased activity toward methyl-ke-
tones versus those which are ethyl-ketones or cyclic-ketones. 
The top five most active ketones; PFPA, phenoxy-2-pro-
panone, 2-hexanone, methyl isobutyl ketone and 3-methyl-2-
butanone are all methyl-ketones. This specificity is also 
25 observed in the large differences in activity toward 2-hex-
anone (155.7 mU/mg) versus 3-hexanone (1.6 mU/mg). 
Despite the structural similarities, the methyl-ketone 2-hex-
anone, exhibits approximately 100-fold higher activity. Simi-
larly, the enzyme requires at least a one carbon linkage 
30 between the alpha carbon and the substrate's phenyl ring. 
Kinetic parameters, kcat and KM, were determined for the 
enzyme and each of the reductive amination substrates; 35 
respectively. The original assay conditions of 500 mM 
NH4 Cl/NH4 0H buffer did not saturate the enzyme with 
respect to NH3 . The kcat value for this AmD H enzyme with all 
three substrates saturated in aqueous NH4 Cl/NH4 0H buffer 
This is reflected by the unobservable activity toward 
acetophenone, as well as the low deamination activity of 
methyl benzyl amine. 
Thermo stability 
The thermostability of the AmDH was compared to its 
wild-type scaffold using two different methods, circular 
dichroism (CD) and a temperature versus activity profile. The 
mutation of the enzyme scaffold has affected the thermosta-
bility, in addition to the enzyme's function. Both the wild-
at pH 9.6 was 6.85 s- 1 at25° C. This represents a near 15-fold 
enhancementabovethemaximumobservedkcatof0.46 s- 1 of 
the previously developed LeuDH-AmDH. The increase in 
buffer concentration did have a salt effect upon the KM value 
of PFPA, which increased to 7.75 mM under saturated reac-
tion conditions of5 MNH4Cl/NH4 0HbufferpH 9.6 with200 
µM NADH. The KM value for NADH remained low as with 
the wild-type enzyme with a KM value of23.9 µM. 
The significant increase in the KMofNH3 (KM, NH3=l.27 
M) seen in the conversion of para-fluoro phenyl acetone ami-
nation, as compared to the amination of phenylpyruvate (KM 
NH3=64.5 mM) can be attributed to decreased activation of th~ 
alpha carbon caused by changes in electron density with the 
new substrate. The original phenylpyruvate structure has a 
carboxyl group neighboring the alpha carbon where the 
nucleophilic attack of ammonia occurs. This carboxyl moiety 
will lessen the electron density at the alpha carbon make the 
nucleophilic attack more favorable compared to the ketone 
substrate. 
The breath of the substrate profile was analyzed through 
the amination and deamination activity toward a number of 
different ketones and amines, respectively. The diversity of 
these ketones varied in structure from small aliphatic ketones 
such as 3-methyl-2-butanone, to larger aromatic ketones with 
additional functionality, such as phenoxy-2-propanone. Sev-
eral other ketone compounds were found to exhibit reason-
able levels of activity (Table 17). 
40 type PheDH and theAmDH exhibit similar characteristics in 
the loss of secondary structure as indicated through CD. Both 
enzymes showed the same gradual loss of structure at tem-
peratures up to 30 degrees Celsius (FIGS. 15and16), imply-
ing that the cause for the early loss of structure is inherent in 
45 the wild-type protein. Beyond 30 degrees, there is an earlier 
onset in the pronounced loss of structure of the double variant 
compared to the wild type; however, the slope folded fraction 
over temperature stays constant, indicative of constant 
enthalpy of melting. The K77S N276L mutations have 
50 slightly destabilized the protein structure, resulting in a melt-
ing point of 59.9° C., 4.4° C. less than the wild type. The 
specific cause for this change is difficult to determine. It likely 
to be either disruption of the 'ideal' packing of the wild-type 
enzyme's hydrophobic core or a net decrease in hydropho-
55 bicity by the amino acid substitutions which leads to a lower 
folding entropy. 
The thermo stability of the double variant K77S N27 6L was 
additionally determined by a temperature versus activity plot, 
showing the results of amination activity measured in 5 M 
60 NH4Cl/NH40HbufferpH9.6,200µMNADH,20mMPFPA 
for 2 minutes (FIG. 17). This plot shows the enzyme's Arrhe-
nius activation through the lower temperature range (10-45° 
C.), although this thermal activation should appear to be 
exponentially increasing. The near linear increase corre-
65 sponds to a low activation energy of 241 J mo1- 1 . The maxi-
mum specific activity was 11.6 U mg- 1 at a temperature of 50° 
C. Above 50° C., the enzyme began to rapidly lose activity as 
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a result of denaturation. This deactivation correlated well 
with the circular dichroism data, where a dramatic loss of 
secondary structure was observed from 50° C. to 70° C. 
Conversion with Cofactor Recycle System 
A reaction system capable of high-level conversions was 5 
demonstrated by pairing the AmDH with a GDH cofactor 
recycle system. The GDH consumes glucose present in solu-
tion to cheaply and efficiently regenerate the NADH cofactor, 
allowing conversion to continue beyond stoichiometric 
depletion ofNADH. In a 100 mL reaction volume containing 10 
20 mM PFPA, conversion was allowed to continue for 48 
hours followed by extraction and 1H-NMR to confirm the 
product formation and conversion levels. The addition of7.48 
mg of the AmDH enzyme converted 89.4% of the 4-fluo-
rophenyl acetone substrate to the product 1-( 4-fluorophenyl)- 15 
propane-2-amine over 48 hours with an isolated yield of 
66.2%. Under the same reaction conditions, 17.46 mg of the 
AmDH enhanced the overall conversion to 93.8% and 73.9% 
yield. Evidence of chirality was indicated by different NMR 
signals of the C3 hydrogens (ll 2.67, 2.49) which are adjacent 20 
to the C2 stereocenter (FIG. 18). 
[ 4-fluorophenyl acetone substrate; 
1H NMR (400 MHz, CDC13 ) ll 7.26-7.00 (m, 4H), 3.68 (s, 
2H), 2.16 (s, 3H). 
(R)-(-)-1-( 4-fluorophenyl)-propane-2-amine product; 
1H NMR (400 MHz, CDC13 ) I\ 7.26-6.95 (m, 4H), 3.12 
(sex, lH, J=3.9 Hz), 2.67 (dd, lH, 6.3 Hz, 13.2 Hz), 2.49 (dd, 
lH, 6.3 Hz, 13.2 Hz), 1.10 (d, 3H, 6.4 Hz)]. 
Enantioselectivity 
25 
Equally important to conversion is maintaining the selec- 30 
tivity of the enzyme after altering the substrate specificity. 
Preservation of the wild type (S)-selectivity towards pheny-
lalanine will result in the asymmetric production of (R)-1-( 4-
fluorophenyl)-propyl-2-amine due to a change in Cahn-In-
gold-Prelaw priority. The product amine resulting from 35 
enzymatic conversion with the co-factor recycle was isolated 
and derivatized using trifluoroacetic anhydride for analysis 
via chiral gas chromatography. An enantiomeric excess of 
>99.8% toward (R)-1-(4-fluorophenyl)-propyl-2-amine was 
confirmed, however, further resolution of the selectivity was 40 
limited by the separation capability of the chiral colunm. 
Throughout all experiments, the (S)-enantiomer remained 
below the detection limits. Even as the enzyme approaches 
levels of conversion beyond 90%, the high enantioselectivity 
toward (R)-1-(4-fluorophenyl)-propyl-2-amine is main- 45 
tained. This renders theAmDH/GDH system a viable method 
for the production of chiral amines. 
Confirmation of the (R)-selectivity was achieved through 
polarimetry, since single enantiomers of ( 4-fluorophenyl)-
propyl-2-amine are not commerically available. Suspension 50 
of the isolated product amine in methanol resulted in a nega-
tive optical rotation (-1.73°, 10 cm path length at 0.3 mM 
amine), confirming the (R)-(-)-enantiomer to known stan-
dards. 
Summary 55 
60 
conversions in excess of 90% when paired with a cofactor 
recycle system. Despite a 4.4 degree Celsius decrease in 
thermostability, the enzyme remains broadly activity over a 
large temperature range from 10 to 50° C., with a maximum 
observed specific activity of 11.6 U mg- 1 . The novel AmDH 
exhibits amination activity towards a range of ketone sub-
strates, which makes it a good starting point for further evo-
lution to increase activity toward specific API targets. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meanings as commonly under-
stood by one of skill in the art to which the disclosed invention 
belongs. Publications cited herein and the materials for which 
they are cited are specifically incorporated by reference. 
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
Example 5 
PheDH-AmDH K77M N276V has Activity with an 
Acetone Cosolvent 
The enzyme tolerates acetone concentrations as high as 
20% v/v. The PFPA substrate has a limited solubility of 40 
mM in aqueous media, but was increased to 60 mM with the 
addition of acetone. The increased substrate concentration 
resulted in a 40% increase in the maximum observable kcat 
(FIG. 20), from 0.11 s- 1 in aqueous solution to a value of0.26 
s-1 with 20% acetone. The KM were affected by the addition 
of acetone, increasing from a value of 4.6 mM to 23.1 mM in 
aqueous and 20% acetone, respectively. hydrophobic sub-
strates. 
Example 6 
A chimeric F-AmDH/L-AmDH Shows Amine 
Dehydrogenase Activity 
Materials and Methods 
Construction of a Chimeric Amine Dehydrogenase 
FIG. 21 shows a diagram of the overall construction of the 
chimeric enzyme. The ligation point of the domains was 
constructed according to (Kataoka et al. J. Biochem., 116, 
931-936, 1994), but overlap PCR was used to generate the 
new construct. 
This construct was cloned into pET2Ha and expressed in 
BL21plys. cells. Expression was successful and yielded 
between 10 mg-16 mg/100 ml culture. The enzyme was puri-
fied using affinity chromatography with Ni-Ni-NTA The 
histag for purification is vector-derived and is located at the 
N-terminus of the enzyme. 
Sequences ofCl-AmDH and C2-AmDH 
Cl-AmDH 
ATGAGCTTAGTAGAAAAAACATCCAT-
CATAAAAGATTTCACTCTTTTTGAAAAA ATGTCT-
GAACATGAACAAGTTGTTTTTTGCAAC-
GATCCGGCGACAGGACTAAGG 
Previous knowledge in the evolution of an amine dehydro-
genase, particularly the influence of binding pocket residues 
Lys77 and Asn276, allowed for a direct route to an active 
AmDH from PheDH. With a reasonably active starting vari-
ant, a stringent high-throughput screening of a single two-site 
library further enhanced the desired reductive amination 
activity to a kcat value of 6.85 s- 1 at 25° C. The high enanti-
oselectivity was maintained throughout the evolution pro-
cess. The enzyme's e.e. value of >99.8% toward the (R)-
enantiomer, even after high levels of conversion, renders it an 
attractive candidate for the asymmetric production of chiral 
amines. The reaction can be simply and cheaply driven to 
60 GCCATTATCGCTATTCATGACACCA-
CACTCGGACCTGCGCTCGGCGGCT GCCGCATG-
CAGCCTTATAACAGTGTGGAAGAAGCAT-
TGGAAGATGCTCTTCGCC 
TTTCCAAAGGAATGACTTACAGT-
65 TGCGCGGCGTCCGATGTCGACTTTGGCGGCG 
GAAAAGCAGTCATTATCGGTGATCCGCA-
GAAAGATAAATCTCCAGAACTGTTCC GCGCGTTTG-
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GCCAATTTGTTGATTCGCTTGGCGGC-
CGTTTCTATACAGGTACTG 
ATATGGGAACGAATATGGAAGATTTCAT-
62 
TTGT-
GCTTTGATTTTGATCGTTGCAAAGCGAAAG 
CGAGCAAAATTTTTGATACCACCCTGGC-
GATTTTTGCGCGTGCGAAAGAAGATG GCATTCCTC-
CGGCTGCGGCTGCGGATCGTATTGCG-
5 GAACAGCGTATGAGCGATGCGCGTTAA 
TCACGCCATGAAAGAAACAAACTGCA 
TGGGGTGCCGGAAGCGTATGGCTCT-
TCTGGCAACCCGTCGCCGGCCACGG 
CTTACGGCGTATATCGTGGGAT-
GAAAGCGGCGGCGAAGGAAGCATTTGGCAGTG 
ATTCGCTTGAAGGAAAAGTTGTCGC-
CGTCCAAGGAGTCGGCAATGTCGCCTACC ATTTAT- 10 
GCCGCCATTTGCACGAAGAAGGAGC-
GAAACTCATCGTTACCGACATCA 
ACAAGGAAGCGGTGGCGCGCGCGGTC-
GAGGAATTTGGGGCGAAAGCAGTCGACC CGAAC-
GACATTTACGGCGTGGAGTGCGA-
CATTTTTGCTCCATGCGCGCTCGGCG 
GCATCATCAACGACCAAACGATTCCG-
CAGCTGAAAGCGAAAGTGATCGCCGGCT CGGCGT-
TGAATCAGCTGAAAGAGCCGCGCCATG-
GCGACATGATCCATGAAATGG 
GCATCGTCTATGCACCAGATTATGTGAT-
15 
(SEQ ID N0:64), which is a nucleic acid sequence encoding 
SEQ ID N0:24. 
Substrate Specificity of Cl-AmDH 
All ketone substrates forthe amination direction were mea-
sured at 20 mM and dissolved at 60° C. in 4 M ammonium 
formate buffer. Enzyme specificity was measured at 60° C. 
for 5 min. with NADH as the cofactor at 340 nm. 
Results 
Engineering a Chimeric AmDH 
The template LeuDH-AmDH (L-AmDH) and PheDH-
AmDH (F-AmDH) discussed in Examples 1-4 were used to 
generate a chimeric amine dehydrogenase via domain shuf-
20 fling (referred to as Cl-AmDH). domain shuffling between 
L-AmDH and FcAmDH. Specifically, the NAD-binding 
domain of the F -AmD H was exchanged with the one from the 
L-AmDH. This created a chimeric enzyme with new activi-
ties, a specific preference for benzylic carbonyls, a feature the 
CCGAT-CAACGCCGGCGGCTGCATCAACGTCG 
GAGCTGTACGGCTACAACCGT-
GAACGGGCGATGAAAAAAATCGAGCAAA 
TTTATGACAACATCGAAAAAGTGTTTGC-
CATCGCCAAGCGTGACAACATTCCAA CGTATGTG-
GCCGCTGACCGGATGGCCGAAGAAC-
GAATTGAAACGATGCGCAAAG 
CGCGCAGCCAATTTTTGCAAAACGGC-
CATCATATTTTAAGCCGCCGCCGCGCCC GCTAA 
(SEQ ID N0:63), which is a nucleic acid sequence encoding 
SEQ ID N0:20 with an N-terminal methionine. 
ATGAGCTTAGTAGAAAAAACATCCAT-
CATAAAAGATTTCACTCTTTTTGAAAAA ATGTCT-
GAACATGAACAAGTTGTTTTTTGCAAC-
GATCCGGCGACAGGACTAAGG 
GCCATTATCGCTATTCATGACACCA-
CACTCGGACCTGCGCTCGGCGGCT GCCGCATG-
CAGCCTTATAACAGTGTGGAAGAAGCAT-
TGGAAGATGCTCTTCGCC 
TTTCCAAAGGAATGACTTACAGT-
TGCGCGGCGTCCGATGTCGACTTTGGCGGCG 
GAAAAGCAGTCATTATCGGTGATCCGCA-
GAAAGATAAATCTCCAGAACTGTTCC GCGCGTTTG-
GCCAATTTGTTGATTCGCTTGGCGGC-
CGTTTCTATACAGGTACTG 
ATATGGGAACGAATATGGAAGATTTCAT-
TTGT-TCACGCCATGAAAGAAACAAACTGCA 
TGGGGTGCCGGAAGCGTATGGTGGT-
GCGGGTGATAGCAGCGTGCTGACCG 
CGTTTGGCGTGTTTCAGGGCATGCGTGC-
GAGCGCGGAACATCTGTGGGGCGATC CGAGCCT-
GCGTGGCCGTAAAGTGGGTGTGGCGGGT-
GTGGGCAAAGTGGGCCATC 
ATCTGGTGGAACATCTGCTGGAAGATG-
GTGAA-GTGCGGATGTGGTGATTACCGATGTGC 
GAAAGCGTGAACCGTAGCACCCATAAA-
CATCCGAGCGTGACCGCTGTGG 
CGGATACCGAAGCGCTGATTCGTAC-
CGAAGGCCTGGATATTTATGCTCCGTGCG 
CGCTGGGTGGTGCGCTGGATGATGAT-
AGCGTGCCGGTGCTGACCGCTAAAGTGG TGTGCG-
GTGCGGCAAACCTGCAGCTGGCGCATC-
CGGGTGTGGAAAAAGATCTGG 
CGGATCGTAGCATTCTGTATGCTCCG-
GATTATGTGGTGAACGCAGGTGGCGTGA TTCAG-
GTGGCGGATGAACTGCGTG-
25 
F-AmDH does not display. Overall, the new chimeric AmDH 
has lower specific activities. It also has a much different 
temperature activity profile in the presence of high concen-
trations of formate, which is more comparable to thermo-
philic enzymes than mesophilic enzymes, the group amine 
30 
dehydrogenases belong to. Overall, this enzyme has several 
properties that distinguish it from the previously reported 
amine dehydrogenases. 
Variants were also created by combining the mutations that 
lead to the L-AmDH and F-DH, as well as another new 
35 enzyme by using domain shuffling between a valine based 
AmDH (V-AmDH) and F-AmDH, referred to as C2-AmDH. 
Substrate Specificity of Cl-AmDH 
The results of an assay testing substrate specificity for the 
amination reaction driven by Cl-AmDH is provide in Table 
40 18. 
45 
50 
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TABLE 18 
Substrate specificity of Cl-ArnDH. 
substrate U/ml 
pFPA 13.8 
Acetophenone 1.63 
a-tetralone 0.58 
b-tetralone 0 
Benzophenone 0 
Adamantylmetbylketone 0 
1,3-phenylbutanedione 0.3 
3-metbyl-1-phenylbutanone 0.16 
dibenzylketone 1.39 
3-oxo-phenylbutyricacid 
etbylester 0 
pinacolone 0.72 
U/mg 
1.725 
0.301851852 
0.107407407 
0 
0 
0.07 
0.06 
0.03 
0.257407407 
0 
0.133333333 
Activities were also measured photometrically with 100 
60 
mM (+/-) methylhenzylamine (0.58 U/mg) as well as 100 
mM (R)-methylbenzylamine. (0.98 U/mg), 50 mM (R,S)-
adamanylethlamine (0.04 U/mg) and determined the enanti-
oselectivity for this enzyme to be (R). 
65 
Km andkcat Values forCl-AmDH 
The values for acetophenone, pFPA; NADH and NH3 were 
determined and are summarized in Table XX, all measured at 
60° C. 
US 8,835,136 B2 
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TABLE 19 
Kinetic Values for Cl-ArnDH 
Substrate KM(mM) kcal (s- 1) kcat/KM(M- 1 s- 1) 
Acetophenone 5.2 0.24 48 
pFPA 1.1 1.24 1127 
NH3 350 1.09 
NADH 0.04 0.92 2 x 104 
The Km values show improvement over previously established amine dehydrogenases. 
Temperature Vs Activity Profile for Cl-AmDH 
The temperature activity profile was determined over a 
wide range until the limits of the instrument were reached. 
The enzyme surprisingly is highly active above 60° C. and did 
not show any decline of activity up to 80° C. In contrast it is 
barely active between 20-30° C., so all measurements for 
activity were determined routinely at 60° C. Product conver-
sions were done at 40° C. and 50° C., due to the temperature 
limits for regeneration enzyme, FDH. Temperature activity 
profiles were determined for pFPA and acetophenone (FIGS. 
22A and 22B). 
The TSO (after 30 min-T 50 30) was also determined for the 
Cl-AmDH. The T5030 value was determined to be dependent 
on the buffer, in PBS, the enzyme was staple for 30 min at 50 
C, at 60 C an beyond the enzyme deactivated within the 
timescale of the experiment. In the presence of 4M ammo-
nium formate buffer we found the T 50 30 value was determined 
to be at 70 C. 
Substrate Conversion Using Cl-AmDH andcb-FDH (For-
mate Dehydrogenase from Candida boidinii) 
Product formation was characterized for two substrates. 
The test assay utilized the Cl-AmDH in 24 h conversion at 
40° C. with cofactor regeneration in a biphasic solvent system 
with heptane as the organic layer and 5 M annnonium formate 
<160> NUMBER OF SEQ ID NOS, 64 
<210> SEQ ID NO 1 
<211> LENGTH, 379 
<212> TYPE, PRT 
<213> ORGANISM, Bacillus badius 
<400> SEQUENCE, 1 
SEQUENCE LISTING 
64 
as the aqueous layer. Conversions were also carried out at 50° 
C., which is the upper limit for the cofactor regeneration 
enzymeFDH. 
FIG. 23 shows product formation for methylbenzylamine 
and p-fluorophenylproplyamin, and methylcyclohexanone, 
which shows no product. This is not a quantitative evaluation, 
since amines are more water soluble than their ketone coun-
terparts and only the organic layer was used for chiral gas 
chromatography (GC). The peaks were compared to the cor-
10 responding standard amines and both determined to be R-spe-
cific (FIGS. 24A and 24B). 
FIGS. 24A and 24B show comparison of product forma-
tion using Cl-AmDH with racemic amines using chiral GC. 
FIG. 24A shows production ofadamanthlethylamine, a 16 hr 
15 conversion with Cl-AmDH/FDH system, led to one peak that 
overlaid with the second of the peaks from the racemic stan-
dard resolved on chiral GC, believed to be (R)-configured. 
FIG. 24B shows production ofmethylbenzylamine, a 16 hr 
conversion with Cl-AmDH/FDH system, led to one peak 
20 overlaying with R-methylbenzylamine. 
Summary 
These chimeric amine dehydrogenases exhibit new prop-
erties, e.g. the Cl-AmDH is active on benzylic carbonyls 
(carbonyl groups in a-position to aromatic rings) such as 
25 acetophenone (specific activity 0.3 U/mg) to convert them 
into chiral amines, a feature none of the previous AmDHs 
have, as well as other substrates both not active and already 
active with other AmDH enzymes, such as dibenzylketone 
(spec. act. 1.39 U/mg). 1-tetralone (0.1 U/mg); and as an 
30 example for substrates active with other AmDH enzymes, 
p-fluorophenylacetone (spec. act, 1. 7 U/mg). Another feature 
of this new class of amine dehydrogenases is their tempera-
ture-activity profile. The chimertic enzymes are highly active 
at temperatures between 50-70° C., similar to known thermo-
stable dehydrogenases from thermophilic bacterial sources. 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Lys Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
US 8,835,136 B2 
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-continued 
130 135 140 
Val Pro Glu Ala Tyr Gly Gly Gly Gly Asp Ser Ser Ile Pro Thr Ala 
145 150 155 160 
Met Gly Val Leu Tyr Gly Ile Lys Ala Thr Asn Lys Met Leu Phe Gly 
165 170 175 
Lys Asp Asp Leu Gly Gly Val Thr Tyr Ala Ile Gln Gly Leu Gly Lys 
180 185 190 
Val Gly Tyr Lys Val Ala Glu Gly Leu Leu Glu Glu Gly Ala His Leu 
195 200 205 
Phe Val Thr Asp Ile Asn Glu Gln Thr Leu Glu Ala Ile Gln Glu Lys 
210 215 220 
Ala Lys Thr Thr Ser Gly Ser Val Thr Val Val Ala Ser Asp Glu Ile 
225 230 235 240 
Tyr Ser Gln Glu Ala Asp Val Phe Val Pro Cys Ala Phe Gly Gly Val 
245 250 255 
Val Asn Asp Glu Thr Met Lys Gln Phe Lys Val Lys Ala Ile Ala Gly 
260 265 270 
Ser Ala Asn Asn Gln Leu Leu Thr Glu Asp His Gly Arg His Leu Ala 
275 280 285 
Asp Lys Gly Ile Leu Tyr Ala Pro Asp Tyr Ile Val Asn Ser Gly Gly 
290 295 300 
Leu Ile Gln Val Ala Asp Glu Leu Tyr Glu Val Asn Lys Glu Arg Val 
305 310 315 320 
Leu Ala Lys Thr Lys His Ile Tyr Asp Ala Ile Leu Glu Val Tyr Gln 
325 330 335 
Gln Ala Glu Leu Asp Gln Ile Thr Thr Met Glu Ala Ala Asn Arg Met 
340 345 350 
Cys Glu Gln Arg Met Ala Ala Arg Gly Arg Arg Asn Ser Phe Phe Thr 
355 360 365 
Ser Ser Val Lys Pro Lys Trp Asp Ile Arg Asn 
370 375 
<210> SEQ ID NO 2 
<211> LENGTH, 379 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 2 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
66 
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-continued 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr Gly Gly Gly Gly Asp Ser Ser Ile Pro Thr Ala 
145 150 155 160 
Met Gly Val Leu Tyr Gly Ile Lys Ala Thr Asn Lys Met Leu Phe Gly 
165 170 175 
Lys Asp Asp Leu Gly Gly Val Thr Tyr Ala Ile Gln Gly Leu Gly Lys 
180 185 190 
Val Gly Tyr Lys Val Ala Glu Gly Leu Leu Glu Glu Gly Ala His Leu 
195 200 205 
Phe Val Thr Asp Ile Asn Glu Gln Thr Leu Glu Ala Ile Gln Glu Lys 
210 215 220 
Ala Lys Thr Thr Ser Gly Ser Val Thr Val Val Ala Ser Asp Glu Ile 
225 230 235 240 
Tyr Ser Gln Glu Ala Asp Val Phe Val Pro Cys Ala Phe Gly Gly Val 
245 250 255 
Val Asn Asp Glu Thr Met Lys Gln Phe Lys Val Lys Ala Ile Ala Gly 
260 265 270 
Ser Ala Asn Leu Gln Leu Leu Thr Glu Asp His Gly Arg His Leu Ala 
275 280 285 
Asp Lys Gly Ile Leu Tyr Ala Pro Asp Tyr Ile Val Asn Ser Gly Gly 
290 295 300 
Leu Ile Gln Val Ala Asp Glu Leu Tyr Glu Val Asn Lys Glu Arg Val 
305 310 315 320 
Leu Ala Lys Thr Lys His Ile Tyr Asp Ala Ile Leu Glu Val Tyr Gln 
325 330 335 
Gln Ala Glu Leu Asp Gln Ile Thr Thr Met Glu Ala Ala Asn Arg Met 
340 345 350 
Cys Glu Gln Arg Met Ala Ala Arg Gly Arg Arg Asn Ser Phe Phe Thr 
355 360 365 
Ser Ser Val Lys Pro Lys Trp Asp Ile Arg Asn 
370 375 
<210> SEQ ID NO 3 
<211> LENGTH, 379 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 3 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Trp Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
68 
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-continued 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr Gly Gly Gly Gly Asp Ser Ser Ile Pro Thr Ala 
145 150 155 160 
Met Gly Val Leu Tyr Gly Ile Lys Ala Thr Asn Lys Met Leu Phe Gly 
165 170 175 
Lys Asp Asp Leu Gly Gly Val Thr Tyr Ala Ile Gln Gly Leu Gly Lys 
180 185 190 
Val Gly Tyr Lys Val Ala Glu Gly Leu Leu Glu Glu Gly Ala His Leu 
195 200 205 
Phe Val Thr Asp Ile Asn Glu Gln Thr Leu Glu Ala Ile Gln Glu Lys 
210 215 220 
Ala Lys Thr Thr Ser Gly Ser Val Thr Val Val Ala Ser Asp Glu Ile 
225 230 235 240 
Tyr Ser Gln Glu Ala Asp Val Phe Val Pro Cys Ala Phe Gly Gly Val 
245 250 255 
Val Asn Asp Glu Thr Met Lys Gln Phe Lys Val Lys Ala Ile Ala Gly 
260 265 270 
Ser Ala Asn Glu Gln Leu Leu Thr Glu Asp His Gly Arg His Leu Ala 
275 280 285 
Asp Lys Gly Ile Leu Tyr Ala Pro Asp Tyr Ile Val Asn Ser Gly Gly 
290 295 300 
Leu Ile Gln Val Ala Asp Glu Leu Tyr Glu Val Asn Lys Glu Arg Val 
305 310 315 320 
Leu Ala Lys Thr Lys His Ile Tyr Asp Ala Ile Leu Glu Val Tyr Gln 
325 330 335 
Gln Ala Glu Leu Asp Gln Ile Thr Thr Met Glu Ala Ala Asn Arg Met 
340 345 350 
Cys Glu Gln Arg Met Ala Ala Arg Gly Arg Arg Asn Ser Phe Phe Thr 
355 360 365 
Ser Ser Val Lys Pro Lys Trp Asp Ile Arg Asn 
370 375 
<210> SEQ ID NO 4 
<211> LENGTH, 366 
<212> TYPE, PRT 
<213> ORGANISM, Bacillus stearothermophilus 
<400> SEQUENCE, 4 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Met 
50 55 60 
Thr Tyr Lys Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
70 
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-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Glu Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Asn Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Val Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg 
325 330 335 
Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys Ala Arg Ser Gln Phe 
340 345 350 
Leu Gln Asn Gly His His Ile Leu Ser Arg Arg Arg Ala Arg 
355 360 365 
<210> SEQ ID NO 5 
<211> LENGTH, 366 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 5 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Met 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
72 
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-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Asn Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Val Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro 
325 
Met Ala Glu Glu Arg Ile Glu Thr Met 
340 345 
Leu Gln Asn Gly His His Ile Leu Ser 
355 
<210> SEQ ID NO 6 
<211> LENGTH, 366 
<212> TYPE, PRT 
360 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
Thr Tyr Val Ala Ala 
330 
Arg Lys Ala Arg Ser 
350 
Arg Arg Arg Ala Arg 
365 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 
Asp Arg 
335 
Gln Phe 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Met 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
74 
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-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Val Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Val Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg 
325 330 335 
Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys Ala Arg Ser Gln Phe 
340 345 350 
Leu Gln Asn Gly His His Ile Leu Ser Arg Arg Arg Ala Arg 
355 360 365 
<210> SEQ ID NO 7 
<211> LENGTH, 366 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 7 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Met 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
76 
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-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Cys Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Val Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg 
325 330 335 
Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys Ala Arg Ser Gln Phe 
340 345 350 
Leu Gln Asn Gly His His Ile Leu Ser Arg Arg Arg Ala Arg 
355 360 365 
<210> SEQ ID NO 8 
<211> LENGTH, 366 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 8 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Met 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
78 
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-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Val Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Cys Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg 
325 330 335 
Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys Ala Arg Ser Gln Phe 
340 345 350 
Leu Gln Asn Gly His His Ile Leu Ser Arg Arg Arg Ala Arg 
355 360 365 
<210> SEQ ID NO 9 
<211> LENGTH, 366 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 9 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Met 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
80 
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-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Cys Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Cys Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg 
325 330 335 
Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys Ala Arg Ser Gln Phe 
340 345 350 
Leu Gln Asn Gly His His Ile Leu Ser Arg Arg Arg Ala Arg 
355 360 365 
<210> SEQ ID NO 10 
<211> LENGTH, 366 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 10 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Ser 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
82 
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83 
-continued 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 125 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe Gly Ser Ser Gly Asn 
130 135 140 
Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala 
145 150 155 160 
Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu Gly Lys Val Val Ala 
165 170 175 
Val Gln Gly Val Gly Asn Val Ala Tyr His Leu Cys Arg His Leu His 
180 185 190 
Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile Asn Lys Glu Ala Val 
195 200 205 
Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala Val Asp Pro Asn Asp 
210 215 220 
Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly 
225 230 235 240 
Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys Ala Lys Val Ile Ala 
245 250 255 
Gly Ser Ala Asp Leu Gln Leu Lys Glu Pro Arg His Gly Asp Met Ile 
260 265 270 
His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly 
275 280 285 
Gly Cys Ile Asn Val Ala Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg 
290 295 300 
Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe 
305 310 315 320 
Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg 
325 330 335 
Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys Ala Arg Ser Gln Phe 
340 345 350 
Leu Gln Asn Gly His His Ile Leu Ser Arg Arg Arg Ala Arg 
355 360 365 
<210> SEQ ID NO 11 
<211> LENGTH, 357 
<212> TYPE, PRT 
<213> ORGANISM: Streptomyces cinnamonensis 
<400> SEQUENCE, 11 
Thr Glu Ala Asp Asn Gly Val Leu His Thr Leu Phe His Ser Asp Gln 
1 5 10 15 
Gly Gly His Glu Gln Val Val Leu Cys Gln Asp Arg Ala Ser Gly Leu 
20 25 30 
Lys Ala Val Ile Ala Ile His Ser Thr Ala Leu Gly Pro Ala Leu Gly 
35 40 45 
Gly Thr Arg Phe Tyr Pro Tyr Ala Thr Glu Glu Glu Ala Val Ala Asp 
50 55 60 
Val Leu Asn Leu Ser Arg Gly Met Ser Tyr Lys Asn Ala Met Ala Gly 
65 70 75 80 
Leu Asp His Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro Glu Gln 
85 90 95 
Ile Lys Ser Glu Asp Leu Leu Leu Ala Phe Gly Arg Phe Val Ala Ser 
100 105 110 
84 
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-continued 
Leu Gly Gly Arg Tyr Val Thr Ala Cys Asp Val Gly Thr Tyr Val Ala 
115 120 125 
Asp Met Asp Val Val Ala Arg Glu Cys Arg Trp Thr Thr Gly Arg Ser 
130 135 140 
Pro Glu Asn Gly Gly Ala Gly Asp Ser Ser Val Leu Thr Ala Phe Gly 
145 150 155 160 
Val Phe Gln Gly Met Arg Ala Ser Ala Glu His Leu Trp Gly Asp Pro 
165 170 175 
Ser Leu Arg Gly Arg Lys Val Gly Val Ala Gly Val Gly Lys Val Gly 
180 185 190 
His His Leu Val Glu His Leu Leu Glu Asp Gly Ala Asp Val Val Ile 
195 200 205 
Thr Asp Val Arg Glu Glu Ser Val Asn Arg Ser Thr His Lys His Pro 
210 215 220 
Ser Val Thr Ala Val Ala Asp Thr Glu Ala Leu Ile Arg Thr Glu Gly 
225 230 235 240 
Leu Asp Ile Tyr Ala Pro Cys Ala Leu Gly Gly Ala Leu Asp Asp Asp 
245 250 255 
Ser Val Pro Val Leu Thr Ala Lys Val Val Cys Gly Ala Ala Asn Asn 
260 265 270 
Gln Leu Ala His Pro Gly Val Glu Lys Asp Leu Ala Asp Arg Ser Ile 
275 280 285 
Leu Tyr Ala Pro Asp Tyr Val Val Asn Ala Gly Gly Val Ile Gln Val 
290 295 300 
Ala Asp Glu Leu Arg Gly Phe Asp Phe Asp Arg Cys Lys Ala Lys Ala 
305 310 315 320 
Ser Lys Ile Phe Asp Thr Thr Leu Ala Ile Phe Ala Arg Ala Lys Glu 
325 330 335 
Asp Gly Ile Pro Pro Ala Ala Ala Ala Asp Arg Ile Ala Glu Gln Arg 
340 345 350 
Met Ser Asp Ala Arg 
355 
<210> SEQ ID NO 12 
<211> LENGTH, 357 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 12 
Thr Glu Ala Asp Asn Gly Val Leu His Thr Leu Phe His Ser Asp Gln 
1 5 10 15 
Gly Gly His Glu Gln Val Val Leu Cys Gln Asp Arg Ala Ser Gly Leu 
20 25 30 
Lys Ala Val Ile Ala Ile His Ser Thr Ala Leu Gly Pro Ala Leu Gly 
35 40 45 
Gly Thr Arg Phe Tyr Pro Tyr Ala Thr Glu Glu Glu Ala Val Ala Asp 
50 55 60 
Val Leu Asn Leu Ser Arg Gly Met Ser Tyr Ser Asn Ala Met Ala Gly 
65 70 75 80 
Leu Asp His Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro Glu Gln 
85 90 95 
Ile Lys Ser Glu Asp Leu Leu Leu Ala Phe Gly Arg Phe Val Ala Ser 
100 105 110 
86 
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Leu Gly Gly Arg Tyr Val Thr Ala Cys Asp Val Gly Thr Tyr Val Ala 
115 120 125 
Asp Met Asp Val Val Ala Arg Glu Cys Arg Trp Thr Thr Gly Arg Ser 
130 135 140 
Pro Glu Asn Gly Gly Ala Gly Asp Ser Ser Val Leu Thr Ala Phe Gly 
145 150 155 160 
Val Phe Gln Gly Met Arg Ala Ser Ala Glu His Leu Trp Gly Asp Pro 
165 170 175 
Ser Leu Arg Gly Arg Lys Val Gly Val Ala Gly Val Gly Lys Val Gly 
180 185 190 
His His Leu Val Glu His Leu Leu Glu Asp Gly Ala Asp Val Val Ile 
195 200 205 
Thr Asp Val Arg Glu Glu Ser Val Asn Arg Ser Thr His Lys His Pro 
210 215 220 
Ser Val Thr Ala Val Ala Asp Thr Glu Ala Leu Ile Arg Thr Glu Gly 
225 230 235 240 
Leu Asp Ile Tyr Ala Pro Cys Ala Leu Gly Gly Ala Leu Asp Asp Asp 
245 250 255 
Ser Val Pro Val Leu Thr Ala Lys Val Val Cys Gly Ala Ala Asn Leu 
260 265 270 
Gln Leu Ala His Pro Gly Val Glu Lys Asp Leu Ala Asp Arg Ser Ile 
275 280 285 
Leu Tyr Ala Pro Asp Tyr Val Val Asn Ala Gly Gly Val Ile Gln Val 
290 295 300 
Ala Asp Glu Leu Arg Gly Phe Asp Phe Asp Arg Cys Lys Ala Lys Ala 
305 310 315 320 
Ser Lys Ile Phe Asp Thr Thr Leu Ala Ile Phe Ala Arg Ala Lys Glu 
325 330 335 
Asp Gly Ile Pro Pro Ala Ala Ala Ala Asp Arg Ile Ala Glu Gln Arg 
340 345 350 
Met Ser Asp Ala Arg 
355 
<210> SEQ ID NO 13 
<211> LENGTH, 149 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 13 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
88 
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-continued 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr 
145 
<210> SEQ ID NO 14 
<211> LENGTH, 230 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 14 
Gly Gly Gly Gly Asp Ser Ser Ile Pro Thr Ala Met Gly Val Leu Tyr 
1 5 10 15 
Gly Ile Lys Ala Thr Asn Lys Met Leu Phe Gly Lys Asp Asp Leu Gly 
20 25 30 
Gly Val Thr Tyr Ala Ile Gln Gly Leu Gly Lys Val Gly Tyr Lys Val 
35 40 45 
Ala Glu Gly Leu Leu Glu Glu Gly Ala His Leu Phe Val Thr Asp Ile 
50 55 60 
Asn Glu Gln Thr Leu Glu Ala Ile Gln Glu Lys Ala Lys Thr Thr Ser 
65 70 75 80 
Gly Ser Val Thr Val Val Ala Ser Asp Glu Ile Tyr Ser Gln Glu Ala 
85 90 95 
Asp Val Phe Val Pro Cys Ala Phe Gly Gly Val Val Asn Asp Glu Thr 
100 105 110 
Met Lys Gln Phe Lys Val Lys Ala Ile Ala Gly Ser Ala Asn Leu Gln 
115 120 125 
Leu Leu Thr Glu Asp His Gly Arg His Leu Ala Asp Lys Gly Ile Leu 
130 135 140 
Tyr Ala Pro Asp Tyr Ile Val Asn Ser Gly Gly Leu Ile Gln Val Ala 
145 150 155 160 
Asp Glu Leu Tyr Glu Val Asn Lys Glu Arg Val Leu Ala Lys Thr Lys 
165 170 175 
His Ile Tyr Asp Ala Ile Leu Glu Val Tyr Gln Gln Ala Glu Leu Asp 
180 185 190 
Gln Ile Thr Thr Met Glu Ala Ala Asn Arg Met Cys Glu Gln Arg Met 
195 200 205 
Ala Ala Arg Gly Arg Arg Asn Ser Phe Phe Thr Ser Ser Val Lys Pro 
210 215 220 
Lys Trp Asp Ile Arg Asn 
225 230 
<210> SEQ ID NO 15 
<211> LENGTH, 139 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 15 
Glu Leu Phe Gln Tyr Met Glu Lys Tyr Asp Tyr Glu Gln Val Leu Phe 
1 5 10 15 
Cys Gln Asp Lys Glu Ser Gly Leu Lys Ala Ile Ile Val Ile His Asp 
90 
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-continued 
20 25 30 
Thr Thr Leu Gly Pro Ala Leu Gly Gly Thr Arg Met Trp Met Tyr Asn 
35 40 45 
Ser Glu Glu Glu Ala Leu Glu Asp Ala Leu Arg Leu Ala Arg Gly Ser 
50 55 60 
Thr Tyr Met Asn Ala Ala Ala Gly Leu Asn Leu Gly Gly Gly Lys Thr 
65 70 75 80 
Val Ile Ile Gly Asp Pro Arg Lys Asp Lys Asn Glu Ala Met Phe Arg 
85 90 95 
Ala Phe Gly Arg Phe Ile Gln Gly Leu Asn Gly Arg Tyr Ile Thr Ala 
100 105 110 
Val Asp Val Gly Thr Thr Val Ala Asp Met Asp Ile Ile Tyr Gln Glu 
115 120 
Thr Asp Tyr Val Thr Gly Ile Ser Pro Glu Phe 
130 135 
<210> SEQ ID NO 16 
<211> LENGTH, 227 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 16 
125 
Gly Ser Ser Gly Asn Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg 
1 5 10 15 
Gly Met Lys Ala Ala Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu 
20 25 30 
Gly Lys Val Val Ala Val Gln Gly Val Gly Asn Val Ala Tyr His Leu 
35 40 45 
Cys Arg His Leu His Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile 
50 55 60 
Asn Lys Glu Ala Val Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala 
65 70 75 80 
Val Asp Pro Asn Asp Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro 
85 90 95 
Cys Ala Leu Gly Gly Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys 
100 105 110 
Ala Lys Val Ile Ala Gly Ser Ala Asp Leu Gln Leu Lys Glu Pro Arg 
115 120 125 
His Gly Asp Met Ile His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr 
130 135 140 
Val Ile Asn Ala Gly Gly Cys Ile Asn Val Ala Asp Glu Leu Tyr Gly 
145 150 155 160 
Tyr Asn Arg Glu Arg Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn 
165 170 175 
Ile Glu Lys Val Phe Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr 
180 185 190 
Val Ala Ala Asp Arg Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys 
195 200 205 
Ala Arg Ser Gln Phe Leu Gln Asn Gly His His Ile Leu Ser Arg Arg 
210 215 220 
Arg Ala Arg 
225 
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<210> SEQ ID NO 17 
<211> LENGTH, 227 
<212> TYPE, PRT 
93 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 17 
Gly Ser Ser Gly Asn Pro Ser Pro Ala Thr Ala Tyr Gly Val Tyr Arg 
1 5 10 15 
Gly Met Lys Ala Ala Ala Lys Glu Ala Phe Gly Ser Asp Ser Leu Glu 
20 25 30 
Gly Lys Val Val Ala Val Gln Gly Val Gly Asn Val Ala Tyr His Leu 
35 40 45 
Cys Arg His Leu His Glu Glu Gly Ala Lys Leu Ile Val Thr Asp Ile 
50 55 60 
Asn Lys Glu Ala Val Ala Arg Ala Val Glu Glu Phe Gly Ala Lys Ala 
65 70 75 80 
Val Asp Pro Asn Asp Ile Tyr Gly Val Glu Cys Asp Ile Phe Ala Pro 
85 90 95 
Cys Ala Leu Gly Gly Ile Ile Asn Asp Gln Thr Ile Pro Gln Leu Lys 
100 105 110 
Ala Lys Val Ile Ala Gly Ser Ala Leu Asn Gln Leu Lys Glu Pro Arg 
115 120 125 
His Gly Asp Met Ile His Glu Met Gly Ile Val Tyr Ala Pro Asp Tyr 
130 135 140 
Val Ile Asn Ala Gly Gly Cys Ile Asn Val Ala Asp Glu Leu Tyr Gly 
145 150 155 160 
Tyr Asn Arg Glu Arg Ala Met Lys Lys Ile Glu Gln Ile Tyr Asp Asn 
165 170 175 
Ile Glu Lys Val Phe Ala Ile Ala Lys Arg Asp Asn Ile Pro Thr Tyr 
180 185 190 
Val Ala Ala Asp Arg Met Ala Glu Glu Arg Ile Glu Thr Met Arg Lys 
195 
Ala Arg Ser 
210 
Arg Ala Arg 
225 
Gln Phe Leu 
<210> SEQ ID NO 18 
<211> LENGTH, 147 
<212> TYPE, PRT 
200 
Gln Asn Gly His His 
215 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
Ile 
220 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 18 
205 
Leu Ser Arg Arg 
Thr Glu Ala Asp Asn Gly Val Leu His Thr Leu Phe His Ser Asp Gln 
1 5 10 15 
Gly Gly His Glu Gln Val Val Leu Cys Gln Asp Arg Ala Ser Gly Leu 
20 25 30 
Lys Ala Val Ile Ala Ile His Ser Thr Ala Leu Gly Pro Ala Leu Gly 
35 40 45 
Gly Thr Arg Phe Tyr Pro Tyr Ala Thr Glu Glu Glu Ala Val Ala Asp 
50 55 60 
Val Leu Asn Leu Ser Arg Gly Met Ser Tyr Ser Asn Ala Met Ala Gly 
65 70 75 80 
94 
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-continued 
Leu Asp His Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro Glu Gln 
85 90 95 
Ile Lys Ser Glu Asp Leu Leu Leu Ala Phe Gly Arg Phe Val Ala Ser 
100 105 110 
Leu Gly Gly Arg Tyr Val Thr Ala Cys Asp Val Gly Thr Tyr Val Ala 
115 120 125 
Asp Met Asp Val Val Ala Arg Glu Cys Arg Trp Thr Thr Gly Arg Ser 
130 
Pro Glu Asn 
145 
<210> SEQ ID NO 19 
<211> LENGTH, 210 
<212> TYPE, PRT 
135 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
140 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 19 
Gly Gly Ala Gly Asp Ser Ser Val Leu Thr Ala Phe Gly Val Phe Gln 
1 5 10 15 
Gly Met Arg Ala Ser Ala Glu His Leu Trp Gly Asp Pro Ser Leu Arg 
20 25 30 
Gly Arg Lys Val Gly Val Ala Gly Val Gly Lys Val Gly His His Leu 
35 40 45 
Val Glu His Leu Leu Glu Asp Gly Ala Asp Val Val Ile Thr Asp Val 
50 55 60 
Arg Glu Glu Ser Val Asn Arg Ser Thr His Lys His Pro Ser Val Thr 
65 70 75 80 
Ala Val Ala Asp Thr Glu Ala Leu Ile Arg Thr Glu Gly Leu Asp Ile 
85 90 95 
Tyr Ala Pro Cys Ala Leu Gly Gly Ala Leu Asp Asp Asp Ser Val Pro 
100 105 110 
Val Leu Thr Ala Lys Val Val Cys Gly Ala Ala Asn Leu Gln Leu Ala 
115 120 125 
His Pro Gly Val Glu Lys Asp Leu Ala Asp Arg Ser Ile Leu Tyr Ala 
130 135 140 
Pro Asp Tyr Val Val Asn Ala Gly Gly Val Ile Gln Val Ala Asp Glu 
145 150 155 160 
Leu Arg Gly Phe Asp Phe Asp Arg Cys Lys Ala Lys Ala Ser Lys Ile 
165 170 175 
Phe Asp Thr Thr Leu Ala Ile Phe Ala Arg Ala Lys Glu Asp Gly Ile 
180 185 190 
Pro Pro Ala Ala Ala Ala Asp Arg Ile Ala Glu Gln Arg Met Ser Asp 
Ala Arg 
210 
195 200 205 
<210> SEQ ID NO 20 
<211> LENGTH, 376 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 20 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
96 
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-continued 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr Gly Ser Ser Gly Asn Pro Ser Pro Ala Thr Ala 
145 150 155 160 
Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala Ala Lys Glu Ala Phe Gly 
165 170 175 
Ser Asp Ser Leu Glu Gly Lys Val Val Ala Val Gln Gly Val Gly Asn 
180 185 190 
Val Ala Tyr His Leu Cys Arg His Leu His Glu Glu Gly Ala Lys Leu 
195 200 205 
Ile Val Thr Asp Ile Asn Lys Glu Ala Val Ala Arg Ala Val Glu Glu 
210 215 220 
Phe Gly Ala Lys Ala Val Asp Pro Asn Asp Ile Tyr Gly Val Glu Cys 
225 230 235 240 
Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly Ile Ile Asn Asp Gln Thr 
245 250 255 
Ile Pro Gln Leu Lys Ala Lys Val Ile Ala Gly Ser Ala Leu Asn Gln 
260 265 270 
Leu Lys Glu Pro Arg His Gly Asp Met Ile His Glu Met Gly Ile Val 
275 280 285 
Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly Gly Cys Ile Asn Val Ala 
290 295 300 
Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg Ala Met Lys Lys Ile Glu 
305 310 315 320 
Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe Ala Ile Ala Lys Arg Asp 
325 330 335 
Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg Met Ala Glu Glu Arg Ile 
340 345 350 
Glu Thr Met Arg Lys Ala Arg Ser Gln Phe Leu Gln Asn Gly His His 
355 360 365 
Ile Leu Ser Arg Arg Arg Ala Arg 
370 375 
<210> SEQ ID NO 21 
<211> LENGTH, 376 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 21 
98 
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-continued 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr Gly Ser Ser Gly Asn Pro Ser Pro Ala Thr Ala 
145 150 155 160 
Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala Ala Lys Glu Ala Phe Gly 
165 170 175 
Ser Asp Ser Leu Glu Gly Lys Val Val Ala Val Gln Gly Val Gly Asn 
180 185 190 
Val Ala Tyr His Leu Cys Arg His Leu His Glu Glu Gly Ala Lys Leu 
195 200 205 
Ile Val Thr Asp Ile Asn Lys Glu Ala Val Ala Arg Ala Val Glu Glu 
210 215 220 
Phe Gly Ala Lys Ala Val Asp Pro Asn Asp Ile Tyr Gly Val Glu Cys 
225 230 235 240 
Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly Ile Ile Asn Asp Gln Thr 
245 250 255 
Ile Pro Gln Leu Lys Ala Lys Val Ile Ala Gly Ser Ala Asp Leu Gln 
260 265 270 
Leu Lys Glu Pro Arg His Gly Asp Met Ile His Glu Met Gly Ile Val 
275 280 285 
Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly Gly Cys Ile Asn Val Ala 
290 295 300 
Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg Ala Met Lys Lys Ile Glu 
305 310 315 320 
Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe Ala Ile Ala Lys Arg Asp 
325 330 335 
Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg Met Ala Glu Glu Arg Ile 
340 345 350 
Glu Thr Met Arg Lys Ala Arg Ser Gln Phe Leu Gln Asn Gly His His 
355 360 365 
Ile Leu Ser Arg Arg Arg Ala Arg 
370 375 
<210> SEQ ID NO 22 
<211> LENGTH, 376 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
100 
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101 
-continued 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 22 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr Gly Ser Ser Gly Asn Pro Ser Pro Ala Thr Ala 
145 150 155 160 
Tyr Gly Val Tyr Arg Gly Met Lys Ala Ala Ala Lys Glu Ala Phe Gly 
165 170 175 
Ser Asp Ser Leu Glu Gly Lys Val Val Ala Val Gln Gly Val Gly Asn 
180 185 190 
Val Ala Tyr His Leu Cys Arg His Leu His Glu Glu Gly Ala Lys Leu 
195 200 205 
Ile Val Thr Asp Ile Asn Lys Glu Ala Val Ala Arg Ala Val Glu Glu 
210 215 220 
Phe Gly Ala Lys Ala Val Asp Pro Asn Asp Ile Tyr Gly Val Glu Cys 
225 230 235 240 
Asp Ile Phe Ala Pro Cys Ala Leu Gly Gly Ile Ile Asn Asp Gln Thr 
245 250 255 
Ile Pro Gln Leu Lys Ala Lys Val Ile Ala Gly Ser Ala Leu Leu Gln 
260 265 270 
Leu Lys Glu Pro Arg His Gly Asp Met Ile His Glu Met Gly Ile Val 
275 280 285 
Tyr Ala Pro Asp Tyr Val Ile Asn Ala Gly Gly Cys Ile Asn Val Ala 
290 295 300 
Asp Glu Leu Tyr Gly Tyr Asn Arg Glu Arg Ala Met Lys Lys Ile Glu 
305 310 315 320 
Gln Ile Tyr Asp Asn Ile Glu Lys Val Phe Ala Ile Ala Lys Arg Asp 
325 330 335 
Asn Ile Pro Thr Tyr Val Ala Ala Asp Arg Met Ala Glu Glu Arg Ile 
340 345 350 
Glu Thr Met Arg Lys Ala Arg Ser Gln Phe Leu Gln Asn Gly His His 
355 360 365 
Ile Leu Ser Arg Arg Arg Ala Arg 
370 375 
<210> SEQ ID NO 23 
<211> LENGTH, 359 
102 
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103 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, Synthesized polypeptide 
<400> SEQUENCE, 23 
Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe Glu 
1 5 10 15 
Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala Thr 
20 25 30 
Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro Ala 
35 40 45 
Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala Leu 
50 55 60 
Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala Ala 
65 70 75 80 
Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp Pro 
85 90 95 
Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe Val 
100 105 110 
Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr Asn 
115 120 125 
Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val Gly 
130 135 140 
Val Pro Glu Ala Tyr Gly Gly Ala Gly Asp Ser Ser Val Leu Thr Ala 
145 150 155 160 
Phe Gly Val Phe Gln Gly Met Arg Ala Ser Ala Glu His Leu Trp Gly 
165 170 175 
Asp Pro Ser Leu Arg Gly Arg Lys Val Gly Val Ala Gly Val Gly Lys 
180 185 190 
Val Gly His His Leu Val Glu His Leu Leu Glu Asp Gly Ala Asp Val 
195 200 205 
Val Ile Thr Asp Val Arg Glu Glu Ser Val Asn Arg Ser Thr His Lys 
210 215 220 
His Pro Ser Val Thr Ala Val Ala Asp Thr Glu Ala Leu Ile Arg Thr 
225 230 235 240 
Glu Gly Leu Asp Ile Tyr Ala Pro Cys Ala Leu Gly Gly Ala Leu Asp 
245 250 255 
Asp Asp Ser Val Pro Val Leu Thr Ala Lys Val Val Cys Gly Ala Ala 
260 265 270 
Asn Leu Gln Leu Ala His Pro Gly Val Glu Lys Asp Leu Ala Asp Arg 
275 280 285 
Ser Ile Leu Tyr Ala Pro Asp Tyr Val Val Asn Ala Gly Gly Val Ile 
290 295 300 
Gln Val Ala Asp Glu Leu Arg Gly Phe Asp Phe Asp Arg Cys Lys Ala 
305 310 315 320 
Lys Ala Ser Lys Ile Phe Asp Thr Thr Leu Ala Ile Phe Ala Arg Ala 
325 330 335 
Lys Glu Asp Gly Ile Pro Pro Ala Ala Ala Ala Asp Arg Ile Ala Glu 
340 345 350 
Gln Arg Met Ser Asp Ala Arg 
355 
<210> SEQ ID NO 24 
<211> LENGTH, 360 
104 
US 8,835,136 B2 
105 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polypeptide 
<400> SEQUENCE, 24 
-continued 
Met Ser Leu Val Glu Lys Thr Ser Ile Ile Lys Asp Phe Thr Leu Phe 
1 5 10 15 
Glu Lys Met Ser Glu His Glu Gln Val Val Phe Cys Asn Asp Pro Ala 
20 25 30 
Thr Gly Leu Arg Ala Ile Ile Ala Ile His Asp Thr Thr Leu Gly Pro 
35 40 45 
Ala Leu Gly Gly Cys Arg Met Gln Pro Tyr Asn Ser Val Glu Glu Ala 
50 55 60 
Leu Glu Asp Ala Leu Arg Leu Ser Lys Gly Met Thr Tyr Ser Cys Ala 
65 70 75 80 
Ala Ser Asp Val Asp Phe Gly Gly Gly Lys Ala Val Ile Ile Gly Asp 
85 90 95 
Pro Gln Lys Asp Lys Ser Pro Glu Leu Phe Arg Ala Phe Gly Gln Phe 
100 105 110 
Val Asp Ser Leu Gly Gly Arg Phe Tyr Thr Gly Thr Asp Met Gly Thr 
115 120 125 
Asn Met Glu Asp Phe Ile His Ala Met Lys Glu Thr Asn Cys Ile Val 
130 135 140 
Gly Val Pro Glu Ala Tyr Gly Gly Ala Gly Asp Ser Ser Val Leu Thr 
145 150 155 160 
Ala Phe Gly Val Phe Gln Gly Met Arg Ala Ser Ala Glu His Leu Trp 
165 170 175 
Gly Asp Pro Ser Leu Arg Gly Arg Lys Val Gly Val Ala Gly Val Gly 
180 185 190 
Lys Val Gly His His Leu Val Glu His Leu Leu Glu Asp Gly Ala Asp 
195 200 205 
Val Val Ile Thr Asp Val Arg Glu Glu Ser Val Asn Arg Ser Thr His 
210 215 220 
Lys His Pro Ser Val Thr Ala Val Ala Asp Thr Glu Ala Leu Ile Arg 
225 230 235 240 
Thr Glu Gly Leu Asp Ile Tyr Ala Pro Cys Ala Leu Gly Gly Ala Leu 
245 250 255 
Asp Asp Asp Ser Val Pro Val Leu Thr Ala Lys Val Val Cys Gly Ala 
260 265 270 
Ala Asn Leu Gln Leu Ala His Pro Gly Val Glu Lys Asp Leu Ala Asp 
275 280 285 
Arg Ser Ile Leu Tyr Ala Pro Asp Tyr Val Val Asn Ala Gly Gly Val 
290 295 300 
Ile Gln Val Ala Asp Glu Leu Arg Gly Phe Asp Phe Asp Arg Cys Lys 
305 310 315 320 
Ala Lys Ala Ser Lys Ile Phe Asp Thr Thr Leu Ala Ile Phe Ala Arg 
325 330 335 
Ala Lys Glu Asp Gly Ile Pro Pro Ala Ala Ala Ala Asp Arg Ile Ala 
340 345 350 
Glu Gln Arg Met Ser Asp Ala Arg 
355 360 
<210> SEQ ID NO 25 
<211> LENGTH, 8 
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107 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polypeptide 
<400> SEQUENCE, 25 
Asp Tyr Lys Asp Asp Asp Asp Lys 
1 5 
<210> SEQ ID NO 26 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polypeptide 
<400> SEQUENCE, 26 
Tyr Pro Tyr Asp Val Pro 
1 5 
<210> SEQ ID NO 27 
<211> LENGTH, 10 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polypeptide 
<400> SEQUENCE, 27 
Ile Leu Lys Lys Ala Thr Ala Tyr Ile Leu 
1 5 10 
<210> SEQ ID NO 28 
<211> LENGTH, 10 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polypeptide 
<400> SEQUENCE, 28 
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu 
1 5 10 
<210> SEQ ID NO 29 
<211> LENGTH, 60 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (27) .. (27) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (29) .. (30) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (32) .. (32) 
<223> OTHER INFORMATION, "R" can be A or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (34) .. (34) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (35) .. (35) 
<223> OTHER INFORMATION, "R" can be A or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (37) .. (37) 
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-continued 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 29 
agggctgaac ggccgctaca ttacggbgnn trabrtkggc acgaccgttg ccgatatgga 60 
<210> SEQ ID NO 30 
<211> LENGTH, 61 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (27) .. (27) 
<223> OTHER INFORMATION, "Y" can be C or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (28) .. (28) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (30) .. (30) 
<223> OTHER INFORMATION, "Y" can be C or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (32) .. (33) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (35) .. (35) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<400> SEQUENCE, 30 
atccatatcg gcaacggtcg tgccmayvty anncvccgta atgtagcggc cgttcagccc 60 
t 61 
<210> SEQ ID NO 31 
<211> LENGTH, 59 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (28) .. (28) 
<223> OTHER INFORMATION, "D" can be A, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (29) .. (29) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (30) .. (30) 
<223> OTHER INFORMATION, "W" can be A or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (32) .. (32) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (34) .. (34) 
<223> OTHER INFORMATION, "D" can be A, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (35) .. (35) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (36) .. (36) 
<223> OTHER INFORMATION, "W" can be A or T 
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-continued 
<400> SEQUENCE, 31 
attcatgaca cgacgctcgg cccggcgdbw gbcdbwacgc gcatgtggat gtacaattc 59 
<210> SEQ ID NO 32 
<211> LENGTH, 59 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (24) .. (24) 
<223> OTHER INFORMATION, "W" can be A or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (26) .. (26) 
<223> OTHER INFORMATION, "H" can be A, C, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (28) .. (28) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (30) .. (30) 
<223> OTHER INFORMATION, "W" can be A or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (31) .. (31) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (32) .. (32) 
<223> OTHER INFORMATION, "H" can be A, C, or T 
<400> SEQUENCE, 32 
gaattgtaca tccacatgcg cgtwvhgvcw vhcgccgggc cgagcgtcgt gtcatgaat 59 
<210> SEQ ID NO 33 
<211> LENGTH, 34 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (16) .. (17) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (18) .. (18) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 33 
gattatgtga tcaacnnkgg cggcgtcatc aacg 
<210> SEQ ID NO 34 
<211> LENGTH, 34 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (17) .. (17) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (18) .. (19) 
34 
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<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<400> SEQUENCE, 34 
cgttgatgac gccgccmnng ttgatcacat aatc 
<210> SEQ ID NO 35 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (14) 
<223> OTHER INFORMATION, "D" can be A, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (15) .. (15) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (16) .. (16) 
<223> OTHER INFORMATION, "S" can be C or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (23) .. (23) 
<223> OTHER INFORMATION, "D" can be A, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (24) .. (24) 
<223> OTHER INFORMATION, "B" can be C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, "S" can be C or G 
<400> SEQUENCE, 35 
caacgccggc ggcdbsatca acdbsgccga tgagctgtac ggc 
<210> SEQ ID NO 36 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (19) .. (19) 
<223> OTHER INFORMATION, "S" can be C or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (20) .. (20) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (28) .. (28) 
<223> OTHER INFORMATION, "S" can be C or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (29) .. (29) 
<223> OTHER INFORMATION, "V" can be A, C, or G 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (30) .. (30) 
<223> OTHER INFORMATION, "H" can be A, C, or T 
<400> SEQUENCE, 36 
gccgtacagc tcatcggcsv hgttgatsvh gccgccggcg ttg 
<210> SEQ ID NO 37 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
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-continued 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (23) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (24) .. (24) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 37 
ctgaacggcc gctacattac gnnkgttgac gttggcacga ccg 
<210> SEQ ID NO 38 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (20) .. (20) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (21) .. (22) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<400> SEQUENCE, 38 
cggtcgtgcc aacgtcaacm nncgtaatgt agcggccgtt cag 
<210> SEQ ID NO 39 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (15) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (16) .. (16) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 39 
cgccggcggc gtcnnkaacg tcgccgatga gctgta 
<210> SEQ ID NO 40 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (21) .. (21) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (23) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<400> SEQUENCE, 40 
tacagctcat cggcgacgtt mnngacgccg ccggcg 
<210> SEQ ID NO 41 
<211> LENGTH, 45 
<212> TYPE, DNA 
116 
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<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 8,835,136 B2 
-continued 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (20) .. (21) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (22) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 41 
cgtcatcaac gtcgccgatn nkctgtacgg ctacaaccgt gaacg 
<210> SEQ ID NO 42 
<211> LENGTH, 45 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (24) .. (24) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (25) .. (26) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<400> SEQUENCE, 42 
cgttcacggt tgtagccgta cagmnnatcg gcgacgttga tgacg 
<210> SEQ ID NO 43 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (15) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (16) .. (16) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 43 
cgccggctcg gcgnnkaatc agctgaaaga gccgcg 
<210> SEQ ID NO 44 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (21) .. (21) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (23) 
<223> OTHER INFORMATION, "N" can be A, C, G, or T 
<400> SEQUENCE, 44 
cgcggctctt tcagctgatt mnncgccgag ccggcg 
<210> SEQ ID NO 45 
<211> LENGTH, 33 
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<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
-continued 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (18) .. (19) 
<223> OTHER INFORMATION, "D" can be A, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (20) .. (20) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 45 
cccgcggcat gacgtacddk aacgcggccg ccg 
<210> SEQ ID NO 46 
<211> LENGTH, 33 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (14) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (15) .. (16) 
<223> OTHER INFORMATION, "H" can be A, C, or T 
<400> SEQUENCE, 46 
cggcggccgc gttmhhgtac gtcatgccgc ggg 
<210> SEQ ID NO 47 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (15) 
<223> OTHER INFORMATION, "D" can be A, G, or T 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (16) .. (16) 
<223 > OTHER INFORMATION, "K" can be G or T 
<400> SEQUENCE, 47 
cgccggctcg gcgddkaatc agctgaaaga gccgcg 
<210> SEQ ID NO 48 
<211> LENGTH, 36 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic degenerate primer for mutagenesis 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (21) .. (21) 
<223> OTHER INFORMATION, "M" can be A or C 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (23) 
<223> OTHER INFORMATION, "H" can be A, C, or T 
<400> SEQUENCE, 48 
cgcggctctt tcagctgatt mhhcgccgag ccggcg 
<210> SEQ ID NO 49 
120 
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<211> LENGTH, 38 
<212> TYPE, DNA 
121 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 49 
ggaattccat atgagcttag tagaaaaaac atccatca 
<210> SEQ ID NO 50 
<211> LENGTH, 34 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 50 
ccgctcgagt attagttgcg aatatcccat tttg 
<210> SEQ ID NO 51 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 51 
gcctttccaa aggaatgact tacatgtgcg cggcgtccg 
<210> SEQ ID NO 52 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 52 
cggacgccgc gcacatgtaa gtcattcctt tggaaaggc 
<210> SEQ ID NO 53 
<211> LENGTH, 51 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 53 
US 8,835,136 B2 
-continued 
ggcggccgtt tctatacagg tgtggatatg ggaacgaata tggaagattt c 
<210> SEQ ID NO 54 
<211> LENGTH, 51 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 54 
gaaatcttcc atattcgttc ccatatccac acctgtatag aaacggccgc c 
<210> SEQ ID NO 55 
<211> LENGTH, 45 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 55 
122 
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gcaatcgccg gttcagccgt gaatcagctg cttacggagg atcac 
<210> SEQ ID NO 56 
<211> LENGTH, 45 
<212> TYPE, DNA 
<213> ORGANISM: artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Mutational primer applied to B. badius PheDH 
<400> SEQUENCE, 56 
gtgatcctcc gtaagcagct gattcacggc tgaaccggcg attgc 
<210> SEQ ID NO 57 
<211> LENGTH, 35 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 57 
gggaattcca tatgagtatc gacagcgcac tgaac 
<210> SEQ ID NO 58 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 58 
ccatgattac gccaagcttg c 
<210> SEQ ID NO 59 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 59 
cgacaacgac agcgactgcc tagggcccgt cgactgcag 
<210> SEQ ID NO 60 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 60 
ctgcagtcga cgggccctag gcagtcgctg tcgttgtcg 
<210> SEQ ID NO 61 
<211> LENGTH, 39 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 61 
gggggcgatg acgttgatga tggcagtgag caaccttcc 
<210> SEQ ID NO 62 
<211> LENGTH, 39 
<212> TYPE, DNA 
124 
45 
45 
35 
21 
39 
39 
39 
US 8,835,136 B2 
125 126 
-continued 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic primer 
<400> SEQUENCE, 62 
ggaaggttgc tcactgccat catcaacgtc atcgccccc 39 
<210> SEQ ID NO 63 
<211> LENGTH, 1134 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polynucleotide 
<400> SEQUENCE, 63 
atgagcttag tagaaaaaac atccatcata aaagatttca ctctttttga aaaaatgtct 60 
gaacatgaac aagttgtttt ttgcaacgat ccggcgacag gactaagggc cattatcgct 120 
attcatgaca ccacactcgg acctgcgctc ggcggctgcc gcatgcagcc ttataacagt 180 
gtggaagaag cattggaaga tgctcttcgc ctttccaaag gaatgactta cagttgcgcg 240 
gcgtccgatg tcgactttgg cggcggaaaa gcagtcatta tcggtgatcc gcagaaagat 300 
aaatctccag aactgttccg cgcgtttggc caatttgttg attcgcttgg cggccgtttc 360 
tatacaggta ctgatatggg aacgaatatg gaagatttca ttcacgccat gaaagaaaca 420 
aactgcattg ttggggtgcc ggaagcgtat ggctcttctg gcaacccgtc gccggccacg 480 
gcttacggcg tatatcgtgg gatgaaagcg gcggcgaagg aagcatttgg cagtgattcg 540 
cttgaaggaa aagttgtcgc cgtccaagga gtcggcaatg tcgcctacca tttatgccgc 600 
catttgcacg aagaaggagc gaaactcatc gttaccgaca tcaacaagga agcggtggcg 660 
cgcgcggtcg aggaatttgg ggcgaaagca gtcgacccga acgacattta cggcgtggag 720 
tgcgacattt ttgctccatg cgcgctcggc ggcatcatca acgaccaaac gattccgcag 780 
ctgaaagcga aagtgatcgc cggctcggcg ttgaatcagc tgaaagagcc gcgccatggc 840 
gacatgatcc atgaaatggg catcgtctat gcaccagatt atgtgatcaa cgccggcggc 900 
tgcatcaacg tcgccgatga gctgtacggc tacaaccgtg aacgggcgat gaaaaaaatc 960 
gagcaaattt atgacaacat cgaaaaagtg tttgccatcg ccaagcgtga caacattcca 1020 
acgtatgtgg ccgctgaccg gatggccgaa gaacgaattg aaacgatgcg caaagcgcgc 1080 
agccaatttt tgcaaaacgg ccatcatatt ttaagccgcc gccgcgcccg eta a 1134 
<210> SEQ ID NO 64 
<211> LENGTH, 1083 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic polynucleotide 
<400> SEQUENCE, 64 
atgagcttag tagaaaaaac atccatcata aaagatttca ctctttttga aaaaatgtct 60 
gaacatgaac aagttgtttt ttgcaacgat ccggcgacag gactaagggc cattatcgct 120 
attcatgaca ccacactcgg acctgcgctc ggcggctgcc gcatgcagcc ttataacagt 180 
gtggaagaag cattggaaga tgctcttcgc ctttccaaag gaatgactta cagttgcgcg 240 
gcgtccgatg tcgactttgg cggcggaaaa gcagtcatta tcggtgatcc gcagaaagat 300 
aaatctccag aactgttccg cgcgtttggc caatttgttg attcgcttgg cggccgtttc 360 
tatacaggta ctgatatggg aacgaatatg gaagatttca ttcacgccat gaaagaaaca 420 
US 8,835,136 B2 
127 128 
-continued 
aactgcattg ttggggtgcc ggaagcgtat ggtggtgcgg gtgatagcag 
gcgtttggcg tgtttcaggg catgcgtgcg agcgcggaac atctgtgggg 
ctgcgtggcc gtaaagtggg tgtggcgggt gtgggcaaag tgggccatca 
catctgctgg aagatggtgc ggatgtggtg attaccgatg tgcgtgaaga 
cgtagcaccc ataaacatcc gagcgtgacc gctgtggcgg ataccgaagc 
accgaaggcc tggatattta tgctccgtgc gcgctgggtg gtgcgctgga 
gtgccggtgc tgaccgctaa agtggtgtgc ggtgcggcaa acctgcagct 
ggtgtggaaa aagatctggc ggatcgtagc attctgtatg ctccggatta 
gcaggtggcg tgattcaggt ggcggatgaa ctgcgtggct ttgattttga 
gcgaaagcga gcaaaatttt tgataccacc ctggcgattt ttgcgcgtgc 
ggcattcctc cggctgcggc tgcggatcgt attgcggaac agcgtatgag 
taa 
We claim: 25 1. A recombinant amine dehydrogenase compnsmg an 
amino acid sequence with at least 90% sequence identity to 
SEQ ID N0:2, wherein the recombinant amine dehydroge-
nase catalyzes the formation of a chiral amine product. 
2. The recombinant amine dehydrogenase of claim 1 com-
prising SEQ ID N0:2. 
3. The recombinant amine dehydrogenase of claim 1 con-
sisting of SEQ ID N0:2. 
4. A method of making a chiral amine comprising reacting 
30 
a substrate with an effective amount the amine dehydroge-
nase of claim 1 in a reaction mixture comprising a cofactor to 35 
produce a chiral amine. 
5. The method of claim 4 wherein the cofactor is NADH. 
6. The method of claim 5 wherein reaction mixture further 
comprises glucose and glucose dehydrogenase (GDH) or for-
mate and formate dehydrogenase (FDH). 
cgtgctgacc 480 
cgatccgagc 540 
tctggtggaa 600 
aagcgtgaac 660 
gctgattcgt 720 
tgatgatagc 780 
ggcgcatccg 840 
tgtggtgaac 900 
tcgttgcaaa 960 
gaaagaagat 1020 
cgatgcgcgt 1080 
1083 
7. The method of claim 6 wherein the reaction mixture 
further comprises an organic solvent. 
8. The method of claim 7 wherein the solvent is acetone. 
9. The method of claim 4 wherein the reaction is carried out 
by whole cell catalysis. 
10. The method of claim 4 wherein the reaction is carried 
out in an enzyme membrane reactor. 
11. The method of any of claim 4 wherein the substrate is 
a methylketone. 
12. The method of claim 11 wherein the methylketone is 
selected from the group consisting of PFPA, phenoxy-2-pro-
panone, 2-hexanone, methyl isobutyl ketone and 3-methyl-2-
butanone. 
* * * * * 
